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ABSTRACT 
 
This Ph.D. thesis is located in the medicinal chemistry research field. Peptides are 
among the most studied entities as potential drug candidates, due to their natural 
abundance and biological implications. However, as drugs they possess several 
disadvantages because of low bioavailability and short half-life. Peptidomimetics try to 
overcome such drawbacks, maintaining meanwhile the biological activity. These 
mimics can also be useful to define bioactive forms of natural peptides, for instance 
through insertion of conformational constrictions able to reduce the peptide inherent 
flexibility. 
Thus, I explored the synthesis and the evaluation of some conformationally constrained 
peptidomimetics which potentially could be employed into different scientific fields 
and pharmaceutical contexts. Once prepared these scaffolds, I evaluated their 
secondary structure by means of spectroscopic methods including NMR and IR 
techniques. After insertion into more complex structures, strictly related to biologically 
active compounds, I verified their therapeutic potential. In some cases I could achieve 
very interesting biological results, in the range of activity of the natural corresponding 
peptides or of the reference lead compounds. I also tried to rationalize the biological 
activity outcomes, by joining them with molecular mechanics and docking-based 
structural investigation. 
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LIST OF ABBREVIATIONS 
 
AA   Amino Acid 
Aba   Amino benzazepinone 
Ac    Acetyl 
AD   Alzheimer Disease 
Ala    Alanine 
aq.    Aqueous 
BBB   Blood-Brain Barrier 
Boc    tert-Butyloxycarbonyl 
BOP   Benzotriazol-1-yloxytris(dimethylamino)phosphonium 
hexafluorophosphate 
Bt    Benzotriazole 
BzR   Benzodiazepine Receptor site 
CADD  Computer Aided Drug Design 
calcd.   Calculated 
Cbz   Carbobenzyloxy 
conc.   Concentrated 
Cys   Cysteine 
CSA   Camphorsulfonic acid 
DBU   Diazabicyclo[5,4,0]-undec-7-ene 
DCM   Dichloromethane 
DIPEA  N,N-Diisopropylethylamine 
DKP   DiKetoPiperazine 
DOR   -Opioid Receptor 
DMF   Dimethylformamide 
DMSO  Dimethylsulfoxide 
Dmt   Dimethyltyrosine 
EM-1   Endomorphin-1 
EM-2   Endomorphin-2 
equiv   Equivalent 
ESI   Electron spray ionization 
Fmoc   9-Fluorenylmethoxycarbonyl 
GDP   Guanosine diphosphate 
Gly   Glycine 
GPCRs  G-protein coupled receptors 
GTP   Guanosine triphosphate 
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HATU 2-(1H-7-Azabenzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HBTU  2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium  
hexafluorophosphate 
Hex   Hexane 
HOAt   1-Hydroxy-7-azabenzotriazole 
HOBt   1-Hydroxybenzotriazole 
HPLC   High performance liquid chromatography 
IBCF   isobutyl chloroformate 
Ile   Isoleucine 
IMDA  IntraMolecular Diels-Alder 
IP3   Inositol triphosphate 
IR   Infrared 
KOR   -Opioid Receptor 
LC   Liquid Chromatography 
Leu   Leucine 
Lys   Lysine 
Me   Methyl 
MC/MM  Monte Carlo/multiple minimum 
MOR   -Opioid Receptor 
MS   Mass Spectrometry 
NMR   Nuclear Magnetic Resonance 
NOESY  Nuclear Overhauser Enhanced Spectroscopy 
Ph   Phenyl 
Phe   Phenylalanine 
Phthal  Phthalimide 
POP   Prolyl Oligopeptidase 
ppm   Parts per million 
Pro   Proline 
PS   Pictet-Spengler 
PyBOP  Benzotriazol-1-yloxytrispyrrolidinophosphonium 
hexafluorophosphate 
QSAR  Quantitative Structure-Activity Relationship 
RDS   Rate Determining Step  
RP   Reverse Phase 
Rf   Retention factor 
rt   Room temperature 
SAR   Structure-Activity Relationship 
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ss   Saturated Solution 
SEM   Standard error of the mean 
Ser   Serine 
Tbac   2,3,4,5-tetrahydro-1H-benzo[c]azepine-4-carboxylic acid 
TBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate 
tBu   tert-Butyl 
TEA   Triethylamine 
TfOH   Trifluoromethanesulfonic acid 
TFA   Trifluoroacetic acid 
TFAA   Trifluoroacetic anhydride 
THBC  Tetrahydro--carboline 
THF   Tetrahydrofuran 
Tic 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid 
Thr   Threonine 
TLC   Thin layer chromatography 
Trp   Tryptophan 
Tyr   Tyrosine 
UV   Ultraviolet 
Val   Valine 
VT-NMR  Variable Temperature - NMR 
v/v   Volume per unit volume 
Xaa   Unspecified amino acid 
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1.1 Proteins 
 
The most abundant biomolecules in living organisms are proteins, long polymers of 
amino acids, representing more than 50% of the dry weight of animals and bacteria. 
Some proteins act like a catalyst, functioning as enzymes, other as signal receptors or 
transporters, which carry specific substances within or outside cells. Proteins are mainly 
a combination of the twenty different α-amino acids types present in nature and differ 
in number, composition and sequence. However, the main properties of a protein 
largely depend on the three-dimensional structure. While denatured proteins (not bent) 
have similar characteristics between them, the native (which are in their functional 
conformation), own unique properties and characteristics.  
Therefore, four different 
levels in the organization of 
the structure of a protein can 
be distinguished. 
The primary structure is the 
specific sequence of amino 
acids. The nature of the 
covalent binding of the polypeptidic chain imposes restrictions to the structure. The 
peptide bond assumes a partial double bond character, with the six atoms of the 
peptidic group in a rigid coplanar configuration. Peptide groups show, with few 
exceptions, a trans conformation, i.e. with the side chains outside from the plane 
containing the amide linkages (Figure 1). It’s so possible specify the 
conformation of the polypeptides backbone according to the torsion 
angles around the Cα-N bond (φ) and the Cα-C bond (ψ) of each of its 
amino acid residues. 
The secondary structure is referred to local spatial conformation of 
some parts of a polypeptide. The types of stable secondary structure 
and universally distributed among the proteins are relatively few. The 
most relevant conformations are α-helices (Figure 2), β-sheets (Figure 
3) and foldings or loops. In the secondary structure two key factors 
minimize the potential energy of the molecule: the minimization of 
the steric hindrance between side chains and the optimization of the 
formation of intrachain hydrogen bonds. The secondary structure of a 
polypeptidic segment is described by values of bond angles φ and ψ of 
each residue in that segment. 
 
Terminal 
COOH 
Terminal 
NH2 
Figure 1. Trans conformation of a polypeptidic chain. 
Terminal NH2 
Terminal 
COOH Figure 2. 
An -helix 
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The tertiary structure of a protein defines the disposition of all its atoms in the three-
dimensional space. While the secondary structure of a polypeptidic chain is related to a 
particular spatial order of amino-acidic residues which are adjacent in the primary 
structure, the tertiary structure considers the long-range connections existing in the 
amino-acidic sequence (Van der Waals forces). It is possible to distinguish two general 
classes of proteins based on their tertiary structure: fibrous, which perform numerous 
structural functions and are constituted by the repetition of a simple element of the 
secondary structure, and globular, with a more complex tertiary structure, in which 
there are different types of secondary structure in the same polypeptidic chain. In 
general, tertiary structure derives from interactions between the hydrophobic groups of 
polypeptide brought by the side chains of the amino acids of which it is made. 
Lastly, the quaternary structure is determined by interactions between the multi-
subunit proteins subunits (multimerics) or by the proteins folding of large size. In 
general, the combination of two or more polypeptides occur through weak bonds, such 
as disulfide bridges, in a very specific way. Finally, some proteins contain also a non-
polypeptidic part called prosthetic group, which gives to the protein a particular 
reactivity (such as EME hemoglobin group). 
As previously stated, proteins play an important role in many biological events. 
Interactions between receptors/enzymes and relatively small peptidic molecules occur 
at different level. Amino acid side chains are important for hydrogen bonding with 
basic or acid groups, lipophilic interactions or - stacking. Moreover, the amino acidic 
sequence may interact with its secondary structure, usually a turn motif is commonly 
recognized by most of the mammalian receptors (i.e. GPCRs). 
A correct classification of turns is important to identify structural similarities between 
different proteins and make structural predictions about amino acid sequences.[1] 
                                               
[1] Koch O., Klebe G. “Turns revisited: A uniform and comprehensive classification of normal, open, and reverse turn 
families minimizing unassigned random chain portions” Proteins, 2009, 74, 353–367 
Figure 3. A -sheet structure. 
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A reverse-turn in a protein structure is defined as a site where a polypeptide chain 
reverses its overall direction. According to the 
number of amino acids involved in the turn, 
there are different denominations: -turn (i, 
i+4), -turn (i, i+3), -turn (i, i+2) forming rings 
respectively to 7, 10 and 13 atoms closed by an 
hydrogen bond. This classification, however, is 
complicated by the irregular structure of the 
turns. In fact, the reverse-turn backbone 
(Figure 4), unlike the α-helices and β-sheets, 
has a variable conformation. Parameters 
usually evaluated are mainly geometric and 
allow to identify eleven different types of β-turns.  
A peptidic turn can be displayed and easily understood from Figure 5 where the 
intramolecular hydrogen bonds are summarized and explained for all the possible turn 
structures.  
 
Figure 5. Visual distinction between ,  and  turn. 
Reverse turns play an important role in globular proteins from both a structural and 
functional point of view.[2] Among the reverse turns, -turn, usually featuring a 10-
membered ring intramolecular hydrogen-bonded network, has been extensively 
investigated in the past. Recent studies suggest that even -turns, although less 
frequently observed in proteins compared to -turns, play key roles in certain biological 
functions.[3] For instance, the role of -turn motifs in molecular recognition processes 
                                               
[2] Chou K.C. “Prediction of tight turns and their types in proteins” Anal. Biochem. 2000, 286, 1–16 
[3] Prabakaran P., Gan J., Wu Y.O., Zhang M.Y., Dimitrov D.S., Ji X. “Structural mimicry of CD4 by a cross-reactive 
HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs” J. Mol. Biol. 2006, 357, 82–99 
Figure 4. Reverse-turn classification. 
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involving HIV-neutralization has just begun to unfold.[4] It is known that the 
recognition of a turn conformation normally involves only interactions between 
residues of the side chains of the ligand with the receptor. Based on this general 
behavior, our approach to the synthesis of peptidic turns can therefore be regarded as a 
synthesis of scaffolds with the amino acid component which potentially can be 
conformationally constrained or completely replaced by non-peptide alternative rigid 
scaffolds, designed to support fragments mimicking the side peptidic chains in the 
correct orientation with the binding site. 
 
  
                                               
[4] Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanﬁeld R.L., Burton D.R., Wilson I.A. “Structure of 
antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization” J. Mol. 
Biol. 2008, 375, 969–978  
  
17 
1.2 Peptidomimetics 
 
Proteins are vital for basically every known organism. Therefore the investigation of 
their structure, the development of a deeper understanding of protein–protein 
interactions and the design of novel peptides, which selectively interact with proteins, 
are fields of active research. Small peptides consisting of the 20 natural amino acids 
typically show high conformational flexibility and a low in-vivo stability which 
hampers their application as tools in medicinal diagnostics or molecular biology. One 
very versatile strategy to overcome such drawbacks is the use of peptidomimetics.  
Peptidomimetics[5] are small protein-like molecules designed to mimic natural peptides 
or proteins. These mimetics should have the ability to bind to their natural targets in the 
same way as the natural peptide sequences do and hence should produce the same 
biological effects. It is possible to design these molecules in such a way that they show 
the same biological effects as their peptide role models but with enhanced properties 
like a higher proteolytic stability, higher bioavailability and also often with improved 
selectivity or potency. This makes them interesting targets for the discovery of new 
drug candidates.[6] For the development of potent peptidomimetics it is necessary to 
understand the forces that lead to protein–protein interactions in the nanomolar range 
or even with higher affinities. These strong interactions between peptides and their 
corresponding proteins are mainly based on side chain interactions, indicating that the 
peptide backbone itself is not an absolute requirement for high affinities. This allows 
chemists to design peptidomimetics basically from any scaffold known in chemistry by 
replacing the amide backbone partially or completely by other structures. Most 
important is that the backbone is able to place the amino acid side chains in a defined 
3D-position to allow interactions with the target protein. Therefore it is necessary to 
develop an idea of the required structure of the peptidomimetic to show a high activity 
against its biological target. 
A common strategy to achieve these results is the manipulation of the amino acids’ side 
chains or the peptide structure itself. Conformationally restricted and metabolically 
more stable peptidomimetics are obtained using unnatural amino acids. In general, two 
different starting points exist for the modification of peptides at the amino acid level. 
One is the peptide backbone which can be replaced by bioisosteres (e.g. triazoles, 
                                               
[5] Wu Y.D., Gellman S. “Peptidomimetics” Acc. Chem. Res., 2008, 41, 1231-1232 
[6] (a) Hirschmann R. “Medicinal Chemistry in the Golden Age of Biology: Lessons from Steroid and Peptide 
Research” Angew. Chem. Int. Ed. Engl. 1991, 30, 1278-1301. (b) Hruby V.J., Al-Obeidi F., Kazmierski W. “Emerging 
approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and 
dynamic considerations.” Biochem. J. 1990, 268, 249-262. (c) Rizo J., Gierasch L.M. “Constrained Peptides: Models 
of Bioactive Peptides and Protein Substructures” Annu. Rev. Biochem. 1992, 61, 387-418 
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thioamides or alkenes). On the other hand, the amino acid side chain can be modified 
by mean of a different substitution, for instance a quaternary amino acid or a natural 
amino acid coming from the D-series. Structural rigidifications, for example by the use 
of cyclization strategies, is a widely used synthetic approach. There several methods 
which can be summarized as: 
 Head-to-Tail 
 Side chain-to-side chain 
 Backbone-to-side chain 
 Same side chain 
Although new ways were developed for the head-to-tail cyclization of peptides, most of 
them are still formed by the cyclization of activated precursors in solution phase, which 
means in most cases the use of standard peptide coupling conditions using 
HOBt/HBTU or HOAt/HATU as activating reagents. One interesting example for the 
head-to-tail cyclization of natural products is the Cyclosporine O.[7] In the same field, 
the RGD (Arg-Gly-Asp) sequence is the starting point for numerous cyclic 
peptidomimetics. In some examples RGD is flanked by other amino acids to form a ring 
system. These compounds offer the possibility to present the side chains of the RGD 
sequence in a specific conformation. DKP is the smallest head-to-tail cyclized 
peptidomimetic and has also been applied as a scaffold in the RGD sequence.[8]  
The most common methods to lock peptide chains into defined structures like α-helices 
by the formation of cyclic analogues are the disulfide linkage via the oxidation of two 
Cys residues and the formation of amide bonds between the side chain residues of the 
amino acids Lys and Asp/Glu.  
A further way to introduce global constraints into peptides is the formation of backbone 
to side chain cyclizations. One example for such a molecule is the cyclic derivative (Tyr-
c[--Orn-2-Nal--Pro-NMe-Ala]) of the natural occurring -casomorphin-5.  
Side chain cyclization is one of the most obvious strategy for the synthesis of 
constrained peptidomimetics and has been applied on both aromatic and non aromatic 
amino acids. Regarding aromatic amino acids, it will be fully explained during next 
chapters, whereas for non aromatic amino acids there are several examples in the field 
                                               
[7] Li P., Xu J.C. “Total Synthesis of Cyclosporin O Both in Solution and in the Solid Phase Using Novel Thiazolium-, 
Immonium-, and Pyridinium-Type Coupling Reagents:  BEMT, BDMP, and BEP1” J. Org. Chem. 2000, 65, 2951–
2958  
[8] Marchini M., Mingozzi M., Colombo R., Guzzetti I., Belvisi L., Vasile F., Potenza D., Piarulli U., Arosio D., Gennari 
C. “Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin 
ligands” Chemistry, 2012, 18, 6195-6207  
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of proline analogues. In the same topic, ring-closing metathesis is a precious tool for 
organic chemists and it has been exploited for the synthesis of new cyclic amino acid. [9]  
 
Figure 6. Examples of a) head-to-tail b) side chain-to side chain c) backbone-to-side chain cyclization.  
 
N-methylation is a very common modification, but also occurs in the sequences of 
natural peptides. N-Methylated analogues of biologically relevant peptides have been 
intensively examined to derive more information about the structural effects of N-
alkylation. They normally show increased proteolytic stability, increased membrane 
permeability (lipophilicity) and altered conformational preferences of the amide bond 
properties.[10] These effects result from the different property changes in the peptide 
going along with the introduction of N-methylation. Firstly, there are steric constraints 
introduced by the N-alkyl group, which have an effect not only on the conformational 
freedom of the peptide backbone but also on the side chain of the neighbouring amino 
acid. Secondly, the number of inter- and intramolecular hydrogen bonds decreases due 
to the removal of the backbone NH groups. And thirdly, the attached carbonyl group 
shows an increased basicity and decreased polarity. 
In this context, and more specifically related to this work, another common strategy 
involves -amino acids as building blocks. -peptides have particular appeal for 
extending our understanding of protein structure and stabilization into the realm of 
                                               
[9] Harris P.W.R., Brimble M.A., Gluckman P.D. “Synthesis of Cyclic Proline-Containing Peptides via Ring-Closing 
Metathesis” Org. Lett. 2003, 11, 1847-1850 
[10] Fairlie D.P., Abbenante G., March D.R. “Macrocyclic peptidomimetics - forcing peptides into bioactive 
conformations” Curr. Med. Chem. 1995, 2, 654–686 
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folded, non biological polymers, because -amino acids represent the smallest step 
away from -amino acids in the “backbone space”. Like -peptides (i.e. peptides 
composed of -amino acids), -peptides contain amide bonds capable of stabilizing 
intramolecular hydrogen bonds. A large body of structural and synthetic work has laid 
a solid groundwork for current investigations into -peptides.[11] That’s why we chose 
-amino acid containing peptidomimetic as a suitable starting point for the synthesis of 
interesting and pharmaceutical valuable drug candidates. An extensive dissertation on 
-peptides features is reported in the next section.  
 
  
                                               
[11] Cheng R.P., Gellman S., DeGrado W.F. “Peptides: From Structure to Function” Chem. Rev., 2001, 101, 3219-3232 
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1.2.1 -Peptides 
 
A new dimension to the field of biomimetic structures has been introduced by 
Seebach,[12] through the recognition that the repertoire of polypeptide conformations 
can be greatly expanded by the creation of structures that incorporate backbone 
homologated amino acids,[13] synthetically accessible from the proteinogenic amino 
acids. -Peptides consists of homologated amino acids, the new carbon atom expands 
the possibilities of functionalization and the stereochemical aspect of this class of 
building blocks. This is very important in medicinal chemistry because natural-like (i.e. 
-hPhe, -hTrp) and unnatural side chains can occupy much more different spatial 
positions while interacting with receptors. The employment of -amino acids in 
peptidomimetic chemistry offer many advantages, such as an high stability towards 
proteolytic enzymes, more possibility of chemical diversity and, in most cases, more 
predictable secondary structures.[14] In addition, quite recently, Gellman outlined the 
numerous advantages of heterogeneous (mixed - and -) backbone peptidomimetics 
with respect to homogeneous ones.[15] In fact, the heterogeneous approach allows many 
different combinations, starting from - and -amino acid building blocks, each of 
which offers a potentially distinctive way to project sets of side chains in space and to 
generate preferential conformations.[16] 
-amino acids and -peptides with proteinogenic side chains R can be divided into 
three main types (Figure 7): 3 and 2, insertion of a CH2 group between the CO and the 
-carbon and between the -carbon and the nitrogen, respectively; 2,3, -amino acid 
with an additional proteinogenic side chain (for example, Me) in the -position with syn 
(R,R or S,S) or anti (R,S or S,R) configuration; finally 2,2 or 3,3 with a double 
substitution on the same carbon atom. Such substitution might be identical, leading to 
an achiral  amino-acid, or  different. 
                                               
[12] (a) Seebach D., Gardiner J. “-Peptidic Peptidomimetics” Acc. Chem. Res., 2008, 41, 1366-1375 (b) Wu Y.D., Han 
W., Wang D.P., Gao Y., Zhao Y.L. “Theoretical Analysis of Secondary Structures of -Peptides” Acc. Chem. Res., 
2008, 41, 1418-1427.  
[13] Giannis A., Kolter T. “Peptidomimetics for Receptor Ligands – Discovery, Development and Medical 
Perspectives” Angew. Chem., Int. Ed., 1993, 32, 1244-1267 
[14] Grauer A., König B. “Peptidomimetics – A Versatile Route to Biologically Active Compounds” Eur. J. Org. Chem., 
2009, 30, 5099-5111 
[15] Horne W.S., Gellman S. “Foldamers with Heterogeneous Backbones” Acc. Chem. Res., 2008, 41, 1399-1408 
[16] Vasudev P.G., Chatterjee S., Shamala N., Balaram P. “Structural Chemistry of Peptides Containing Backbone 
Expanded Amino Acid Residues: Conformational Features of , γ, and Hybrid Peptides” Chem. Rev., 2011, 111, 
657-687 
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Figure 7. Generic -Amino acids. 
 
C3-substituted -amino acid may be prepared by homologation of -amino acids via 
Arndt-Eistert homologation,[17] by mean of a more classical Kolbe protocol,[18] or by a 
number of other practical routes,[19] providing a convenient and highly diverse source of 
enantiomerically pure monomers possessing proteinogenic-like or unnatural side 
chains. C2-substituted -amino acid synthesis have been fully explored and a recent 
review covers most of the synthetic approaches.[20] Evans’ oxazolidinones methodology 
remain one of the most exploited method for enantioselective synthesis of pure 2-
amino acids.[21] 
The conformations of -peptides can be analyzed in terms of the main chain torsional 
angles, which are assigned the angles , , , and  (Figure 8) in the convention of 
Balaram. 
 
Figure 8. Definition for the torsional angles in -peptides. 

                                               
[17] Hughes A.B., Sleebs B.E. “Effective Methods for the Synthesis of N-Methyl b-Amino Acids from All Twenty 
Common a-Amino Acids Using 1,3-Oxazolidin-5-ones and 1,3-Oxazinan-6-ones” Helv. Chim. Acta, 2006, 89, 
2611-2637 
[18] Sobolewski D., Kowalcyzk W., Prahl A., Derdowska I., Slaninova J., Zaborcki J., Lammek B. “Analogues of 
arginine vasopressin and its agonist and antagonist modified in the N-terminal part of the molecule with L--
homophenylalanine” J. Peptide Res. 2005, 65, 465-471 
[19] Juaristi, E. “Enantioselective Synthesis of -Amino Acids” Wiley-VCH: New York, 1997 
[20] Lelais G., Seebach D. “2-Amino acids – Synthesis, Occurance in Natural Products and Components of -
Peptides” Biopolymers, 2004, 76, 296-243 
[21] Gessier F., Schaeffer L., Kimmerlin T., Flogel O., Seebach D. “Preparation of b2-Amino Acid Derivatives (2hThr, 
2hTrp, 2hMet, 2hPro, 2hLys, Pyrrolidine-3-carboxylic Acid) by Using DIOZ as Chiral Auxiliary” Helv. Chim. 
Acta, 2005, 88, 2235-2249 
  
23 
-Peptides offer various secondary structures, even in a four to six small peptide, 
unaccessibile to -amino acids. In particular the typical -helix can be expanded to 
different intramolecular hydrogen bonds stabilizing helical structures. These are 
summarized in Figure 9 and they are strictly related to the absolute and relative 
configuration of the monomers. Secondary structures of -peptides are significantly 
affected by side chain properties, on the other hand the secondary structure of -
peptides seems to be mainly determined by the substitution patterns. Peptides formed 
from 3-amino acids derived from natural L-amino acids adopt preferentially left-
handed 14-helices. -Peptides with alternating 2- and 3-monosubstituted residues can 
adopt the 10/12-helix conformation.[22] The characteristic feature of this helix is an 
intertwined network of 10- and 12- membered hydrogen-bonded rings.  
 
Figure 9. Structure of the -helix, 14-helix, 12-helix and 10/12-helix. 
 
-Peptides carrying proteinogenic side chains can mimic their progenitors, the -
peptides. Helical mimics will be likely to consist of six or more -amino acid residues, 
while turn and hairpin-mimicking -peptides might consist of as few as two -amino 
acid moieties. As demonstrated with a -peptidic tetrapeptide, there is a chance that the 
short-chain -peptides are orally bioavailable and are excreted within a reasonably 
short half-life, a prerequisite considered essential for a drug candidate by most 
                                               
[22] Seebach D., Abele S., Gademann K., Guichard, G., Hintermann T., Jaun B., Matthews, J.L., Schreiber, J.V., Oberer 
L., Hommel U., Widmer H. “β2- and β3-Peptides with Proteinaceous Side Chains: Synthesis and solution 
structures of constitutional isomers, a novel helical secondary structure and the influence of solvation and 
hydrophobic interactions on folding” Helv. Chim. Acta 1998, 81, 932 
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medicinal chemists and clinical researchers. Proteolytic cleavage and metabolic 
processes do not seem to be an issue with -peptides.[23] 
In Figure 10 is summarized the hydrogen bonding pattern for most common helices 
secondary structures accessible to -peptides. This pattern becomes much more 
interesting because -amino acid building blocks offer an higher degree of 
diversification. Moreover an heterogeneous backbone allows chemists to rationally 
design synthetic oligomers that exhibit natural biopolymer conformational behavior. 
 
 
Figure 10. Hydrogen bonding pattern for -peptides. 
 
  
                                               
[23] Nunn C., Langenegger M.R.D., Schuepbach E., Kimmerlin T., Micuch P., Hurth K., Seebach D., Hoyer D. “2/3-
Di- and /3-Tetrapeptide Derivatives as Potent Agonists of Somatostain sst4 Receptors” Naunyn-Schmiedeberg’s 
Arch. Pharmacol. 2003, 367, 95–103 
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1.2.2 Aromatic AAs based Scaffolds 
 
In the field of phenylalanine there are several possible modification reported and 
applied in many research topics, in particular medicinal chemistry. We can divide such 
mimics into two main categories: the linear one and the conformationally constrained. 
Among the linear mimics, one of the most exploited is the -Methyl substitution[24] and 
the aromatic ring methylation.[25] The introduction of a new stereogenic center gives 
more tools for a structure-activity relationship investigation. Since methods of 
asymmetric synthesis of -methyl aromatic amino acids have been developed, serial 
substitutions of biologically important aromatic amino acids with four -methylated 
stereoisomers became an important tool for investigating topographical requirements of 
peptide receptors for the side chain conformations.[26] The -methyl derivatives of Phe, 
Tyr, and Trp have been incorporated into various biologically active peptides[27] to 
better understand structure-activity relationship. 
 
 
Figure 11. Linear and constrained Phenylalanine mimics. 
 
                                               
[24] Azizeh B.Y., Shenderovich M.D., Trivedi D., Li G., Sturm N.S., Hruby V.J., “Topographical Amino Acid 
Substitution in Position 10 of Glucagon Leads to Antagonists/Partial Agonists with Greater Binding 
Differences” J. Med. Chem. 1996, 39, 2449–2455 
[25] Haskell-Luevano C., Toth K., Boteju L., Job C., Castrucci A., Hadley M.E., Hruby V.J. “β-Methylation of the Phe7 
and Trp9 Melanotropin Side Chain Pharmacophores Affects Ligand−Receptor Interactions and Prolonged 
Biological Activity” J. Med. Chem. 1997, 40, 2740–2749 
[26] Hruby, V.J. “Conformational and Topographical Considerations in the Design of Biologically Active Peptides” 
Biopolymers 1993, 33, 1073-1082 
[27] Toth G., Russell, K.C., Landis G., Kramer T. H.; Fang, L., Knapp R., Davis, P., Yamamura H. I.; Hruby V.J. “Ring 
Substituted and Other Conformationally Constrained Tyrosine Analogues of [D-Pen2, D-Pen5]enkephalin with 
Opioid Receptor Selectivity” J. Med. Chem. 1992, 35, 2384-2391 
 26 
On the other hand phenylalanine is a suitable starting point for the synthesis of 
conformationally constrained peptidomimetics which may drive the aromatic ring 
orientation in the proper hydrophobic region. 
Within natural amino-acids, phenylalanine, tryptophan and tyrosine play a 
fundamental role in molecular recognition events because of aromatic ring presence. 
Giving also a more lipophilic profile to the peptide and being involved in -interaction 
or hydrophobic cavity insertion. It is known that a good peptidomimetic drug 
candidate must cross the blood-brain barrier (BBB) or cell wall due to its intrinsic 
lipophilicity, when active transport is not a solution.  
Benzazepinones have been widely studied as well. Specially for conformational and 
structural investigation within small peptides.[28] Recently, Tourwé and co-workers 
observed that in a series of Ac-Aba-Xaa-NHMe containing tetrapeptide models, the 
spirocyclic derivative, Ac-spiro-Aba-Gly-NHMe exclusively formed a -turn, while 
other lactams, such as Ac-Aba-Gly-NHMe adopted mainly an extended 
conformation.[29] 
Furthermore, in a recent work,[30] a combination of these common Phe mimics were 
exploited for the synthesis of a potent DOR radioantagonist. In particular a systematic 
combination of -methyl substituted Phe stereoisomers coupled with Tic nucleus; 
proving how many efforts are dedicated to the synthesis of conformationally 
constrained peptidomimetics in the drug discovery process related to GPCRs ligands. 
Similarly this article reviews the emergence of derivatives based on the Tyr-Tic and 
Dmt-Tic pharmacophores as lead structures, and discusses potential clinical and 
therapeutic applications.[31] 
Generally, these compounds are synthesized, also as pure enantiomers, with the Pictet-
Spengler reaction in its variations from Phe, Tyr, m-Tyr, Trp and His, which allows to 
obtain the desired product in good yields. Approaches using more complex building 
blocks have been also proposed, involving the generation of benzenoid systems 
                                               
[28] Tömböly Cs., Ballet S., Feytens D., Kover K.E., Borics A., Lovas S., Al-Khrasani M., Furst Z., Toth G., Benyhe S., 
Tourwé D. “Endomorphin-2 with a -Turn Backbone Constraint Retains the Potent μ-Opioid Receptor Agonist 
Properties” J. Med. Chem. 2008, 51, 173-177 
[29] Van Rompaey K., Ballet S., Tömböly Cs., De Wachter R., Vanommeslaeghe K., Biesmans M., Willem R., Tourwé 
D. “Synthesis and evaluation of the -turn properties of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and of 
their spirocyclic derivative” Eur.J. Org. Chem. 2006, 13, 2899–2911 
[30] Birkas E., Kertesz I., Toth G., Bakota L., Gulya K., Szucs M. “Synthesis and pharmacological characterization of a 
novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH” 
Neuropeptides, 2008, 42 (1), 57-67 
[31] Lazarus L.H., Bryant S.D., Cooper P.S., Guerrini R., Balboni G., Salvadori S. “Design of δ-opioid peptide 
antagonists for emerging drug applications” Drug Discovery Today 1998, 3 (6), 284-294 
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through cycloaddition reactions. This may solve problems connected with the use of 
less nucleophilic substrates, substituted with electron withdrawing groups.[32] 
The Tic skeleton (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) is probably the 
structure which, in recent years and in this context, was more developed and studied. [33] 
Many conformational analyses of this compound and of its derivatives are in fact 
available.[34] Tic containing peptidomimetics have often been used effectively in studies 
of the quantitative structure-activity relationship (QSAR). The tetrahydroisoquinoline 
unit is an important structural element in many alkaloids and pharmaceuticals. The Tic 
skeleton has been used many times as a rigid analogue of Phe and Tyr, for example in 
the design of peptidic antagonists of opioid receptors, showing useful therapeutic 
applications. 
The Tic skeleton, in fact, allows to limit the torsional dihedral angle ψ, blocking the 
conformation of the side chain and bringing an hydrophobic aromatic residual 
important to cross the blood-brain barrier. 
The Tic structure resulted for these reasons unique in its effects, even in comparison to 
potential promising residues, being crucial in the process of recognition of the ligand by 
the receptor. Modular aspects that have proved to be decisive for the activity are: the α 
stereogenic center, the hydrophobicity of the side chains, the derivatization of nitrogen 
and carbon terminal atoms, the reduction of some amide bonds of the peptidic chain 
and the possibility to use vinyl homologues. 
The Pictet-Spengler cyclization[35] is an intramolecular reaction, promoted by acidic 
conditions, between a nucleophilic aromatic ring and an electrophilic iminium ion or 
acyl iminium ion. A new carbon-carbon bond is formed, increasing the skeleton 
complexity, and a new stereocenter is present when using any aldehyde but 
                                               
[32] Sambasivarao K. “The Building block Approach to unusual α-amino acid derivatives and peptides” Acc. Chem. 
Res. 2002, 36, 342-351 
[33] (a) Liskamp R.M.J. “Conformationally restricted amino acids and dipeptides, peptidomimetics and secondary 
structure mimetics” Recl. Trav. Chim. Pays-Bas. 1994, 113, 1-19. (b) Grieco P., Campiglia P., Gomez-Monterrey I., 
Novellino E. “Synthesis of new β-turn dipeptide mimetic based on tetrahydroisoquinoline moiety” Tetrahedron 
Lett. 2002, 43 (36), 6297-6299. (c) Gibson S.E., Guillo N., Jones J.O., Buck I.M., Kalindjian S.B., Roberts S., Tozer 
M.J. “CCK2 receptor antagonists containing the conformationally constrained phenylalanine derivatives, 
including the new amino acid Xic” Eur. J. Med. Chem. 2002, 37 (5), 379-389. 
[34] (a) Lesma G., Meschini E., Recca T., Sacchetti A., Silvani A. “Synthesis of tetrahydroisoquinoline-based 
pseudopeptides and their characterization as suitable reverse turn mimetics” Tetrahedron 2007, 63, 5567–5578 (b) 
Landoni N., Lesma G., Sacchetti A., Silvani A. “Pyrroloisoquinoline-based tetrapeptide analogues mimicking 
reverse-turn secondary structures” J. Org. Chem. 2007, 72, 9765-9768 (c) Arbor S., Marshall G.R. “A virtual 
library of constrained cyclic tetrapeptides that mimics all four side-chain orientations for over half the reverse 
turns in the protein data bank” J. Comput. Aided. Mol. Des. 2009, 23, 87–95. 
[35] (a) Pictet A., Spengler T. Ber. Dtsch. Chem. Ges. 1911, 44, 2030-2036 (b) Tatsui G.J. Pharm. Soc. Jpn. 1928, 48, 92 
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formaldehyde. Most of the peptidomimetic synthesized in this project rely on this 
strategy for the introduction of a conformational restriction. 
This reaction is widely employed in the synthesis of tetrahydro-isoquinolines and 
tetrahydro-carbolines where the nucleophile is a phenyl ring or an indole.[36] Depending 
on the activation of the nucleophile, reaction conditions go from room temperature and 
acid catalysis (formic acid) to stronger conditions like refluxing solvent and strong acid 
(trifluoroacetic). 
Nucleophilicity can be summarized with the following ascending order:  
Phenyl < MeO-Phenyl < Indole 
These aromatic rings can be traced to natural amino acids like Phe, Tyr, Dopa and Trp. 
Most indicated electrophiles come from aldehydes, or acetals, affording products in 
good yield instead of ketones which tend to give lower conversion and longer reaction 
time. In Scheme 1a and 1b are described the general reaction mechanisms for the 
synthesis of N-acyl-Tic and N-acyl-Thbc skeletons. These chemical modifications occur 
also on the amines, with no need for a coupling, however it is more peculiar for 
activated aromatic ring like indole instead of phenyl. 
 
 
 
Scheme 1a. Reaction Mechanism for N-acyl iminium ion. 
 
The first step is the formation of an iminium ion, the dehydration process is 
fundamental for the formation of such intermediate and is more evident in the N-acyl 
iminium pathway. This step is followed by electrophilic substitution at the position 2. 
The desired product is formed after deprotonation, to restore aromaticity and obtain a 
neutral derivative. This reaction is a classical favored 6-endo-trig cyclization. 
                                               
[36] Cox E.D., Cook J.M. “The Pictet-Spengler condensation: a new direction for an old reaction” Chem. Rev. 1995, 95, 
1797-1842 
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Stereocontrol of the new stereocenter is a demanding task. Usually is very difficult for 
phenylalanine derivatives, whereas enantiopure tryptophan are more inclined to afford 
the kinetically favored cis diastereomer for structural reasons. Quite recently have been 
developed a catalytic system to promote enantioselectively the PS cyclization.[37] Till 
now, there are few stereoselective catalytic examples and often they require difficult 
reaction conditions (long time, low temperature), whereas the substrate scope is limited.  
The PS cyclization on the indole ring is slightly different (Scheme 1b) because of the 
indolic nitrogen participating in the mechanism. There are two possible mechanism, the 
C2 and the C3 addition. C2 addition is the favored pathway and leads to the desired 
tetrahydro--carboline core. C3 addition is non productive and leads to a 
spiroindolinone intermediate. This intermediate is reversible and might undergo a ring 
opening and then a productive C2 addition. When position C2 is substituted, C3 
addition becomes favored and spiro derivatives can be isolated. However, C3 addition 
is in general disfavored because is a 5-endo-trig cyclization and is disallowed according 
to Baldwin’s rules. 
 
 
Scheme 1b. Reaction Mechanism for N-acyl iminium ion on Trp. 
  
                                               
[37] (a) Seayad J., Seayad A.M., List B. “Catalytic Asymmetric Pictet-Spengler Reaction” J. Am. Chem. Soc. 2006, 128, 
1086-1087 (b) Raheem I.T., Thiara P.S., Peterson E.A., Jacobsen E.N. “Enantioselective Pictet−Spengler-Type 
Cyclizations of Hydroxylactams:  H-Bond Donor Catalysis by Anion Binding” J. Am. Chem. Soc. 2007, 129, 
13404-13405 
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1.3 G-Protein Coupled Receptors 
 
G-protein-coupled receptors (GPCRs) are a family of biological receptors constituted by 
seven transmembrane segments (α-helices), located on the cell surface. They are able to 
mediate cellular responses to extracellular stimuli, both endogenous chemicals or 
exogenous (external environmental agents). Once triggered by an extracellular signal, 
GPCRs activates heterotrimeric G proteins, which interact with different receptors, 
including guanosine nucleotides GTP and GDP, and with the GPCR itself at the level of 
the third long cytoplasmic loop, corresponding to the region of the molecule which is 
coupled to the G protein. The G protein activated, in fact, exchanges the bound GDP 
with the GTP. Then the GTP-protein dissociates from the occupied receptor, binding 
itself to another adjacent receptor and altering its activity. An important aspect of the 
signaling mechanism is that the ligand does not pass through the membrane. Instead, 
the signal is transferred to the inside of the cell by conformational changes in the 
receptor protein, which are coupled to ligand-binding events. 
 
Figure 12. Activation of the G alpha subunit of a GPCR. 
 
The activation of a GPCR triggers a cascade intracellular transduction of the signal, with 
numerous internal messengers, which produce the cellular change that characterizes or 
begins the physiological process. The human genome encodes between 700 and 1000 
members of this family of receptors. About 60% of the known GPCRs represent sensory 
receptors, associated with taste, sight and smell; while only 300-400 GPCRs have a non-
sensory function. Of these last category, about 175 receptors are considered "orphans", 
that is still devoid of an identified ligand. 
The GPCRs are generally formed of a single polypeptidic chain of approximately 400-
3000 amino-acidic residues, consisting of an extracellular N-terminal residue of variable 
length (7-3000 AAs), seven transmembrane α-helices (20-27 AAs), three endo- and three 
exo-loops (5-250 AAs) and an intracellular C-terminal residues (12-400 AAs) (Figure 12). 
The region of the seven transmembrane α-helices (7TM) is usually highly conserved, 
whereas other domains considerably vary among different GPCRs. 
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Historically, G protein-coupled receptors have been grouped in three classes but, up to 
now, were also identified other receptors that cannot properly be included in these. 
The "Class A" is the largest group of GPCRs, most of which have a N-terminal residue 
very short and a highly conserved 7TM region. These receptors are structurally related 
to rhodopsin or adrenergic receptors and bind several amines, purines, and peptidic 
ligands. About 900 olfactory receptors belong to this class. 
The "Class B" consists of the secretin-related receptors, which have six conserved 
cysteine and a binding domain for an hormonal ligand in their long N-terminal residue. 
These receptors bind large peptidic ligands such as glucagon. 
To the "Class C" belong neurotransmitter receptors with long N-terminal residues (500-
600 aa) and without homology in the 7TM region with other families of GPCRs. To this 
family belong for example the GABA and the Ca2+ receptors. 
In addition to these three families it is possible to find many more recent introductions 
like the "Class D", which reunites the STE2 GPCRs containing a large amount of 
hydrophobic residues grouped into seven domains, the "Class E" to which belongs the 
cAMP receptors and the "Class F" which comprises GPCR 
Frizzled/TAS2.[38] 
Almost half of the drugs currently registered exerts its 
therapeutic effect by binding to GPCRs, but the target 
receptors are limited to about thirty, over a total of thousand, 
and only few of these are peptide-activated. A lot of drugs 
used today binds with the hydrophobic transmembrane 
region of the GPCRs, but it’s supposed that the majority of 
extracellular peptidic ligands interact primarily with the 
extracellular loops or with the N-terminal domain of the 
GPCR. For these reasons, a better knowledge of the protein-
protein interactions, which are usually very complex and 
involve large surface areas, it’s important to design new drugs 
that are able to interact at the best with these receptors.[39] 
                                               
[38] (a) Attwood T.K., Findlay J.B. “Fingerprinting G-protein-coupled receptors” Protein Eng. 1994, 7 (2), 195–203. (b) 
Dann C.E., Hsieh J.C., Rattner A., Sharma D., Nathans J., Leahy D. J. “Insights into Wnt binding and signaling 
from the structures of two Frizzled cysteine-rich domains” Nature, 2001, 412, 86–90. (c) Foord S.M., Bonner T.I., 
Neubig R.R., Rosser E.M., Pin J.P., Davenport A.P., Spedding M., Harmar A. “J. International Union of 
Pharmacology. XLVI. G protein-coupled receptor list” Pharmacol. Rev. 2005, 57 (2), 279–88. (d) Kolakowski L.F. 
Jr. “GPCRDb: a G-protein-coupled receptor database” Receptors Channels, 1994, 2 (1), 1–7.  
[39] Tyndall J.D.A., Pfeiffer B., Abbenante G., Fairlie D.P. “Over one hundred peptide-activated G Protein-Coupled 
Receptors recognize ligands with turn structure” Chem. Rev. 2005, 105, 793-826. 
Figure 13. The bovine 
rhodopsin GPCR. 
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Since few three-dimensional structure of a GPCR (the photoactivated bovine rhodopsin 
reported into Figure 13) are currently known, and only in its inactive state, the 
development of drugs that interact with G protein-coupled receptors is heavily based 
on ligand-based drug design. This strategy considers the structure of certain known 
ligands, basing the design of the new drug on these, rather than on the structure of the 
GPCR, less easy to interpret. Analyzing the main ligands for a wide range of GPCRs can 
be observed an universal recognition element: the reverse turn motif, generally adopted 
in solution by these ligands and closely associated with the binding capacity and 
therefore with the bioactivity. 
In contrast with -helices and -sheets, turns are irregular secondary structures, sites 
where the polypeptidic chain turns down on itself and also responsible for the 
globularity of the proteins. In particular, -turns are a specific secondary structure motif 
which is commonly recognized by most of the GPCRs family. 
The geometric characteristics observed for a structure which can actually be considered 
as a good -turn mimic are: dα distance between Cα atoms of the first and last residue 
respectively; the absolute value of the virtual torsion angle  defined as C(1)-Cα(2)-Cα(3)-
N(4) and the presence of the characteristic hydrogen bond C(1)O…HN(4). 
The usually adopted classification criterion was proposed by Ball and co-workers. 
According to that, each tetrapeptidic sequence in which the distance Cα(1)-Cα(4) appears 
to be less than 7 Å and in a region that lacks of 
-helices, may be described as a -turn.[40] The 
specific type of -turn (Figure 14) is then 
classified according to the peptide geometry. 
The geometric characteristics observed for a 
structure which can actually be considered as 
a good β-turn mimic are: dα distance between 
Cα atoms of the first and last residue 
respectively; the absolute value of the virtual 
torsion angle  defined as C(1)-Cα(2)-Cα(3)-N(4) and the presence of the characteristic 
hydrogen bond C(1)O…HN(4). 
                                               
[40] Ball J.B., Hughes R.A., Alewood P.F., Andrews P.R. “-turn topography” Tetrahedron, 1993, 49 (17), 3467-3478 
Figure 14. -turn parameters. 
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Figure 15.-turn structure. 
 
Although there are slight variations in the -turn classification of based on the torsion 
angles φ and ψ, similar distributions of -turns were identified, as well as a large 
number (30-50%) of non-ideal or distorted -turns (usually defined as -turns having 
only one torsion angle that differs by 45-50° from ideal values) and one or more 
categories not well defined (types VI and VII). In type I and type II β-turn peptide 
skeleton adopts an “U-shaped” conformation. These motifs are characterized by specific 
angular and torsional parameters in addition to an important 10-membered 
intramolecular H-bond that orient two peptide units from each end. It’s so possible, 
with the synthesis of structurally constrained dipeptides, mimic the scaffold structure of 
the natural -turns in a given target molecule, exploiting two features of the 
peptidomimetic (an amine group and a carboxylic group) to replicate the constriction 
deriving from the hydrogen bond. The presence of substituent functional groups on the 
chosen ring as base system or the presence within it of heteroatoms provide another 
opportunity for diversification. The nature of these substituents can be varied to direct 
the hydrophobic or hydrophilic interactions in the molecule in order to maximize the 
affinity for the biological target. There is a clear evidence that shows how the side chain 
of the peptide is often extremely important in the peptide-receptor interactions.  
Today there is a growing interest towards this type of peptidomimetics since it was 
established that the conformational constriction has an important role in the biological 
activity of peptides, making them more potent agonists or antagonists against certain 
receptors. There is also a net gain in terms of specificity and stability against organic 
proteases. In this way it’s possible to overcome most of the problems in the therapeutic 
use of these molecules. These mimetics may also be interesting for the conformational 
study of the ligand-receptor system and the bioactive structure. 
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In the next chapters I will present the thesis goal based on the information gathered. 
This work concerns the synthesis of peptidomimetics, some of them possessing a 
specific reverse-turn conformation, as potentially active ligands for well defined GPCRs 
and proteases. Peptidomimetics’ strategy relies on three main ideas which can be 
summarized into three concepts: -amino acids based, conformational restriction 
through side chain cyclization and secondary structure inducers. 
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2.1 Opioid Receptors 
 
The opioid receptors,[41] belonging to the class of GPCRs, are widely distributed in the 
nervous system and in the peripheral tissues of animals. An accurate evaluation at the 
molecular level of the ligand binding pathways into these receptors may play a key role 
in the design of new molecules with more desirable properties and reduced side effects. 
Agonists of these receptors have the ability to attenuate the acute and chronic pain, 
while antagonists may alleviate the reliance on opiate alkaloids and alcohol; they can be 
used as immunosuppressants after transplantation and are effective in the treatment of 
autism and the Tourette syndrome.[42] Gene disruption studies in mice show that the 
target for the majority of the effects of opioid alkaloids, whether beneficial or adverse, is 
the -OR2. The -OR belongs to the  subfamily of “Class A” G-protein-coupled 
receptors with two closely related family members known as the - and -opioid 
receptors. The -OR constitutes the main opioid target for the management of new drug 
candidates. 
The opioid receptors are divided into three classes: δ, μ and κ, which differ for the bond 
profile with the ligand molecule. Morphine and codeine are the main active opioid 
alkaloids in opium and they possess an high affinity with almost no selectivity over all 
opioid receptors. Whereas the endogenous opioid ligands of mammals as enkephalin, 
endorphins and dynorphin, are not particularly selective in respect of the different 
classes of receptors, but endomorphin and deltorphin are respectively μ- and δ-
selective, with a high biological stability and the ability to cross the blood-brain barrier. 
These peptides are then the starting point for a drug design leading to the preparation 
of analogous molecules with agonist or antagonist activity respect to these receptors. 
However, opioid drugs are highly addictive, with the acetylated form of morphine, 
heroin, being the best-known example. Because of this, the clinical efficacy of opioid 
drugs is often limited by the development of tolerance and dependence. 
The first example of synthesis of a selective antagonist of receptor δ has involved the 
replacement, within peptides derived from the amphibian skins, of the amino acid in 
position two with a Tic skeleton. This allows for the generation of short-chain peptides 
with a total selectivity towards the δ receptors. These peptides show a lot of advantages 
such as low molecular weight, the ability to cross the blood-brain barrier, a limited 
number of conformations and a good resistance towards the proteolytic degradation. 
                                               
[41] Stevens C.W. “The evolution of vertebrate opioid receptors” Front. Biosci. 2009, 14, 1247–1269 
[42] Masakazu E. “Recent advances in selective opioid receptor agonist and antagonist”, Med. Res. Rev. 2004,  24 (2), 
182-212 
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Starting from these results the tetrahydroisoquinolinic skeleton assumed a lead role in 
the study of strategies for the synthesis of opioid receptors structure. 
Given the importance of DOR, MOR, and KOR in modulating opioid analgesia, it comes 
as no surprise that they have been the subject of intense research for developing potent 
opioid analgesics with fewer unwanted side effects. These side effects include sedation, 
euphoria, changes in thermoregulation, inhibition of gastrointestinal motility, 
respiratory depression, muscle rigidity and physical dependence. 
However, to better understand the structural basis for MOR function, very recently a 
crystallographic study of this receptor has been performed.[43] In Figure 16 is reported 
the overall view of the mouse MOR complexed with an irreversible morphinan agonist. 
This discovery is going to modify the entire drug discovery approach towards new 
analgesics. Shifting from a ligand-based drug design, established for the past decades 
on SAR studies, supported by deep computational and NMR-based conformational 
analysis, to a structure-based drug design, assisted by a more reliable and effective 
docking study, a useful tool for prediction in computer aided drug design (CADD).   
 
Figure 16. Overall view of the -OR structure bound to morphinan. 
 
                                               
[43] (a) Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Mathiesen J.M., Sunahara R.K., Pardo L., Weis W.I., Kobilka 
B.K. Granier S. “Crystal structure of the -opioid receptor bound to a morphinan antagonist” Nature, 2012, 485, 
321-327 (b) Granier S., Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Weis W.I., Kobilka B.K. “Structure of the 
-opioid receptor bound to naltrindole” Nature, 2012, 485, 400-404 
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Surprisingly MOR crystallizes as a dimeric structure, this suggests that the association 
may represent a higher-order oligomer in mammals. Consistent with a role for 
oligomerization in MOR function, the authors observed that the amino acids involved 
in the dimer interface display a high degree of homology with the DOR. Replacing the 
residues of MOR with the corresponding residues from DOR would not be predicted to 
interfere with dimer formation. This  analysis also suggests that a -OR–-OR dimer 
could share the same interface. Interestingly, in the -OR TM5–TM6 dimer, the two 
binding sites are coupled through a network of packing interactions at the dimeric 
interface. This network could provide a structural explanation for the distinct 
pharmacological profiles obtained for -OR heterodimers and for the allosteric effects of 
one protomer on the pharmacological properties of the other. This dimeric interface 
thus provides potential insights into the mechanism of allosteric regulation of one 
GPCR protomer by the other. 
These crystallographic data are very recent and, till now, not yet exploited for 
computational design. During next years, these worthy piece of information will be the 
starting point for drug candidates screening and for a much more faithful structure-
activity relationship investigation. 
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2.2 Endomorphins 
 
Among the endogenous peptides active towards GPCRs, in particular opioid receptors, 
there are several small molecules recently discovered: Endorphins, Endomorphins, 
Enkephalins, Dynorphin or Nociceptin. They are all involved in the pain perception 
biological process. In particular, Endomorphins are small tetrapeptide isolated from 
mammalian brain in 1997.[44] Endomorphins are two derivative which differ for the 
third residue, in EM-2 the Trp is replaced by a Phe. 
Endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2, EM-2) is a highly potent and selective -
opioid receptor agonist neuropeptide. The amidated Endomorphin-2 (EM-2) 
tetrapeptide has been shown to be -opioid receptor 
agonist exhibiting a very high -receptor affinity and 
selectivity.[45] Because of the C-terminal amidation, 
EMs display the longest proteolytic half-lives among 
the known endogenous opioid peptides.  
Metabolism of EMs is first the cleavage of Pro2-Trp3 
and Pro2-Phe3 peptide bonds by the intervention of 
Serine Proteases. This family of proteolytic enzyme is 
known to metabolize most of the proline based 
neuropeptides. Among this family, Prolyl 
OligoPeptidease (POP) has been implicated in many 
physiological processes and is supposed to play a role 
in EMs metabolism.[46] 
 Since the -opioid receptor agonists display the most 
potent antinociceptive activity, EM-2 is an important 
model in the search towards new analgesics. Despite 
of the recent advances in the structural investigation 
of complex molecules, the comprehension of the 3D 
features for the interaction between opioid peptides and receptors remains an elusive 
task. This has to be attributed to the opioid peptides’ nature which can assume different 
conformations and to opioid receptors’ flexibility. Due to this inherent mobility of the 
ligand-receptor system massive efforts devoted to the definition of a rigid bioactive 
                                               
[44] Zadina J.E., Hackler L., Ge L.J., Kastin A.J. “A potent and selective endogenous agonist for the μ-opiate receptor” 
Nature, 1997, 386, 499-502  
[45] Horvath G. “Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous -opioid receptor 
agonists” Pharmacology & Therapeutics, 2000, 88, 437-463 
[46] Garcia-Horsman J.A., Mannisto P.T., Venalainen J.I. “On the role of Prolyl Oligopeptidase in health and disease” 
Neuropeptides, 2007, 41, 1-24 
Figure 17. Endomorphins. 
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conformation might be overstressed.[47] Structural investigation of EM-2 reveals the high 
conformational freedom of the Phe side chains and also the inherent flexibility of the 
peptide backbone, indicating many probable bioactive conformations, ranging from -
turns to extended conformations.[28,48] The relevant role of the proper spatial orientation 
of the aromatic rings and in particular of the benzylic side chains at position 3 and 4 is 
well established, but not fully clarified.  
Three main structural features must be undisclosed: the “message-address” concept, the 
pharmacophore elements and the cis-trans isomerisation about the Tyr1–Pro2 peptide 
bond.[49] 
EMs can be divided into two main portion: the message fragment are the N-terminal 
Tyr1-Pro2-Trp3 and Tyr1-Pro2-Phe3 tripeptide units. The address fragment is the 
remaining C-terminal Phe4-NH2 peptide. These two sequences play a key role in the 
molecular recognition and binding event. The 3D structure of the message fragment is 
supposed to contribute to the bioactive conformation and to the binding process. On the 
other hand the message fragment might contribute to the structural stability and to the 
selectivity. 
The pharmacophore unit are mainly related to hydrophobic interaction of the aromatic 
ring, the hydroxyl function of Tyr1 and the amine which interacts with Asp147. Pro2 is 
considered to be a stereochemical spacer and is responsible for the correct orientation of 
the pharmacophore groups.[50] Moreover is responsible to induce a cis-trans 
isomerisation. 
Indeed, these tetrapeptides exist as an equilibrium mixture between the two isomers. 
The interconversion barrier is sufficiently low to allow a reversible conformational 
transition. The ratio of the two isomers depends on the solvent, but the trans- 
conformation is considered to be the bioactive form.  
  
                                               
[47] Gentilucci L., Tolomelli A. “Recent Advances in the Investigation of the Bioactive Conformation of Peptides 
Active at the -opioid Receptor. Conformational Analysis of Endomorphins” Curr. Top. Med. Chem. 2004, 4, 105-
121 
[48] (a) Torino D., Mollica A., Pinnen F., Feliciani F., Lucente G., Fabrizi G., Portalone G., Davis P., Lai J., Ma S.W., 
Porreca F., Hruby V.J. “Synthesis and Evaluation of New Endomorphin-2 Analogues Containing (Z)-α,β-
Didehydrophenylalanine (ΔZPhe) Residues” J. Med. Chem. 2010, 53, 4550-4554 (b) Keresztes A., Szu cs M., Borics 
A., Kövér K.E., Forró E., Fülöp F., Tömböly C., Péter A., Páhi A., Fábián G., Murányi M., Tóth G. “New 
Endomorphin Analogues Containing Alicyclic β-Amino Acids: Influence on Bioactive Conformation and 
Pharmacological Profile” J. Med. Chem. 2008, 51, 4270-4279 
[49] Leitgeb B. “Structural Investigation of Endomorphins by Experimental and Theoretical Methods: Hunting for the 
Bioactive Conformation” Chem & Biodiv. 2007, 4, 2703-2724 
[50] Paterlini M.G., Avitable F., Ostrowski B.G., Ferguson D.M., Portoghese P.S. “Stereochemical requirements for 
receptor recognition of the mu-opioid peptide endomorphin-1” Biophys. J. 2000, 78, 590-599 
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2.2.1. Endomorphins Mimics: State of the art 
 
During the past years a lot of efforts have been spent in the synthesis of EMs analogues 
with the aim to achieve a better structure-activity information.[51] 
Modifications at Tyr1- and N-terminal positions require caution because of their 
pharmacological relevance.[52] Usually the phenolic moiety is kept intact while 
alkylation of the Tyr1 aromatic ring is quite usual. The most exploited Tyr mimic is Dmt 
(dimethyl tyrosine) which showed in many cases a maintenance for opioid receptor 
affinity because of a better hydrophobic interaction in the binding pocket.[53]  
  
Figure 18. General structural features for EM-1 (EM-2). 
Regarding Pro2, modifications have been performed with the aim of a better proteolytic 
stability and to force the Tyr1 pharmacophore residue in a specific 3D conformation. 
Replacement with unnatural D isomer (D-Pro2) lead to a remarkable longer half-life and 
a new 3D shape of the molecule. However, an extensive investigation using -Pro 
derivative has been performed.[54] Moreover -Pro offers a good systematic 
                                               
[51] Keresztes A., Borics A., Toth G. “Recent Advances in Endomorphin Engineering” Chem. Med. Chem. 2010, 5, 1176-
1196  
[52] Szatamari I., Biyashev D., Tomboly C., Toth G., Macsai M., Szabo G., Borsodi A., Lengyel I. “Influence of 
degradation on binding properties and biological activity of endomorphin-1” Biochem Biophys. Res. Commun. 
2001, 284, 771-776 
[53] (a) Li. T., Fujita Y., Tsuda Y., Miyazaki A., Ambo A., Sasaki Y., Jinsma Y., Bryant S.D., Lazarus L.H., Okada Y. 
“Development of potent -opioid receptor ligands using unique tyrosine analogues of Endomorphin-2.” J. Med. 
Chem. 2005, 48, 586-592 (b) Jinsmaa Y., Marczak E., Fujita Y., Shiotani K., Miyazaki A., Li T., Tsuda Y., Ambo A., 
Sasaki Y., Bryant S.D., Okada Y., Lazarus L.H. “Potent in vivo antinociception and opioid receptor preference of 
the novel analogue [Dmt1]Endomorphin-1” Pharmacol Biochem Behav. 2006, 84, 252-258 
[54] Fulop F., Martinek T.A., Toth G.K. “Application of alicyclic β-amino acids in peptide chemistry” Chem. Soc. Rev. 
2006, 35, 323-334 
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manipulation tool for EMs secondary structure depending on the absolute and relative 
configuration; inducing a bent structure instead of an extended one. A very recent work 
exploited this strategy and the author were also able to preferentially induce a trans- 
conformation around the Pro2 peptide bond.[55] On the other hand, a systematic study 
on the ring size of the Pro and its stereochemical configuration showed analogues with 
a very high affinity and selectivity towards MOR.[48b] 
A contemporary double replacement of the dipeptide Tyr1-Pro2 with Dmt-Pro and 
other isomers displayed, in one case, one of the highest MOR affinities ever observed, in 
the very low nanomolar scale. Apparently, active compounds substituted by a Pro 
prefer a bent conformation instead of an extended structure.[56] 
Summarizing, Pro-targeting single and multiple modifications result in proteolytically 
stable analogues and maintaining, in most cases, a biological activity comparable to 
EM-1 and EM-2. 
 
Figure 19. Proline based amino acids incorporated in place of Pro2. 
 
The last point of functionalization is the Phe3-Phe4 residue bearing the carboxy amide 
pendant. I reported previously some common example for Phe replacement. It’s very 
important to remember that Phe3 aromatic ring is mandatory for MOR binding. 
Furthermore, the aromaticity cannot be replaced by an hydrophobic ring such as 
cyclohexil. Application of the Phe mimetic Phg and Hfe at position 3 and 4 resulted in 
equally or less potent analogues relative to EM-2.[57] In general has been observed that 
the presence of an hydrophobic aromatic ring is highly recommended for maintaining a 
good opioid affinity, while the proper spatial orientation might reach a low nanomolar 
interaction and a higher selectivity. Incorporation of -MePhe at either position 3 or 4 
alterates the population of rotamers and involves the research for the most suitable 
                                               
[55] Borics A., Mallareddy J.R., Timari I., Ko v r K.E., Keresztes A., Tóth G. “The Effect of Pro2 Modifications on the 
Structural and Pharmacological Properties of Endomorphin‑2” J. Med. Chem. 2012, 55, 8418-8428 
[56] Mallareddy J.R., Borics A., Keresztes A., Ko v r K.E., Tourw  D., Tóth G. “Design, Synthesis, Pharmacological 
Evaluation, and Structure-Activity Study of Novel Endomorphin Analogues With Multiple Structural 
Modifications” J. Med. Chem. 2011, 54, 1462-1472 
[57] Gao Y., Liu X., Liu W., Qi Y., Liu X., Zhou Y., Wang R. “Opioid receptor binding and antinociceptive activity of 
the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3 or 4” Bioorg. 
Med. Chem. Lett. 2006, 16, 3688-3692 
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diastereomeric couple.[58] Author observed that only the replacement of Phe4 with the 
(2S,3S)--MePhe lead to peptides which exhibited MOR affinities higher than parent 
endomorphins 1 and 2, also increasing enzymatic stability. 
A systematic study on the aromatic ring spatial orientation was performed by 
constraining Phe side chains with dehydrophenylalanine in configuration Z 
alternatively at position 3, 4 or both.[48a] This work suggests that Phe3 aromatic ring 
requires a certain flexibility and the conformationally constrained Phe4 inducing an 
extended conformation. 
With the aim of contemporary replace the Pro2-Phe3 portion of EM-2, Tourwé and co-
workers exploited a well known conformationally constrained Phe mimic, that is spiro-
Aba.[28] Secondly, such substitution in a very small tetrapeptide was able to block the 
trans-conformation around Tyr1-Pro2 bond and also to induce a stable -turn. The small 
library of synthesized analogues, possessing different configuration, revealed to be 
slightly active, only with the Tyr-(R)-spiro-Aba-Gly-Phe-NH2 derivative. However it 
showed a high selectivity toward MOR.  
Phe4 is a critical part of the address sequence as well. The aromatic ring is required for 
binding and EMs analogues without an hydrophobic aromatic residue, properly 
oriented, suffers a lower potency. However, the C-terminal amide has been deeply 
modified in order to understand its possible implication in the binding process. 
Comparison of the binding results revealed that a polar function maintains or increases 
the affinity while a bulky or non-polar termination does not favor MOR binding.[59] 
Surprisingly, the exploitation of -amino acids for Trp or Phe replacement has been 
poorly investigated. The main reason relies on the poor biological results obtained so 
far. Gentilucci and co-workers systematically replaced each amino acid of EM-1 with a 
-Xaa or -homo-Xaa.[60] This strategy allowed to obtain a series of derivative which 
displayed a good proteolytic stability, an extensive pharmacokinetic study supports this 
statement, whereas the MOR affinity in the nanomolar range was comparable to 
reference only for -L-hPro2 containing peptidomimetic. Same approach was not 
                                               
[58] Tomboly C., Kover K.E. Antal P., Tourwé D., Biyashev D., Benyhe S., Borsodi A., Al-Khrasani M., Ronai A.Z., 
Toth G. “Structure-Activity Study on the Phe Side Chain Arrangement of Endomorphins Using 
Conformationally Constrained Analogues” J. Med. Chem. 2004, 47, 735-743 
[59] Wang C., Yao J., Yua Y., Shao X., Cui Y., Liu H., Lai L., Wang R. “Structure–activity study of endomorphin-2 
analogues with C-terminal modifications by NMR spectroscopy and molecular modeling” Bioorg. Med. Chem. 
2008, 16, 6415-6422 
[60] (a) Cardillo G., Gentilucci L., Melchiorre P., Spampinato S. “Synthesis and Binding Activity of Endomoprhin-1 
Analogues Containing -Amino Acids” Bioorg. Med. Chem. Lett. 2000, 10, 2755-2758 (b) Cardillo G., Gentilucci L., 
Qasem A.R., Sgarzi F., Spampinato S. “Endomorphin-1 Analogues Containing -Proline are -Opioid Receptor 
Agonists and Display Enhanced Enzymatic Hydrolysis Resistance” J. Med. Chem. 2002, 45, 2571-2578 
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employed in the synthesis of EM-2 mimetics, probably due to the lack of encouraging 
results. 
In this biological and chemical context, we started our research conjugating different 
ideas in order to synthesize EM-2 analogues possessing three main features. They 
should be -amino acid based, with a proteinogenic like side chain. So we focused our 
attention to 2-hPhe and 3-hPhe. Moreover, they present a conformational restriction 
on the corresponding Phe4 portion, to possibly induce a preferential turn conformation, 
and not constrained on Phe3 because of previous mimics synthesized by Hruby and co-
workers which displayed a decrease in potency. In comparison to other research 
groups, we also planned to simultaneously replace the Phe3-Phe4 portion of EM-2 and to 
give a synergic positive effect to the resulting analogues library. Working on both the 
residues, we were able to specifically tune relative aromatic ring distance and spatial 
orientation due to the stereochemical configuration and conformational restriction.  
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2.3 Computational Design 
Focusing our attention on 2-hPhe- and 3-hPhe-based dipeptide mimics, a computer-
assisted conformational analysis was performed[61] on compounds 1-4, in order to 
evaluate the reverse turn-like mimicry, bearing in mind that an important feature in 
stabilizing the reverse turn conformation is the presence of intramolecular hydrogen 
bonds. For homodipeptide segments, two hydrogen bonded rings can in principle be 
formed, with hydrogen bond directionalities that run in normal direction (4-1, 12-
membered hydrogen bond) and reversed direction (1-2, 10-membered hydrogen bond). 
According to the literature, a 2-aa-3-aa segment should favor folding with formation 
of a 10-membered hydrogen-bonded ring. On the other hand, a 3-aa-2-aa segment 
should stabilize 12-membered hydrogen-bonded conformations. 
The computational procedure consisted in an unconstrained Monte Carlo/Energy 
Minimization conformational search using the molecular mechanics MMFF94 force 
field,[62,63] in vacuo. For each compound only conformations within 6 kcal/mol of the 
global minimum were kept. Results are reported in Table 1 as percentage of conformers 
which show an intramolecular hydrogen bond. The conformational analysis shows that 
homologated dipeptide derivatives 1 and 3 seem to prefer 8-membered H-bond 
conformations, while constrained segments 2 and 4 are more inclined to reverse turn 
conformations, with prevalence of 12-membered H-bonds in both cases.  
 
                                               
[61] In collaboration with Dr. A. Sacchetti, Politecnico di Milano. 
[62] Halgren T.A. “Merck molecular force field: I. Basis, form, scope, parameterization and performance of MMFF94” 
J. Comput. Chem. 1996, 17, 490-519 
[63] Hydrogen bonds are defined as non-bonded contacts between a nitrogen or oxygen and an hydrogen attached to 
nitrogen or oxygen, separated by a distance ranging from 1.6Å to 2.1Å and making an X-H--Y (X,Y = N,O) angle 
>120°. 
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Figure 20. Dipeptides computer assisted design. 
 
Table 1. Conformers Distribution. 
 
H Bond (directionality) 1a 1b 2a 2b 3a 3b 4a 4b 
n° of conf. < 6Kcal/mol 23 32 29 35 36 41 36 34 
8H Ring (4-2) 11%,# 16% 37% 23% 45%, # 19% 0% 9% 
8H Ring (3-1) 26%,# 19%, # -- -- 17% 19%, # -- -- 
10H Ring (1-2) 0% 3% 0% 3% 0% 2% 0% 0% 
12H Ring (4-1) 4% 16%, # 20% ,# 3%,# 14% 7%, # 25%, # 6%, # 
# H bond present in the energy minimum 
 
Because of these promising data, I planned a synthetic pathway to verify the dipeptides 
secondary structure. Same scaffolds, as methyl esters, were also inserted in EM-2 
tetrapeptide and subjected to biological evaluation. 
General disconnection involves the coupling between two -hPhe monomers protected 
as Boc or methyl ester. Thus the conformational restriction occurs on a single -hPhe 
exploiting a PS cyclization to give a six or seven member ring depending on the 
building block employed.  
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2.4 Synthesis 
 
The target compounds 1-4 were synthesised from the key precursors 3-hPhe and 2-
hPhe. Preparation of variously protected 3-hPhe derivatives 10 and 11 was 
accomplished following the protocol of stereospecific classical homologation of the 
corresponding L-Phe, by means of Kolbe reaction (Scheme 2).[60a] The whole synthetic 
pathway has been optimized and it is column-free until compound 9. Reduction of 
nitrile 9, with contemporary Boc deprotection, occurs under strong acidic condition in 
good chemical yield. Free amine is obtained by basic extraction of AcOEt solution with 
NaHCO3 ss. 
 
 
Scheme 2. Synthesis of 3-hPhe. 
 
Direct Pictet-Spengler condensation on compound 10 to afford 14, does not occur even 
under strong acidic conditions. I suppose that the lack of iminium ion stabilization, 
present in -AAs, is the main reason. Indeed, after protection of the amino group with a 
temporary protective group, stable under acidic conditions (i.e. Cbz), the PS cyclization 
undergoes smoothly in decent yield, using trioxane as formaldehyde source. The 
reaction is followed by Cbz deprotection and allowed us to obtain the homo-Tic 
derivative 14 (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid). 
 
 
Scheme 3. 3-hPhe building blocks preparation. 
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At the very beginning, I also planned to synthesize 3-hPhe derivatives using a faster 
Arndt-Eistert homologation procedure,[64] but the overall yield were not suitable for a 
gram scale synthesis. Mainly because of the usage of TMSCHN2 instead of 
diazomethane. Because of the synthetic issues previously described in the PS cyclization 
step, I also tried the Arndt-Eistert homologation on a Tic protected derivative but it 
seemed completely unreactive under this conditions.[65] 
  
 
Scheme 4. Arndt-Eistert alternative route. 
 
2-hPhe could be obtained in both the enantiomeric forms following an efficient 
protocol developed by Gellman[66] which relies on the synthetic sequence depicted in 
Scheme 5. Key step is the Michael addition of a chiral hydroxylamine to the -
benzylacrylate 22. Procedure has been improved by using just 1 equivalent of precious 
auxiliary at 45 °C instead of 2 eq. at room temperature. The addition is followed by 
cyclization to give a diastereomeric mixture of -substituted isoxazolidinones 24a and 
                                               
[64] Arvidsson P.I., Frackenpohl J., Seebach D. “Syntheses and CD-Spectroscopic Investigations of Longer-Chain -
Peptides: Preparation by Solid-Phase Couplings of Single Amino Acids, Dipeptides, and Tripeptides” Helvetica 
Chim. Acta 2003, 86, 1523-1553 
[65] Cesar J., Dolenc M.S. “Trimethylsilyldiazomethane in the preparation of diazoketones via mixed anhydride and 
coupling reagent methods: a new approach to the Arndt-Eistert synthesis” Tetrahedron Lett. 2001, 42, 7099-7102 
[66] Lee H.S., Park J.S., Kim B.M., Gellman S.H. “Efficient Synthesis of Enantiomerically Pure β2-Amino Acids via 
Chiral Isoxazolidinones” J. Org. Chem. 2003, 68, 1575-1578 
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24b, separable by column chromatography. After hydrogenolytic removal of chiral 
auxiliary and ring opening, 2-hPhe unprotected amino acids were recovered as 
optically pure enantiomers.  
 
 
 
Scheme 5. Synthesis of 2-hPhe. 
 
Derivatives 25a,b were alternatively protected at the acidic or aminic position for 
peptide coupling and afforded 26a,b and 27a,b. Compounds 27a,b were then converted 
to the corresponding Cbz-protected 28a,b and subjected to Pictet-Spengler reaction, 
affording in good yield benzazepines 29a,b. The cyclization is stereoretentive, it 
requires the presence of a stabilizing carbamate and occurs in short time with 
reasonable yield. Cbz group is removed with Pd/C 10% under hydrogen atmosphere in 
six hours, to prevent hydrogenation of the benzylic bond. Longer reaction time showed 
the presence of a toluene derivative, identified by 1H NMR presence of a methyl signal. 
PS cyclization directly on dipeptides worked sluggishly, with lower yields and 
regioselectivity issues to be taken in account. That’s why, in all the examples presented, 
I prepared the cyclized -hPhe and then coupled to a second monomer. Moreover, to 
induce the desired regioselectivity, amino groups have to be protected as imides which 
are not as easy as Boc to be installed and removed. 
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Scheme 6. 2-hPhe building blocks preparation. 
 
With 2-hPhe, 3-hPhe and the corresponding constrained derivatives available, I 
pursuit the synthesis of different dipeptidomimetic scaffolds 31-37, by standard peptide 
coupling chemistry (Scheme 7-8). In addition to the planned constrained and linear 
dipeptides, I also synthesized 3-hPhe-3-hPhe 33 and 36 and 2-hPhe-2-hPhe 37. 
 
 
Scheme 7. Peptide Coupling – Constrained scaffolds. 
 52 
 
 
Scheme 8. Peptide Coupling – Linear scaffolds. 
 
The aim was to extend the chemical space in our -amino acid containing EM-2 
peptidomimetics and evaluate most of the possible combinations. 
I observed, from a preliminary coupling agent screening, that for cyclic derivatives 
BOP-Cl is the most suitable reagent, while for linear one, the cheap and well known 
EDC – HOBt couple is sufficient for reasonable yield. 
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Compounds 31a,b and 32a,b were then converted into methyl amide using a solution of 
methylamine in ethanol. I investigated the secondary structure conformation by 
employing a combination of different techniques and instrumentation: 1H NMR, VT-
NMR and IR. Results will be presented in next paragraph.  
 
 
Scheme 9. Synthesis methyl amides. 
 
With the aim of introducing new modifications in the field of -amino acids 
peptidomimetics I also tried to focus on benzazepinonic scaffolds. This strategy was an 
extension of existing methodologies for the synthesis of -amino acid based 
benzazepinones.[67] The idea was to isolate an intramolecular source of formaldehyde, 
masked as six member ring 1,3-oxazinan-6-one aminal (41), then subject such 
intermediate to a PS cyclization. In order to prevent regioselectivity issues, 2-hPhe 
amino group was doubly protected as imide; reaction conditions for 41 might promote 
a PS cyclization on the same amino acid. So I chose phthalimide as protective group. 
Synthesis of desired linear dipeptide 40 went easily until I tried different reaction 
condition to promote the cyclization.  
                                               
[67] (a) Ballet S., De Wachter R., Bert U.W., Tourw  D. “Derivatization of 1-phenyl substituted 4-amino-2-benzazepin-
3-ones: evaluation of Pd-catalyzed coupling reactions” Tetrahedron, 2007, 63, 3718-3727 (b) Severino B., Fiorino 
F., Esposito A., Frecentese F., De Angelis F., Perissutti E., Caliendo G., Santagada F. “Efficient microwave-
assisted synthesis of 4-amino-2-benzazepin-3-ones as conformationally restricted dipeptide mimetics” 
Tetrahedron, 2009, 65, 206-211  
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Scheme 10. Benzazepinones synthesis. 
 
Unfortunately, ring closure on a dipeptide skeleton was not straightforward, specially 
for Phe analogues. We were warned of possible synthetic difficulties because of recent 
literature discoveries,[68] where the six member ring oxazinanone formation was 
difficult, with low yields even on a single amino acid. Applying the same approach 
used for oxazolidinones,[67b] I was unable to isolate any product corresponding to 
compound 41. Starting material was recovered unreacted in most cases. Aldehyde 
sources exploited were paraformaldehyde and trioxane, in presence of molecular sieves 
4Å. Protic acids exploited to promote the intramolecular cyclization were CSA, pTSA, 
TFA and TfOH. 
 
  
                                               
[68] (a) Govender T., Arvidsson P.I. “Facile Synthesis of FmoC N-methylated - and - amino acids” Tetrahedron Lett. 
2006, 47, 1691-1694 (b) Hughes A.B., Sleebs B.E. “Effective Methods for the Synthesis of N-Methyl -Amino 
Acids from All Twenty Common -Amino Acids Using 1,3-Oxazolidin-5-ones and 1,3-Oxazinan-6-ones” 
Helvetica Chim. Acta, 2006, 89, 2611-2637 
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2.5 Conformational Analysis 
 
Conformational analysis on compound 2a,b and 4a,b was performed in order to verify 
if such structures were able to induce reverse turn secondary conformation as good as 
predicted by computational study. 1H NMR spectra were recorded in the polar aprotic 
CH3CN-d3 solvent and all analyses were performed on 2.0 mM solutions, that is, in the 
absence of a significant aggregation. To ascertain if amide protons are involved in 
intramolecular hydrogen bonds, the 1H NMR chemical shifts of the amide protons and 
their temperature dependence () have been evaluated. Even if NMR studies were 
made complicated by the presence of multiple rotamers in solution, an essential 
extended conformation could be deduced for compounds 2a,b, while a situation of 
equilibrium between extended and 12-membered H-bonded conformations could be 
invoked for 4a and, to a less extent, for 4b. IR analyses seems to confirm such attitudes. 
 
 
Figure 21. IR Spectrum of 2a. 
 
The IR spectrum of 2a exhibits a shoulder at 3350 cm-1 (hydrogen-bonded state) together 
with a band at 3433 cm-1 (non-hydrogen-bonded state).  This observation suggests an 
extended conformation in solution for these small dipeptides. Same conclusions were 
drawn for analogue 2b. These piece of information were in agreement with NH 1H 
NMR chemical shift, in fact the amidic proton were found in a range between 6.5 and 
6.0 ppm. Such chemical shift, < 7.0, is significant of a non-hydrogen bonded amide 
proton.[69] NH-Boc amidic proton was not predicted for any hydrogen bonded state, 
indeed its chemical shift was below 6  ppm. 
                                               
[69] Lesma G., Meschini E., Recca T., Sacchetti A., Silvani A. “Synthesis of tetrahydroisoquinoline-based 
pseudopeptides and their characterization as suitable reverse turn mimetics” Tetrahedron, 2007, 63, 5567-5578 
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On the other hand, IR analysis of compounds 4a,b exhibited a similar pattern, even if 
the conformational equilibrium is more balanced and the presence of a hydrogen 
bonded state is more evident. The IR spectrum of 4b exhibits a shoulder at 3350 cm-1 
(hydrogen-bonded state) together with a band at 3433 cm-1 (non-hydrogen-bonded 
state).   
 
Figure 22. IR Spectrum of 4b. 
 
I also performed a VT-NMR analysis on compound 4b because the IR spectrum was 
promising. The temperature dependence of amidic protons (two conformers) observed 
is -2.2 ppb/K for the major conformer and -4.5 ppb/K for the minor conformer. This 
variation, related to the NH chemical shift of 6.64 ppm, is in agreement with an 
equilibrium state between extended and reverse turn conformation. The amidic proton 
is then involved in a 12 membered ring. 
 
 
Figure 23. VT-NMR for NH-Me (CD3CN, 2mM, 4b). 
 
We reasoned that the propensity of compounds of type 2 to induce a well defined 
folded structure could be better evaluated in , hybrid tetrapeptide mimics. I pursuit  
the synthesis of 43 (Figure 24), adding two L-alanines to starting compound 31a, by 
standard peptide chemistry (Scheme 11). We chose to elongate 31a, bearing R,S 
configuration, because it was predicted by computational analysis to be more prone to a 
12 membered intramolecular H-bond, favouring folded conformation, than parent 
compound 2b. 
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Figure 24., hybrid tetrapeptide 43. 
 
Table 2. Conformers Distribution. 
 
H Bond 2a (R,S) 2b (S,S) 43 
8H Ring 37 % 23 %  
10H Ring 0 % 3 %  
12H Ring 20 % 3 % 88 % 
16H Ring   100 % 
 
 
 
Scheme 11. Synthesis of 43. 
 
NMR analysis on 43 revealed an intramolecular hydrogen-bonded state for N-H2, 
supported both by downfield chemical shift (7.47 ppm at room temperature) and by a 
reasonably low temperature dependence (-3.8 ppb/K). (Figure 25)  
The presence of an interstrand n.O.e. contact between Boc and Me terminal groups also 
strongly supports a folded conformation for 43, most likely involving a 10-membered 
H-bonded ring.  
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Figure 25. VT-NMR for N-H2 (CD3CN, 2mM, 43). 
 
Finally, the CD spectrum of 43, measured in methanol, displays a quite similar behavior 
with respect to literature data[70] pertinent to 2-aa-3-aa segment containing 
peptidomimetics.  
 
 
Figure 26. CD spectrum of 43. 
 
The reverse turn conformation can be figured out from the CD spectrum of 43 (MeOH, 
2 mM) which indicates the typical wavelengths of a 2-Xaa-3–Xaa backbone assuming 
such secondary structure:  
  Minimum at 212 nm  
  Maximum at 215 nm  
  Minimum at 220 nm  
 
  
                                               
[70] Seebach D., Jaun B., Sebesta R., Mathad R.I., Flogel O., Limbach M., Sellner H., Cottens S. “Synthesis, and Helix 
or Hairpin-Turn Secondary Structures of ‘Mixed’ α/β-Peptides Consisting of Residues with Proteinogenic Side 
Chains and of 2-Amino-2-methylpropanoic Acid (Aib)” Helv. Chim. Acta, 2006, 89, 1801-1825 
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2.6 Biological Evaluation 
 
Starting from dipeptides 31-37, endomorphin-2 analogues were obtained by 
functionalization of the carboxy terminal moiety with isobutyl chloroformate and 
ammonia, followed by peptide coupling with Tyr-Pro, in presence of condensating 
agent, and then isolated as TFA salts.[71] 
Peptidomimetics based on 2hPhe-3hPhe scaffolds were synthesized in a first time, 
while 3hPhe-2hPhe containing scaffolds were prepared as a consequence of the 
preliminary biological results obtained. In this “second generation” family, I expanded 
the conformational space by synthesizing analogues bearing the same substitution 
pattern, 3-3 and 2-2 like compounds 53 and 54. These combinations provide an 
further source of investigation in the aromatic rings distance analysis. 
  
 
Scheme 12. EM-2 Analogues – First Generation. 
 
                                               
[71] In Collaboration with Prof. Gianfranco Balboni – Università degli Studi di Ferrara. 
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Scheme 13. EM-2 Analogues – Second Generation. 
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The new endomorphin-2 analogues were evaluated for their affinity and selectivity for 
- and - opioid receptors using Chinese hamster ovary (CHO) cell membranes stably 
expressing the opioid receptors. The data are summarized in Table 3 and 4. The new 
compounds 48b and 49a, despite the important modifications at their C-termini 
maintained a significant affinity especially for  receptors; their affinities for this 
receptor increased of more than 2 order of magnitude.[72] On the other hand the  
affinity decreased 100 (48b) and 30 fold (49a) in comparison to the reference EM-2.[73] 
Considering the difficulty to obtain endomorphin analogues able to maintain opioid 
affinity, here I report for the first time the synthesis of new derivatives in which the C-
terminal Phe-Phe dipeptide is simultaneously substituted by a peptidomimetic 
structure with the maintenance of opioid affinity. This type of modification is able to 
completely abate the high  selectivity of EM-2 providing compounds endowed with a 
little preference for - receptors. On the basis of very simple considerations about the 
stereochemical configuration of these EM-2 analogues, their activities seem to be 
correlated to the spatial disposition of the third Phe side chain. 
 
Table 3. Opioid Receptor Binding Affinities and Selectivities of EM-2 Analogues.a 
 
Compounds 
Selectivity Affinity - Ki (nm)  SEM 
Ki /Ki Ki /Ki [3H]DAMGO () [3H]Ile5,6Dt-2 () 
EM-2 6.1*10-4 1630 3.24  1.05 5280  1257 
48a 0.97 1.03 1001  222 1034  254 
48b 7.65 0.13 338  37 44.2  17.1 
49a 2.13 0.47 102  28 47.8  22.7 
49b 1.04 0.96 1652  885 1589  299 
 
a Receptor binding data are presented as the means ± SEM of two or three independent assays. 
[3H]DAMGO as  ligand and [3H]Ile5,6-deltorphin-2 as  ligand were used. 
 
The second series of EM-2 mimics was evaluated for DOR and MOR affinities in 
radioligand binding assays under standard conditions using cloned receptors stably 
                                               
[72] In collaboration with Prof. Engin Bojnik. (Institute  of  Biochemistry,  Biological  Research  Centre,  Hungarian 
 Academy  of  Sciences, Szeged) 
[73] Lesma G., Salvadori S., Airaghi F., Bojnik E., Borsodi A., Recca T., Sacchetti A., Balboni G., Silvani A. “Synthesis, 
Pharmacological Evaluation and Conformational Investigation of Endomorphin-2 Hybrid Analogues” Mol. 
Divers. 2012, DOI: 10.1007/s11030-012-9399-5 
 62 
expressed on Chinese hamster ovary (CHO) cells and [3H]DPDPE (cyclo[D-
Pen2,DPen5]enkephalin) and [3H]DAMGO ([D-Ala2,NMePhe4,glyol5-enkephalin), 
respectively, as the radioligands.[74] 
 
In Table 4 are reported the biological results. 
 
Table 4. Opioid Receptor Binding Affinities and Selectivities of EM-2 Analogues. 
 
Compounds 
Selectivity Affinity - Ki (nm) 
Ki /Ki Ki /Ki [3H]DAMGO () [3H]DPDPE () 
EM-2 0.002 639 5.3 3385 
50a 0.03 33 21 695 
50b 0.075 13 14 187 
51a 0.004 245 5.5 1347 
51b 0.007 140 3.3 463 
52 0.012 83 20 1650 
53 0.007 147 19 2798 
54 0.011 9 101 922 
 
With regard to 50-54, relying on preliminary data, these compounds show a very good 
affinity towards -opioid receptor, in the low nanomolar scale for the most active 51a 
and 51b. In particular, molecule 51a has almost the same affinity and selectivity of the 
reference compound. For an EM-2 analogue with multiple structural modifications in 
the Phe-Phe portion, a such high -opioid affinity and selectivityis rather 
uncommon. Other compounds shows a good nanomolar affinity and selectivity 
towards -opioid receptor, but one order of magnitude less than EM-2. Less potent 
derivative is 54 which is 2 orders of magnitude less active than reference. 
Surprisingly the conformationally constrained scaffold are not as active as 51a and 51b, 
confirming that the proper aromatic ring distance and spatial orientation are highly 
influencing the binding process, discriminating a potent lead from a completely inactive 
derivative.  
                                               
[74] In collaboration with Prof. Thomas F. Murray. (Department of Pharmacology,  Creighton University School of 
Medicine, Omaha - Nebraska) 
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Structural studies, in particular 2D proton NMR and docking analysis, have been 
performed in order to fully investigate the three dimensional properties of all the 
analogues synthesized. 
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2.7 Structural Study: 1H NMR 
 
Compounds 48a,b and 49a,b were studied in their conformational behavior by means of 
NMR spectroscopy and computational tools. Due to the poor solubility of our 
molecules in apolar solvents, we performed NMR studies in DMSO-d6 solution. This 
solvent offers some additional advantages in studying biologically active molecules 
since it is considered a good physical approximation of transport fluids 
environments.[75] A very recent comparative structural analysis of MOR ligands with 
similar affinity and selectivity confirmed that DMSO may be a better approximation for 
the mechanical and electrostatic environment of binding to the MOR than D2O is. [76] 
Moreover, being a good hydrogen bond acceptor, it induces rather inter- than 
intramolecular interactions, which may reveal intrinsic conformational preferences and 
may mimic the physical circumstances of receptor-ligand interactions. Proton 
resonances were assigned using a combination of COSY, TOCSY, NOESY, ROESY and 
HSQC experiments.[77] (see Table 5)  
The spectra show the presence of two conformers (cis and trans with respect to the Tyr-
Pro peptide bond) for 49a and 49b, and four conformers (two cis and two trans78) for 48a 
and 48b. A higher prevalence of the trans conformers (trans/cis ratio ranging from 2:1 
for 49a,b to mainly trans for 48a,b) has been observed according to the intensities of NH 
peaks in 1H NMR spectra, in line with the reported outcome for the parent EM-2. The 
question whether endomorphins adopt the cis or trans configuration of Tyr-Pro peptide 
bond, when bound to the receptor, is far from being answered. However, relying on 
total energy measurements, it was recently proposed that the trans isomer of EM-2 and 
analogues could be the mainly bioactive form and that the cis isomer is mainly an 
artifact under the solution conditions.[79] 
                                               
[75] Albrizio S., Carotenuto A., Fattorusso C., Moroder L., Picone D., Temussi P.A., D’Ursi A. “Environmental Mimic 
of Receptor Interaction:  Conformational Analysis of CCK-15 in Solution” J. Med. Chem. 2002, 45, 762–769 
[76] Borics A., Toth G. "Structural comparison of m-opioid receptor selective peptides confirmed four parameters of 
bioactivity" J. Mol. Graph. Modell. 2010, 28, 495-505 
[77] NMR protons labeling for EM-2 hybrid analogues (e.g. compound 48). 
        
[78] The additional conformational isomerism was ascribed to the presence of the tertiary amide in the -hTic moiety. 
[79] (a) Shao X., Gao Y., Zhu C., Liu X., Yao J., Cui Y., Wang R. “Conformational analysis of Endomorphin-2 
analogues with phenylalanine mimics by NMR and molecular modeling” Bioorg. & Med. Chem. 2007, 15, 3539–
3547 (b) Grathwohl C., Wüthrich K. “Nmr studies of the rates of proline cis–trans isomerization in 
oligopeptides” Biopolymers, 1981, 20, 2623–2633 
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Table 5. Proton attribution for compounds 48-49. 
 
Compd. Residue NH H H H H H H H H4 H 
48a 
 
Tyr1           
(trans1) 8.02 4.25 3.08; 2.81       9.36 
(trans2)           
Pro2           
(trans1)  4.37 2.12; 1.80 
1.93; 
1.81 
3.68; 
3.30 
     
(trans2)  4.23 1.90; 1.58 
1.76; 
1.70 
3.61; 
3.19 
     
-hPhe3           
(trans1) 7.94     3.45 
3.34; 
3.27 
2.80; 
2.70 
  
(trans2) 8.11      3.35 2.75   
-hTic4           
(trans1)      1.90 4.04 
2.85; 
2.67 
5.02; 
4.09 
 
(trans2)           
48b 
Tyr1           
(trans1) 8.02 4.25 3.07; 2.85       9.36 
(trans2) 8.00 4.20 3.01; 2.79       8.79 
Pro2           
(trans1)  4.37 2.12; 1.80 
1.93; 
1.81 
3.68; 
3.30 
     
(trans2)  4.23 1.90; 1.58 
1.76; 
1.70 
3.61; 
3.19 
     
-hPhe3           
(trans1)  7.98    3.33 
3.34; 
3.25 
2.75; 
2.81 
  
(trans2)  7.89    3.50 
3.33; 
3.13 
2.72; 
2.90 
  
-hTic4           
(trans1)      
2.10 
1.90 
4.94 
3.12; 
2.68 
5.20; 
4.05 
 
(trans2)      
2.10; 
1.89 
4.88 
3.00; 
2.72 
5.11; 
4.05 
 
49a 
Tyr1           
(cis) 8.17 3.69 2.87; 2.81       9.41 
(trans) 8.00 4.2 3.01; 2.79       9.35 
Pro2           
(cis)  3.75 1.70; 1.61 
1.70; 
1.60 
3.41; 
3.26 
     
(trans)  4.33 1.98; 1.75 
1.88; 
1.78 
3.63; 
3.21 
     
-hPhe3           
(cis) 8.12     2.57 
3.26; 
2.97 
2.77; 
2.58 
  
(trans) 7.82     2.62 
3.22; 
2.98 
2.73; 
2.60 
  
-hPhe4           
(cis) 7.93     2.15 4.21 2.72   
(trans) 7.81     
2.12; 
2.08 
4.21 2.71   
49b 
Tyr1           
(cis) 8.23 3.85 2.95; 2.84       9.35 
(trans) 7.98 4.24 3.06; 2.82       8.73 
Pro2           
(cis)  3.68 1.81; 1.61  3.45;      
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3.27 
(trans)  4.35 2.08; 1.81 
1.91; 
1.83 
3.67; 
3.27 
     
-hPhe3           
(cis) 7.80          
(trans) 7.84     2.62 3.16 
2.63; 
2.70 
  
-hPhe4           
(cis) 7.91     2.20 4.25 
2.72; 
2.60 
  
(trans) 7.73     2.20 4.25 
2.72; 
2.60 
  
 
 
Figure 27. Relevant Inter-residue Correlations, from ROESY Experiments. 
Some non sequential NOE cross-peaks were observed (Figure 27), which highlight a 
few common conformational behaviors: in most products, the Tyr1 aromatic ring seems 
to be folded over the Pro2 segment and the NH of the -hPhe3 interacts with the Pro’s H-
. The most unique interaction for conformationally constrained 48a,b is the one 
between -hTic4 H-2 and -hPhe3 H-1. However, since NMR gave elusive elements 
about conformation (for instance, no strong internal hydrogen bonds could be detected 
by VT-NMR in DMSO-d6, 2 mM solution) a computer aided conformational search has 
been performed, using the observed NOE cross peaks to generate distance constraints. 
Regarding the second series of EM-2 analogues tested (50-54), the same conformational 
issues is present. The trans/cis isomerism around the Pro2 peptidic bond, plus the 
isomerism due to the conformational restriction.  This restriction led to a tertiary amide 
present in solution as two energetically stable isomers. In Figure 28 are summarized the 
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relevant inter-residue NOE interactions. Compounds 50a and 50b present quite unique 
and unusual interactions, in the first case involving the 2-hTbac4 aromatic ring  and the 
benzylic side chain of 3-hPhe3. 50b presents a clear set of signals which underlines a 
Phe3-Phe4 overlap. However, we did not observed any significant inter-residue NOE 
interaction for linear derivatives, revealing preferentially extended conformation. The 
only exceptions regards analogue 53 where the Tyr1 seems completely folded over Pro2 
and the overall structure is quite compressed. Comparing these observations to 
biological results, we can deduce that the aromatic rings require a certain degree of 
flexibility in order to fit positively in the hydrophobic pockets and, at the same time, 
require a correct relative placement on the backbone. Indeed only 51a and 51b, bearing 
the 3-hPhe-2-hPhe inserted scaffolds can reach the low nanomolar scale. Compound 
54 is 2 orders of magnitude less active even though there is a minimal difference, but 
sufficiently important to determine such behavior. 
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Figure 28. Relevant Inter-residue Correlations, from ROESY Experiments. 
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2.8 Structural Study: Docking 
 
Since the crystal structure of the -opioid receptor bound to a morphinan antagonist 
became available[43a] only during the final writing of this thesis, and the same happened 
for the crystal structure of the -receptor bound to naltrindole,[43b] our investigation of 
possible binding modes of the most active ligands 48b and 49a was performed in the 
absence of this data, relying on a rhodopsin-based receptor-ligand homology model.[80] 
From previous investigations on the binding mode of EM-1 and EM-2 on the MOR 
model[81] it seems that endomorphins bind in the core of transmembrane helix 3, 5 and 6, 
with the Tyr1 residue lying at the bottom of the binding site, interacting with the 
carboxyl of Asp147. Many interactions between the aromatic portions of the ligands and 
the receptor are present, together with a hydrogen bond involving the terminal NH 
amide of Phe4 and the carbonyl of Glu229.  
Our docking studies were performed with the software Glide. As starting points for 
both compounds, we used the global minima obtained from the conformational 
analysis performed as previously described, without introducing constraints derived 
from NMR experiments. The structures were docked flexibly in the XP mode on the 
active form of the MOR model[82] and the docking score was calculated using the default 
score functions. The obtained values correlate well with the biological data, the best 
value (-13.43) being obtained for 49a. The score was -12.68 for 48b.  
A visual inspection of the binding modes shows that both compounds bind to the 
receptor similarly to EM-2, with the Tyr1 residue placed at the bottom of the binding 
site and bearing a hydrogen bond with Asp147 (Figure 29). The phenyl moiety of Tyr1 
lies in a hydrophobic region, and interactions with Phe237 and Phe152 are present. Two 
more hydrogen bonds are present between the terminal -hPhe4 and Thr307 and 
Asn230. Favorable interactions between the phenyl of the terminal -hPhe4 and a 
number of aromatic groups (Phe221, His223) in a lipophilic pocket can also be 
                                               
[80] Mosberg H.I., Fowler C.B. “Development and validation of opioid ligand-receptor interaction models: the 
structural basis of  vs  selectivity” J. Pept. Res. 2002, 60, 329–335 
[81] (a) Gentilucci L., Tolomelli A., De Marco R., Artali R. “Molecular Docking of Opiates and Opioid Peptides, a Tool 
for the Design of Selective Agonists and Antagonists, and for the Investigation of Atypical Ligand-Receptor 
Interactions” Curr. Med. Chem. 2012, 19, 1587–1601 (b) Liu X., Kai M., Jin L., Wang R. “Molecular modeling 
studies to predict the possible binding modes of endomorphin analogues in μ opioid receptor” Bioorg. Med. 
Chem. Lett. 2009, 19,5387–5391 (c) Liu X., Kai M., Jin L., Wang R. “Computational study of the 
heterodimerization between μ and δ receptors” J. Comput. Aid. Mol. Des. 2009, 23, 321–332 
[82] The receptor model used is the OPRM_MOUSE_AD_JOM6 obtained by the  web site 
http://mosberglab.phar.umich.edu. 
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evidenced. Notably relevant portions of the two molecules occupy the same receptor 
regions (see Figure 30 for superimposition of docked conformations).  
 
 
Figure 29. Binding mode towards the MOR Model; a) 49a, b) 48b. 
 
 
Figure 30. Superimposition of the Docked Conformations of 49a (Orange) and 48b (Green) 
(RMSD of amide backbone is 1.3Å). 
 
This binding analogy was quite unpredictable on the basis of structural elements. In 
fact, the two compounds have an opposite configuration at the -hPhe3 stereocenter (R 
for 49a and S for 48b) and the terminal residue is a -hPhe4 for 49a and a constrained -
hTic4 for 48b. The bound conformations for both ligands 49a and 48b resulted quite 
different if compared with the free state conformations, as resulted from NMR and 
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conformational analysis. While in the free state these compounds tend to adopt bent 
conformations (with the presence of different intramolecular hydrogen bonds), the 
docked conformations are more extended and no intramolecular hydrogen bonds are 
present. In this case the docking experiment seems to be more able in giving 
explanation about bioactivity, with respect to the conformational studies performed by 
NMR and molecular modeling. 
The docking studies were performed with the use of the Molegro 4.0 suite, having 
MolDock as integrated docking software. We decided to switch to a different docking 
software because we observed an higher accuracy. The docking scoring function of 
MolDock is an extension of the piecewise linear potential (PLP) including new 
hydrogen bonding and electrostatic terms.[83]  
As receptor models we decided to use both the recently isolated crystal structure of the 
µ-opioid receptor bound to a morphinan antagonist (PDB code: 4DKL) and a 
rhodopsin-based receptor-ligand homology model as comparison. Results are reported 
as the Moldock score as implemented in the software. It has to be noticed that the two 
receptors have some significant discrepancy due to the different orientation of some 
residues. The alignment of the two receptor models is quite good with an RMSD of 
1.046Å (in the common region from residue 64 to 286). The binding sites look very 
similar, but some evident differences appear in the orientation of residues Trp318, Gln 
124 and Tyr128. These residues play an important role in defining the cavity space and 
the shape of the binding site thus affecting the binding modes of the ligands.  
The two receptors’ binding site region has been aligned from x-ray structure and from 
homology model. There is a good overlap between the two structures, in particular 
related to the common amino acids involved in binding. 
The use of  the receptor modeled from the x-ray structure gave results which are 
consistent with the biological data. Compound 51b resulted to have the lowest docking 
score followed by EM2. However the two molecules bind to the receptor in quite 
different ways as showed by the ligand-receptor interaction diagrams. On the other 
hand, results from the homology model were not in agreement with the biological data.  
MolDock score: 
                Crystal Structure       Homology Model 
EM2   -154.2   -131.5 
51a   -151.7   -162.6 
51b   -156.4   -151.2 
 
                                               
[83] Thomsen R., Christensen M.H. “MolDock: A New Technique for High-Accuracy Molecular Docking” J. Med. 
Chem. 2006, 49, 3315-3321 
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MolDock score puts in evidence the lower accuracy of the homology model.  
In the following pages I report the docking analysis using the homology model and the 
crystallized receptor to enlighten the most important binding differences observed for 
EM-2 and active compound 51b. 
 
 
 
 
 
Figure 31. Binding mode towards the MOR (EM-2, 51b). (Homology Model) 
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Figure 32. 2D Ligand-Protein interaction of EM-2 and 51b. (Homology Model) 
 
According to the homology model, Asp147 is no more a determinant interaction, while 
Tyr1 seems placed in the same hydrophobic pocket. Comparing the two diagrams, 51b 
is able to fold up better because of the elongated structure. These observations are in 
contrast with the commonly accepted EM-2  binding mode. 
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Figure 33. Binding mode towards the MOR (EM-2, 51b). (Crystal Structure) 
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Figure 34. 2D Ligand-Protein interaction of EM-2 and 51b. (Crystal Structure) 
 
Exploiting the downloaded PDB structure of -opioid receptor, the docking analysis is 
now more reliable. Apparently, EM-2 has important interactions in the hydrophobic 
cavity occupied by Trp318 and an acid/base equilibrium with Asp147, as previously 
reported in literature. However, the new compound 51b seems bind differently. Still 
Tyr1 phenolic moiety has electrostatic interactions, even though amino acids involved 
are different. This preliminary analysis is peculiar because differs from the well 
established EM-2 binding mode. Apparently, the extended conformation of 51b, due to 
the homologation, is helpful for a better fitting.  
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2.9 Conclusions 
 
We investigated the biological activity and the conformational requirements of hybrid 
EM-2 analogues, by NMR spectroscopy, molecular modeling and docking studies. On 
the basis of all data, some considerations can be drawn. Compounds 48b and 49a are 
among the few examples of EM-2 analogues in which the C-terminal Phe3-Phe4 
dipeptide is simultaneously substituted by a peptidomimetic structure with the 
maintenance of opioid affinity. Besides, this type of modification is able to completely 
abate the high  selectivity of EM-2 providing compounds endowed with a slight 
preference for  receptors. 
Molecular modeling, which was performed taking into account distance restraints from 
NMR, suggests a high propensity of all first generation analogues for various turn 
structures. Since conformational studies were performed on isolated molecules in the 
absence of their receptor and therefore the most populated conformational family does 
not necessarily correspond to the bioactive structure, we also performed docking 
studies in order to elucidate the binding mode for their action. The docking procedure 
strongly highlights a common binding mode for 48b, 49a confirming the necessity for 
specific binding interactions, for instance between Asp147 and Tyr1, already identified 
in recent studies.[84]  
On the other hand, a second generation of EM-2 analogues has been prepared and 
tested (50-54). According to preliminary biological results, compounds 51a and 51b 
displayed a low nanomolar affinity for -opioid receptor, in particular 51a showed an 
high degree of selectivity for MOR. Docking studies on the new receptor’s crystal 
structure enlighten some differences between the standard key interaction for EM-2 and 
the active analogues. This piece of information might help explaining the biological 
outcome and the resulting bioactive conformations. 
Finally, we should bear in mind the hypothesis that GPCRs, including opioid receptors, 
exist as dynamic entities that can occupy multiple conformations, depending on the 
accessory proteins within the signaling complex, but also on the ligand.[85] On the basis 
of this argument, caution must be used in providing key structural parameters for 
bioactivity versus opioid receptors.  
                                               
[84] Liu X., Kai M., Jin L., Wang R. “Molecular modeling studies to predict the possible binding modes of 
endomorphin analogues in μ- opioid receptor” Bioorg. Med. Chem. Lett. 2009, 19, 5387-5391 
[85] Urban J.D., Clarke W.P., Von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., 
Christopoulos A., Sexton P.M., Miller K.J., Spedding M., Mailman R.B. “Functional Selectivity and Classical 
Concepts of Quantitative Pharmacology” J. Pharmacol. Exp. Ther. 2007, 320, 1–13 
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2.10 Experimental Details 
 
Chemistry 
All solvents were distilled and properly dried, when necessary, prior to use. All 
chemicals were purchased from commercial sources and used directly, unless otherwise 
indicated. All reactions were run under nitrogen atmosphere, unless otherwise 
indicated. All reactions were monitored by thin layer chromatography (TLC) on 
precoated silica gel 60 F254; spots were visualized with UV light (254 nm) and by 
treatment with 1% aqueous KMnO4 solution, Ninhydrin solution in ethanol or Cerium-
ammonium-molybdate (CAM) reactive. Products were purified by flash 
chromatography on silica gel 60 (230‑400 mesh). 1H and 13C NMR spectra were recorded 
with 300 and 400 Mhz spectrometers using chloroform-d (CDCl3), dimethylsulfoxide-d6 
(DMSO-d6), acetonitrile-d3 (CD3CN) or methanol-d4 (CD3OD). Chemical shifts (δ) are 
expressed in ppm relative to TMS at δ = 0 ppm for 1H NMR and relative to CDCl3 at δ = 
77.16 ppm for 13C NMR. High‑resolution MS spectra were recorded with a FT‑ICR 
(Fourier Transform Ion Ciclotron Resonance) instrument, equipped with an ESI source, 
or a standard MS instrument, equipped with an EI source. Specific rotations were 
measured by a polarimeter “P-1030 Jasco” with 10 cm Optical path cells and 1 ml 
capacity. 
Radioligand Binding Assays[86] 
Rat brain membranes were prepared from Wistar rat brain. The binding experiments 
were performed in 50 mM Tris.HCl buffer, pH 7.4, at a final volume of 1 ml containing 
200-300 g protein. In competition experiments the following conditions were used for 
incubations: [3H]DAMGO (35 °C, 45 min), [3H]Ile5,6-deltorphin-2 (35 °C, 45 min). 
Incubations were started by the addition of the membrane suspension and terminated 
by rapid filtration through Whatman GF/C glass fiber filters using Brandel M24R Cell 
Harvester. The filters were washed three times with ice cold Tris.HCl buffer and dried 
for 3 h at 37 °C, and the radioactivity was measured in UltimaGOLD scintillation 
cocktail using a Packard TriCarb 2300 TR counter. Affinities of competing ligands were 
determined by co-incubation with 10-12-10-5 M freshly prepared solution of the 
unlabeled peptides with 0.5-1 nM tritiated ligand. Nonspecific binding was defined as a 
                                               
[86] (a) Nevin S.T., Kabasakal L., Otvös F., Tóth G., Borsodi A. “Binding characteristics of the novel highly selective 
delta agonist, [3H]Ile5,6deltorphin II” Neuropeptides, 1994, 26, 261–265 (b) Tóth G., Ioja E., Tömböly C., Ballet S., 
Tourw  D., P ter A., Martinek T., Chung N.N., Schiller P.W., Benyhe S., Borsodi A. “β-Methyl Substitution of 
Cyclohexylalanine in Dmt-Tic-Cha-Phe Peptides Results in Highly Potent δ Opioid Antagonists” J. Med. Chem. 
2006, 50, 328–333 
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radioactivity bound in the presence of 10 M naloxone. All assays were performed in 
duplicate and repeated several times. Experimental data were analyzed by GraphPad 
Prism 2.01 software. 
Computational details 
Conformational analysis was performed with the software Spartan ’08[87] using a 
MC/MM protocol with the application of NOE constraints as obtained by NMR. The 
obtained conformers were then optimized with the semiempirical method AM1. The 
structures were then analyzed and clustered according to their secondary structure 
motifs. For docking studies, we used the structure of the mouse - opioid receptor 
model (active state) with JOM6 as ligand, obtained from the Mosberg lab 
(mosberglab.phar.umich.edu). The complex was prepared with the “protein 
preparation wizard” tool as implemented in Maestro 9.0 (Schrodinger)[88] using the 
OPLS2001 force field for the minimization. The receptor grid was generated with Glide 
5.5 (Schrodinger)[89,90] around the JOM6 ligand (a 40x30x50 Å box was used). The ligands 
were docked flexibly into the receptor grid using the extra-precision mode. Up to ten 
poses for each ligand were analyzed and docking scores were generated using the 
standard functions as implemented in the software. The poses were visualized with the 
Maestro 9.0 graphical interface. 
 
  
                                               
[87] Spartan ’08, Wavefunction, Inc. Irvine, CA 
[88] Maestro, version 9.0, Schrödinger, LLC, New York, NY, 2011 
[89] Glide, version 5.5, Schrödinger, LLC, New York, NY, 2011    
[90] Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz 
D.T. “Extra Precision Glide:  Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for 
Protein−Ligand Complexes” J. Med. Chem. 2006, 49, 6177–6196 
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Synthesis of 2: 
 
 
 
tert-butyl ((R)-2-benzyl-3-((S)-3-(2-(methylamino)-2-oxoethyl)-3,4-
dihydroisoquinolin-2(1H)-yl)-3-oxopropyl) carbamate (2a) 
Compound 31a (20 mg, 0.045 mmol) was dissolved at room temperature in a solution of 
methylamine in EtOH (2 ml, 7.5 M). The reaction mixture was stirred for 18 h and 
evaporated to give 2a (19 mg, 98%) as a white solid.  
[]D25 = +38,6 (c 1.0, CHCl3). 1H NMR (400 MHz, CD3CN) δ 7.42 – 6.91 (m, 9H), 6.51 (s, 
1H), 6.01 (s, 1H), 5.13 (d, 1H, J = 18.1 Hz), 4.57 (dd, 1H, J = 12.9, 6.4 Hz), 4.10 (d, 1H, J = 
18.3 Hz), 3.56 (d, 1H, J = 4.5 Hz), 3.50 – 3.29 (m, 1H), 3.29 – 3.03 (m, 2H), 3.03 – 2.49 (m, 
4H), 2.36 (d, 1H, J = 16.2 Hz), 2.31 – 2.24 (m, 1H), 2.11 (dd, 1H, J = 14.9, 5.8 Hz), 1.87 (dd, 
1H, J = 13.4, 7.7 Hz), 1.42 (s, 9H). 13C NMR (101 MHz, CD3CN) δ 174.3, 172.2, 151.9, 
140.9, 133.8, 133.7, 130.6, 130.4, 129.9, 129.8, 129.7, 127.9, 127.9, 127.8, 127.5, 79.7, 50.2, 
44.7, 44.1, 42.4, 40.0, 39.0, 34.2, 29.2, 26.9. HRMS (ESI) calcd. for [C27H35N3O4]+: 465.2628, 
found 466.2234. (MH+) 
 
tert-butyl ((S)-2-benzyl-3-((S)-3-(2-(methylamino)-2-oxoethyl)-3,4-dihydroisoquinolin-
2(1H)-yl)-3-oxopropyl) carbamate (2b) 
Compound 31b (20 mg, 0.045 mmol) was dissolved at room temperature in a solution of 
methylamine in EtOH (2 ml, 7.5 M). The reaction mixture was stirred for 18 h and 
evaporated to give 2b (19 mg, 98%) as a white solid. The following data has been 
collected on a 1:1 rotamer mixture. 
[]D25 = +38,0 (c 1.25, CHCl3). 1H NMR (400 MHz, CDCl3) 7.40 – 7.26 (m, 3H), 7.26 – 7.07 
(m, 4H), 7.06 – 6.99 (m, 2H), 6.43 (bs, 0.5H), 6.21 (bs, 0.5H), 5.91 (bs, 0.5H), 5.50 (bs, 
0.5H), 5.31 – 5.18 (m, 1H), 4.93 (dd, 0.5H, J = 12.2, 6.2 Hz), 4.46 (s, 1H), 4.15 – 4.02 (m, 
1H), 3.61 – 3.51 (m, 0.5H), 3.44 – 3.27 (m, 1H), 3.27 – 3.06 (m, 2.5H), 2.99 - 2.68 (m, 2H), 
 80 
2.69 – 2.58 (m, 3H), 2.26 – 2.13 (m, 1H), 2.09 (ddd, 1H, J = 14.7, 6.8, 2.6 Hz), 1.83 (dd, 
0.5H, J = 14.6, 7.3 Hz), 1.43 (s, 4.5H), 1.34 (s, 4.5H). 13C NMR (101 MHz, CDCl3) δ 174.6, 
174.5, 172.5, 171.6, 157.6, 157.3, 141.6, 140.9, 134.2, 134.1, 133.8, 133.6, 130.8, 130.7, 130.6, 
130.4 (2C), 129.8 (2C), 129.7 (2C), 128.3, 128.0, 127.8 (2C), 127.7 (2C), 127.6 (2C), 127.5, 
79.8 (2C), 50.3, 46.9, 45.5, 45.3, 44.7, 44.4, 44.0, 42.6, 39.8, 39.2, 37.8 (2C), 35.1, 34.0, 29.2, 
29.1, 26.8, 26.7. HRMS (ESI) calcd. for [C27H35N3O4]+: 465.2628, found 466.2655. (MH+) 
 
  
  
81 
1H and 13C NMR of compound 2a 
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1H and 13C NMR of compound 2b 
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Synthesis of 4: 
 
 
 
tert-butyl ((S)-4-((R)-4-(methylcarbamoyl)-4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)-4-
oxo-1-phenylbutan-2-yl)carbamate (4a) 
Compound 32a (20 mg, 0.045 mmol) was dissolved at room temperature in a solution of 
methylamine in EtOH (2 ml, 7.5 M). The reaction mixture was stirred for 18 h and 
evaporated to give 4a (18 mg, 98%) as a white solid. The following data has been 
collected on a 1:1 rotamer mixture. 
[]D25 = -21,6 (c 0.5, CHCl3). 1H NMR (400 MHz, CD3CN) δ 7.39 – 7.28 (m, 2H), 7.28 – 7.05 
(m, 6H), 6.95 (d, 1H, J = 5.9 Hz), 6.63 (bs, 0.5H), 6.51 (bs, 0.5H), 5.56 (d, 0.5H, J = 7.8 Hz), 
5.48 (bs, 0.5H), 4.99 (d, 0.5H, J = 14.0 Hz), 4.61 (d, 0.5H, J = 16.1 Hz), 4.49 (d, 0.5H, J = 16.0 
Hz), 4.34 (d, 0.5H, J = 13.8 Hz), 4.16 (dd, 0.5H, J = 10.7, 6.4 Hz), 4.08 – 3.90 (m, 1H), 3.72 – 
3.47 (m, 1H), 3.46 – 3.20 (m, 1.5H), 2.97 (d, 1H, J = 14.8 Hz), 2.83 – 2.60 (m, 4.5H), 2.56 – 
2.23 (m, 3.5H), 1.42 – 1.27 (m, 9H). 13C NMR (101 MHz, CD3CN) δ 172.9, 172.7, 170.6, 
169.5, 155.2 (2C), 139.8, 139.6, 139.2, 139.0, 138.5, 137.9, 130.7, 129.8, 129.5, 129.3 (2C), 
129.1, 128.4 (2C), 128.3 (2C), 127.8, 127.5 (2C), 126.6 (2C), 126.3, 126.2, 126.1, 79.8 (2C) 
53.4, 52.5, 50.2 (2C), 49.9, 49.7, 45.8, 44.2, 40.1, 39.6, 38.0, 37.5, 37.3, 36.8, 29.9, 27.6 (2C), 
25.2 (2C). HRMS (ESI) calcd. for [C27H35N3O4]+: 465.2628, found 466.2339. (MH+) 
 
tert-butyl ((S)-4-((S)-4-(methylcarbamoyl)-4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)-4-
oxo-1-phenylbutan-2-yl)carbamate (4b) 
Compound 32b (20 mg, 0.045 mmol) was dissolved at room temperature in a solution of 
methylamine in EtOH (2 ml, 7.5 M). The reaction mixture was stirred for 18 h and 
evaporated to give 4b (18 mg, 98%) as a white solid. The following data has been 
collected on a 1:1 rotamer mixture. 
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[]D25 = -25,3 (c 0.5, CHCl3). 1H NMR (400 MHz, CD3CN) δ 7.37 – 7.08 (m, 8H), 7.03 - 6.95 
(m, 1H), 6.72 (bs, 0.5H), 6.57 (bs, 0.5H), 5.55 (d, 0.5H, J = 6.9 Hz), 5.34 (bs, 0.5H), 4.88 (d, 
0.5H, J = 14.4 Hz), 4.51 (s, 1H), 4.41 – 4.16 (m, 1H) 4.15 - 3.87 (m, 1.5H), 3.77 – 3.58 (m, 
1H), 3.58 – 3.09 (m, 2.5H), 2.94 (dd, 1H, J = 27.3, 15.4 Hz), 2.86 – 2.55 (m, 5.5H), 2.55 – 
2.29 (m, 1H), 1.34 (s, 4.5H), 1.31 (s, 4.5H). 13C NMR (101 MHz, CD3CN) δ 175.1, 174.5, 
172.2, 171.1, 156.6 (2C), 141.3, 140.6, 140.5, 140.2, 139.8, 139.3, 132.3, 131.3, 131.2, 131.2, 
130.8 (2C), 130.2, 129.8 (2C), 129.8 (2C), 129.4, 129.0, 128.1 (2C), 127.8, 127.7, 127.6, 79.8, 
79.7, 56.5, 54.8, 54.1, 52.1, 51.5, 51.3, 47.2, 46.0, 45.9, 41.8, 41.6, 39.4, 39.0, 38.6, 29.1 (2C), 
26.7 (2C). HRMS (ESI) calcd. for [C27H35N3O4]+: 465.2628, found 466.2651. (MH+) 
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1H and 13C NMR of compound 4a 
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1H and 13C NMR of compound 4b 
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Synthesis of 14: 
 
 
A solution of 10 (882 mg, 4.56 mmol) in THF (30 ml) was cooled to 0°C. Then 
triethylamine (700 l, 5.02 mmol) and CbzCl (652 l, 4.56 mmol) were added. The 
reaction was quenched after 1h with H2O. The pH was driven to acidic by means of a 
solution of NaHSO4 1M and the mixture was partitioned between AcOEt and H2O. The 
organic layer was washed with H2O, dried (Na2SO4), filtered and concentrated to afford 
crude N-Cbz--hPhe methylester (1,49 g) as a foam. 
1H NMR (400 MHz, CDCl3)  7.40 - 7.10 (m, 10H), 5.32 (d, 1H, J = 7.5 Hz), 5.07 (s, 2H), 
4.25 - 4.20 (m, 1H), 3.67 (s, 3H), 2.95 (dd, 1H, J = 13.5, 7.2 Hz), 2.83 (dd, 1H, J = 13.3, 7.7 
Hz), 2.60 - 2.40 (m, 2H).  
 
(S)-benzyl 3-(2-methoxy-2-oxoethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (13) 
A solution of the crude N-Cbz--hPhe methylester (107 mg, 0.33 mmol) in CH2Cl2 (3 
ml) was cooled to 0° C. Trioxane (59 mg, 0.65 mmol) and TFA (378 l, 4.9 mmol) were 
added. The reaction was stirred at room temperature for 18h, then quenched with water 
and the pH adjusted with NaHCO3 saturated solution. The mixture was partitioned 
between CH2Cl2 and H2O. The organic layer was washed with H2O, dried (Na2SO4), 
filtered and concentrated. The residue was purified by flash column chromatography 
(hexane/AcOEt 85:15) to afford the N-Cbz-3hTic-OMe (89 mg, 82% yield) as a foam. 
[]D25 = +49,4 (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) 7.50 - 7.10 (m, 9H), 5.20 (s, 2H), 
4.98 (bs, 1H), 4.85 (d, 1H, J = 16.8 Hz), 4.40 (d, 1H, J = 16.9 Hz), 3.59 (s, 3H), 3.14 (dd, 1H, 
J = 16.0, 5.5 Hz), 2.77 (d, 1H, J = 15.8 Hz), 2.52 (dd, 1H, J = 14.9, 6.7 Hz), 2.33 (dd, 1H, J = 
14.9, 7.7 Hz). 13C NMR (101 MHz, CDCl3)  172.1, 155.9, 137.4, 133.1, 132.8, 129.8, 129.1, 
128.6, 128.5, 127.6, 127.2, 126.8, 67.9, 52.2, 48.1, 43.9, 37.7, 33.8. FAB-MS-LR m/z 340.15 
(MH+). 
 
(S)-methyl 2-(1,2,3,4-tetrahydroisoquinolin-3-yl) acetate (14) 
To a solution of N-Cbz-3hTic-OMe (837 mg, 2.46 mmol) in MeOH (10 ml), Pd/C 10% 
(80 mg) was added and the reaction was put under H2 atmosphere at room temperature 
 88 
for 6 hours. The crude was filtered over celite and purified  by flash column 
chromatography (Hex/AcOEt 1:1) to afford amine 14 (393 mg, 78% yield) as a colorless 
oil. 
[]D25 = -52,6 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3)  7.24 - 6.92 (m, 4H), 4.15 (d, 1H, 
J = 15.9 Hz), 4.05 (d, 1H, J = 15.9 Hz), 3.71 (s, 3H), 3.45 - 3.25 (m, 1H), 2.81 (dd, 1H, J = 
16.1 Hz, J = 3.9 Hz), 2.61 - 2.39 (dd, 1H, J = 19.0, 9.8 Hz), 2.57 – 2.54 (m, 2H). 13CNMR 
(101 MHz, CDCl3)  172.5, 135.1, 133.9, 129.1, 126.1, 125.9, 51.7, 50.5, 48.1, 40.6, 34.8. 
HRMS (ESI) calcd. for [C12H15NO2]+: 205.1103, found 206.1132. (MH+) 
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1H and 13C NMR spectra of compound 13 
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1H and 13C NMR spectra of compound 14 
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Synthesis of 30: 
 
 
(R)-methyl 2-benzyl-3-(benzyloxycarbonylamino) propanoate (28a) 
2-hPhe (137 mg, 0.71 mmol) is dissolved in THF and cooled to 0 °C. TEA (108 l, 0.78 
mmol) was added followed by CbzCl (111 l, 0.78 mmol). After 2 hours the pH is 
adjusted to acidic by adding NaHSO4 1M. The reaction is extracted with AcOEt and 
washed with brine, water, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography (Hex/AcOEt 8:2) to afford 
the product as a colorless oil (225 mg, 97%). 
 
Rf = 0.28 (Hex/AcOEt 8:2). [α]D25 = +1.3 (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.39 – 
6.97 (m, 10H), 5.14 – 4.94 (m, 3H), 3.54 (s, 3H), 3.45 – 3.31 (m, 1H), 3.30 – 3.19 (m, 1H), 
2.95 – 2.80 (m, 2H), 2.80 – 2.64 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.5, 156.3, 138.1, 
136.5, 128.8 (2C), 128.6 (3C), 128.1 (3C), 126.7 (2C), 66.8, 51.8, 47.2, 41.9, 35.8. HRMS (ESI) 
calcd. for [C19H21NO4]+: 327.1471, found 328.1459. (MH+) 
 
(S)-methyl 2-benzyl-3-(benzyloxycarbonylamino) propanoate (28b) 
2-hPhe (112 mg, 0.58 mmol) is dissolved in THF and cooled to 0 °C. TEA (90 l, 0.64 
mmol) was added followed by CbzCl (91 l, 0.64 mmol). After 2 hours the pH is 
adjusted to acidic by adding NaHSO4 1M. The reaction is extracted with AcOEt and 
washed with brine, water, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography (Hex/AcOEt 8:2) to afford 
the product as a colorless oil (185 mg, 98%). 
Rf = 0.28 (Hex/AcOEt 8:2). [α]D25 = -2.8 (c 0.45, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.39 
– 6.97 (m, 10H), 5.14 – 4.94 (m, 3H), 3.54 (s, 3H), 3.45 – 3.31 (m, 1H), 3.30 – 3.19 (m, 1H), 
2.95 – 2.80 (m, 2H), 2.80 – 2.64 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.5, 156.3, 138.1, 
136.5, 128.8 (2C), 128.6 (3C), 128.1 (3C), 126.7 (2C), 66.8, 51.8, 47.2, 41.9, 35.8. HRMS (ESI) 
calcd. for [C19H21NO4]+: 327.1471, found 328.1439. (MH+) 
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1H and 13C NMR spectra of compound 28 
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(R)-2-benzyl 4-methyl 4,5-dihydro-1H-benzo[c]azepine-2,4(3H)-dicarboxylate (29a) 
A solution of 2-hPhe (102 mg, 0.31 mmol) in CH2Cl2 (1 ml) was cooled to 0 °C, then 
trioxane (111 mg, 1.24 mmol) was added, followed by triflic anhydride dropwise (109 
l, 0.62 mmol). The mixture was stirred for 60 minutes at 0 °C. The reaction is stopped 
by adding NaHCO3 ss, extracted with CH2Cl2, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude was purified by flash chromatography 
(Hex/AcOEt 8:2) to afford the product as a colorless oil (67 mg, 64%). 
The following data has been collected on a 1:1 rotamer mixture. Rf = 0.31 (Hex/AcOEt 
8:2). [α]D25 = -22.9 (c 0.3, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 7.4-7.1 (m, 9H), 5.2 (d, 1H, 
J = 13.0 Hz), 5.1 (d, 1H, J = 13.1 Hz), 4.8 (d, 0.5H, J = 14.9 Hz), 4.70 (d, 0.5H, J = 15.0 Hz), 
4.5 (d, 1H, J =15.1 Hz), 4.37 – 4.29 (m, 1H), 3.72 (s, 1.5H), 3.68 (s, 1.5H), 3.54 – 3.51 (m, 
0.5H), 3.47 – 3.44 (m, 0.5H), 3.25 – 3.17 (m, 2H), 2.92 – 2.61 (m, 1H). 13C NMR (CDCl3, 101 
MHz) δ 175.4, 175.2, 155.8, 155.3, 138.6, 137.9, 137.7, 137.4, 136.7, 136.6, 130.1, 130.0 (2C), 
129.4 (2C), 129.1 (2C), 128.7 (2C), 128.4 (2C), 128.1 (2C), 128.0 (2C), 127.0 (2C), 126.7, 67.5, 
67.3, 52.6, 52.1, 51.9, 51.6, 51.3, 50.4, 43.9, 43.3, 37.3, 36.9. HRMS (ESI) calcd. for 
[C20H21NO4]+: 339.1471, found 340.1442. (MH+) 
 
(S)-2-benzyl 4-methyl 4,5-dihydro-1H-benzo[c]azepine-2,4(3H)-dicarboxylate (29b) 
A solution of 2-hPhe (88 mg, 0.27 mmol) in CH2Cl2 (1 ml) was cooled to 0 °C, then 
trioxane (96 mg, 1.07 mmol) was added, followed by triflic anhydride dropwise (91 l, 
0.54 mmol). The mixture was stirred for 60 minutes at 0 °C. The reaction is stopped by 
adding NaHCO3 ss, extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude was purified by flash chromatography (Hex/AcOEt 
8:2) to afford the product as a colorless oil (60 mg, 65%). 
The following data has been collected on a 1:1 rotamer mixture.  Rf = 0.31 (Hex/AcOEt 
8:2). [α]D25 = +10.0 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.05 (m, 9H), 5.17 
(d, 1H, J = 10.6 Hz), 5.08 (d, 1H, J = 13.7 Hz), 4.81 (d, 0.5H, J = 14.8 Hz), 4.73 (d, 0.5H, J = 
15.1 Hz) 4.48 (dd, 0.5H, J = 13.9, 3.3 Hz), 4.36 - 4.24 (m, 1.5H), 3.74 (s, 1.5H), 3.68 (s, 
1.5H), 3.63 – 3.49 (m, 0.5H), 3.44 (dd, 0.5H, J = 13.9, 10.2 Hz), 3.31 – 3.09 (m, 2H), 2.88 – 
2.71 (m, 1H).  13C NMR (101 MHz, CDCl3) δ 173.4, 173.3, 155.5, 155.2, 138.6, 138.1, 137.9, 
137.4, 136.7, 136.6, 130.2 (2C), 130.1 (2C), 129.4 (2C), 129.1 (2C), 128.4 (2C), 128.0 (2C), 
127.9 (2C), 127.0 (2C), 126.7 (2C), 67.4, 67.2, 52.5, 52.0, 51.9, 51.7, 51.4, 50.3, 43.9, 43.3, 
37.2, 36.7. HRMS (ESI) calcd. for [C20H21NO4]+: 339.1471, found 340.1495. (MH+) 
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1H and 13C NMR spectra of compound 29 
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(R)-methyl 2,3,4,5-tetrahydro-1H-benzo[c]azepine-4-carboxylate (30a) 
Compound 29a (177 mg, 0.52 mmol) was dissolved in dioxane (5 ml). Pd/C 10% (30 mg) 
and AcOH were added. The reaction was stirred under hydrogen atmosphere at rt for 
18h. The mixture was filtered through celite pad and concentrated. The residue was 
purified by flash chromatography to give colorless oil (64 mg, 60%). 
Rf = 0.34 (Hex/AcOEt/TEA 1:1:0.1). [α]D25 = +37.9 (c 1.0, CHCl3). 1H NMR (CDCl3, 400 
MHz) δ: 7.2-7.05 (m, 4H), 3.98 (s, 2H), 3.65 (s, 3H), 3.40 (d, 2H, J =5.85 Hz), 3.25 - 3.20 (m, 
2H), 2.69 – 2.61 (m, 1H), 2.53 (s, 1H). 13C NMR (CDCl3, 101 MHz) δ: 173.5, 141.5, 138.7, 
130.0, 128.0, 126.9, 126.5, 76.2, 54.0, 51.9, 44.1, 38.5. HRMS (ESI) calcd. for [C12H15NO2]+: 
205.1103, found 228.1127. (MNa+) 
 
(S)-methyl 2,3,4,5-tetrahydro-1H-benzo[c]azepine-4-carboxylate (30b) 
Compound 29b (92 mg, 0.27 mmol) was dissolved in dioxane (5 ml). Pd/C 10% (9 mg) 
and AcOH were added. The reaction was stirred under hydrogen atmosphere for 18h at 
rt. The mixture was then filtered through celite pad and concentrated. The residue was 
purified by flash chromatography (Hex/AcOEt/TEA 1:1:0.1) to give a colorless oil (42 
mg, 76%). 
Rf = 0.34 (Hex/AcOEt/TEA 1:1:0.1). [α]D25 = -31.4 (c 1, CHCl3). 1H NMR (CDCl3, 400 MHz) 
δ: 7.20 -7.05 (m, 4H), 3.98 (s, 2H), 3.65 (s, 3H), 3.40 (d, 2H, J = 5.85 Hz), 3.25 - 3.20 (m, 
2H), 2.69 – 2.64 (m, 1H), 2.53 (bs, 1H). 13C NMR (CDCl3, 101 MHz) δ: 173.5, 141.5, 138.7, 
130.0, 128.0, 126.9, 126.5, 76.2, 54.0, 51.9, 44.1, 38.5. HRMS (ESI) calcd. for [C12H15NO2]+: 
205.1103, found 228.1131. (MNa+) 
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General Procedure for Peptide Coupling: 
 
 
 
 
PROCEDURE A: 
 
To a suspension of -hPhe (acid) in dry CH2Cl2 under nitrogen atmosphere was added 
DIPEA (1.1 - 2.0 equiv.). The reaction mixture was cooled to 0°C, HOBt (1.2 equiv.) and 
EDC (1.2 equiv.) were added, after 45 minutes a solution of -hPhe (amine) with DIPEA 
(1.1 - 2.0 equiv.) in CH2Cl2 was added and the reaction was stirred overnight at room 
temperature. The mixture was then diluted with water, extracted with CH2Cl2 and 
washed with 1.0 M HCl, saturated NaHCO3, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. 
 
 
 
PROCEDURE B: 
 
To a suspension of -hPhe (acid) in dry CH2Cl2 under nitrogen atmosphere was added 
TEA (1.1 - 2.0 equiv.). The reaction mixture was cooled to 0°C and BOP-Cl (1.5 equiv.) 
was added, after 45 minutes a solution of -hPhe (amine) with TEA (1.1 - 2.0 equiv.) in 
CH2Cl2 was added and the reaction was stirred overnight at room temperature. The 
mixture was then diluted with water, extracted with CH2Cl2 and washed with 1.0 M 
HCl, saturated NaHCO3, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. 
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Synthesis of 31: 
 
 
 
Methyl 2-((S)-2-((R)-2-benzyl-3-(tert-butoxycarbonylamino)propanoyl)-1,2,3,4-
tetrahydroisoquinolin-3-yl) acetate (31a). 
Following the general procedure B for peptide coupling. Acid 26a (81 mg, 0.29 mmol), 
amine 14 (60 mg, 0.29 mmol), TEA (90 l, 0.64 mmol), BOP-Cl (111 mg, 0.44 mmol) and 
CH2Cl2 (1.5 ml) afforded after flash chromatography (Hex/AcOEt 75:25) a foam (111 mg, 
82%). 
[]D25 = +43,3 (c 0.5, CHCl3). 1H NMR (400 MHz, CD3CN, mixture of two conformers in 
ratio 1:1) 7.38 - 6.95 (m, 9H), 5.21 - 5.19 (m, 0.5H), 5.02 (d, 0.5H, J = 17.8 Hz), 4.75 (d, 
0.5H, J = 16.1 Hz), 4.50 - 4.45 (m, 0.5H), 4.17 (d, 0.5H, J = 17.9 Hz), 4.12 (d, 0.5H, J = 16.1 
Hz), 3.64 (s, 1.5H), 3.61 (s, 1.5H), 3.54 - 3.15 (m, 3H), 3.00 (dd, 0.5H, J = 16.1, 5.5 Hz), 2.85 
(dd, 0.5H, J = 16.1, 9.2 Hz),  2.80 - 2.65 (m, 2H), 2.52 - 2.40 (m, 1H), 2.31 (dd, 0.5H, J = 16.1 
Hz, 9.2 Hz), 2.24 (dd, 0.5H, J = 16.1, 5.5 Hz), 2.16 (dd, 1H, J = 16.3 Hz, 4.7 Hz), 2.06 (dd, 
1H, J = 15.0 Hz, 9.1 Hz), 1.45 (s, 4.5H), 1.43 (s, 4.5H). 13C NMR (101 MHz, CD3CN, 
mixture of two conformers in ratio 1:1) 172.9, 171.3, 155.9, 139.5, 139.2, 132.9-126.0 
(10C), 78.3, 51.4 and 51.2, 48.3, 45.2 and 43.7, 44.2, 41.3, 37.0, 36.9 and 36.3, 35.9 and 32.5, 
27.6 and 27.5 (3C). HRMS (ESI) calcd. for [C27H34N2O5]+: 466.2468, found 467.2496. (MH+) 
Methyl 2-((S)-2-((S)-2-benzyl-3-(tert-butoxycarbonylamino)propanoyl)-1,2,3,4-
tetrahydroisoquinolin-3-yl) acetate (31b). 
Following the general procedure B for peptide coupling. Acid 26b (89 mg, 0.32 mmol), 
amine 14 (67 mg, 0.32 mmol), TEA (101 l, 0.52 mmol), BOP-Cl (124 mg, 0.49 mmol) and  
CH2Cl2 (1.5 ml) afforded after flash chromatography (Hex/AcOEt 75:25) a foam (109 mg, 
73%). 
[]D25 = +42,3 (c 0.5, CHCl3). 1H NMR (400 MHz, CD3CN, mixture of two conformers in 
ratio 1:1) 7.3 - 7.0 (m, 9H), 5.6 - 5.5 (m, 0.5H), 5.34 - 5.08 (m, 0.5H), 4.82-4.78 (m, 0.5H), 
4.42 (d, 0.5H, J = 16.3 Hz), 4.37 (d, 0.5H, J = 16.3 Hz), 4.03 (d, 0.5H, J = 18.1 Hz), 3.61 (s, 
1.5H), 3.58 (s, 1.5H), 3.55 - 3.48 (m, 1H), 3.45 - 3.35 (m, 1H), 3.3 - 3.15 (m, 1.5H), 3.10 (d, 
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0.5H, J = 15.1 Hz), 2.92 (dd, 0.5H, J = 14.8, 7.5 Hz), 2.83 - 2.65 (m, 2.5H), 2.37 (dd, 0.5H, J = 
14.8, 7.2 Hz), 2.24 (dd, 0.5H, J = 14.8, 7.5 Hz), 2.16 (dd, 1H, J = 8.8 Hz, 7.5 Hz), 1.63 (dd, 
1H, J = 16.0, 5.4 Hz), 1.42 (s, 4.5H), 1.36 (s, 4.5H). 13C NMR (101 MHz, CD3CN, mixture of 
two conformers in ratio 1:1) 174.7 and 174.3, 173.2 and 172.6, 155.9, 141.5, 140.8, 134.1-
127.5 (10C), 79.9, 52.8, 49.7, 46.6 and 45.3, 45.6, 44.5 and 44.3, 42.5, 37.9 and 37.8, 34.6 and 
33.7, 29.2 and 29.1 (3C). HRMS (ESI) calcd. for [C27H34N2O5]+: 466.2468, found 467.2438. 
(MH+) 
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1H and 13C NMR of compound 31a 
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1H and 13C NMR of compound 31b 
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Synthesis of 32: 
 
 
 
(R)-methyl 2-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanoyl)-2,3,4,5-tetrahydro-
1H-benzo[c]azepine-4-carboxylate (32a) 
Following the general procedure B for peptide coupling. Acid 11 (88 mg, 0.31 mmol), 
amine 30a (64 mg, 0.31 mmol), Et3N (120 l, 0.86 mmol), BOP-Cl (120 mg, 0.47 mmol) 
and CH2Cl2 (3 ml) afforded after flash chromatography (Hex/AcOEt 6:4) a white solid 
(98 mg, 68%). The following data has been collected on a 1:1 rotamer mixture.  
Rf = 0.31 (Hex/AcOEt 6:4). [α]D25 = -27.6 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.49 
– 7.04 (m, 8H), 6.99 (d, 0.5H, J = 7.3 Hz), 6.87 (bs, 0.5H), 4.99 (d, 0.5H, J = 14.4 Hz), 4.64 
(d, 0.5H, J = 14.0 Hz), 4.46 (d, 0.5H, J = 15.7 Hz), 4.35 (d, 0.5H, J = 15.7 Hz), 4.22 - 4.06 (m, 
1H), 3.84 (d, 0.5H, J = 12.3 Hz), 3.75 (s, 1.5H), 3.66 (s, 1.5H), 3.64 – 3.38 (m, 1H), 3.30 – 
3.09 (m, 2H), 3.07 – 2.92 (m, 1.5H), 2.91 - 2.73 (m, 2.5H), 2.70 (dd, 0.5H, J = 16.0, 4.6 Hz), 
2.50 (dd, 0.5H, J = 16.4, 4.6 Hz), 2.41 – 2.24 (m, 1.5H), 1.43 (s, 4.5H), 1.41 (s, 4.5H). 13C 
NMR (101 MHz, CDCl3) δ 173.3, 172.6, 171.1, 170.2, 155.5 (2C), 138.7, 138.6, 138.5, 137.9, 
137.4, 136.6, 130.8 (2C), 130.0 (2C), 129.8 (2C), 129.3 (2C), 129.1 (2C), 128.5 (2C), 127.9 
(2C), 127.1 (2C), 126.4 (2C), 79.1 (2C), 53.1, 52.0 (2C), 51.6 (2C), 50.8, 49.5, 49.3, 43.5, 42.7, 
40.0, 39.6, 37.0, 36.7, 35.3, 34.5, 28.4. HRMS (ESI) calcd. for [C27H34N2O5]+: 466.2468, found 
467.2457. (MH+) 
 
(S)-methyl 2-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanoyl)-2,3,4,5-tetrahydro-
1H-benzo[c]azepine-4-carboxylate (32b) 
Following the general procedure B for peptide coupling. Acid 11 (68 mg, 0.24 mmol), 
amine 30b (50 mg, 0.24 mmol), Et3N (75 l, 0.54 mmol), BOP-Cl (93 mg, 0.37 mmol) and 
CH2Cl2 (3 ml) afforded after flash chromatography (Hex/AcOEt 7:3) a white solid (49 
mg, 45%). The following data has been collected on a 1:1 rotamer mixture.  
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Rf = 0.32 (Hex/AcOEt 7:3). [α]D25 = 23.1 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.34 – 
7.02 (m, 9H), 5.04 - 4.88 (m, 0.5H), 4.79 – 4.59 (m, 0.5H), 4.52 – 4.25 (m, 1H), 4.25 – 4.05 
(m, 1.5H), 3.75 (s, 1.5H), 3.68 (s, 1.5H), 3.37 – 3.10 (m, 2.5H), 3.10 – 2.92 (m, 1.5H), 2.92 – 
2.54 (m, 3H), 2.54 – 2.15 (m, 2.5H), 1.42 (s, 4.5H), 1.38 (s, 4.5H). 13C NMR (101 MHz, 
CDCl3) δ 173.8, 173.6, 172.8, 170.9, 155.6, 155.5, 138.7, 138.6, 137.9, 137.6, 137.3, 136.8, 
130.9, 130.2, 130.1, 129.9, 129.5, 129.4, 128.9, 128.7, 128.4, 128.0, 127.9, 127.3, 126.9, 126.5, 
79.3, 54.5, 53.4, 52.2, 52.0, 51.7, 51.1, 49.8, 44.3, 43.2, 43.1, 40.6, 40.4, 37.5, 36.6, 36.5, 28.5. 
HRMS (ESI) calcd. for [C27H34N2O5]+: 466.2468, found 467.2444. (MH+) 
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1H and 13C NMR of compound 32a 
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1H and 13C NMR of compound 32b 
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Synthesis of 33: 
 
 
 
Methyl 2-((S)-2-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanoyl)-1,2,3,4-
tetrahydroisoquinolin-3-yl) acetate (33). 
Following the general procedure B for peptide coupling. Acid 11 (58 mg, 0.21 mmol), 
amine 14 (44 mg, 0.21 mmol), Et3N (70 l, 0.47 mmol), BOP-Cl (82 mg, 0.32 mmol) and 
CH2Cl2 (2 ml) afforded after flash chromatography (Hex/AcOEt 7:3) a white solid (59 
mg, 60%). The following data has been collected on a 1:1 rotamer mixture.  
Rf = 0.29 (Hex/AcOEt 7:3). [α]D25 = +7.8 (c 0.45, CHCl3). 1H NMR (400 MHz, CD3CN) δ 
7.51 – 7.08 (m, 9H), 5.57 (t, 1H, J = 9.9 Hz), 5.21 (d, 1H, J = 18.1 Hz), 4.74 (q, 0.5H, J = 5.7 
Hz), 4.66 (d, 0.5H, J = 16.3 Hz), 4.46 (d, 0.5H, J = 16.3 Hz), 4.20 – 4.03 (m, 1H), 3.62 (s, 
1.5H), 3.61 (s, 1.5H), 3.15 (dd, 0.5H, J = 16.4, 5.5 Hz), 3.04 (dd, 0.5H, J = 16.0, 5.6 Hz), 2.93 
– 2.85 (m, 1.5H), 2.84 – 2.71 (m, 1.5H), 2.66 – 2.49 (m, 2H), 2.42 (dt, 1H, J = 10.6, 3.6 Hz), 
2.27 (dd, 0.5H, J = 14.7, 8.0 Hz), 1.35 (s, 4.5H), 1.32 (s, 4.5H). 13C NMR (101 MHz, CD3CN) 
δ 172.9, 172.6, 140.8, 136.7, 135.6, 135.5, 134.5, 133.9, 133.2, 130.8 (2C), 130.6 (2C), 129.8 
(2C), 128.6 (2C), 128.1 (2C), 128.0 (2C), 127.9 (2C), 127.7 (2C), 127.6 (2C), 79.7 (2C), 52.8 
(2C), 51.4, 51.25, 49.8, 46.5, 45.8, 41.9, 41.7, 39.0, 38.6, 37.8 (2C), 34.7, 33.7, 29.1. HRMS 
(ESI) calcd. for [C27H34N2O5]+: 466.2468, found 467.2481. (MH+) 
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1H and 13C NMR of compound 33 
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Synthesis of 34: 
 
 
(S)-methyl-3-((R)-2-benzyl-3-(tert-butoxycarbonylamino)propanamido)-4-Phenyl 
butanoate (34a). 
Following the general procedure B for peptide coupling. Acid 26a (124 mg, 0.44 mmol), 
amine 11 (86 mg, 0.44 mmol), TEA (136 l, 0.98 mmol), BOP-Cl (170 mg, 0.67 mmol) and  
CH2Cl2 (2.2 ml) afforded after flash chromatography (Hex/AcOEt 7:3) a foam (149 mg, 
75%). 
[]D25 = -24,2 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) 7.36 - 7.08 (m, 10H), 5.98 (d, 
1H, J = 9.0 Hz), 4.82 (bs, 1H), 4.45 - 4.35 (m, 1H), 3.65 (s, 3H), 3.55 - 3.45 (m, 1H), 3.4 - 3.3 
(m, 1H), 3.25 - 3.15 (m, 1H), 2.85 - 2.7 (m, 3H), 2.64 - 2.5 (m, 1H), 2.29 (dd, 1H, J = 16.5, 
4.3 Hz), 2.15 - 2.05 (m, 1H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3)  172.6, 171.9, 156.0, 
139, 137.6, 129.1, 128.9, 128.5, 128.4, 126.7, 126.4, 79.3, 51.5, 49.7, 46.7, 42.7, 39.8, 36.7, 
36.6, 28.4. HRMS (ESI) calcd. for [C26H34N2O5]+: 454.2468, found 455.2454. (MH+) 
(S)-methyl-3-((S)-2-benzyl-3-(tert-butoxycarbonylamino)propanamido)-4-Phenyl 
butanoate (34b). 
Following the general procedure B for peptide coupling. Acid 26b (82 mg, 0.30 mmol), 
amine 11 (57 mg, 0.30 mmol), TEA (90 l, 0.64 mmol), BOP-Cl (112 mg, 0.44 mmol) and  
CH2Cl2 (1.5 ml) afforded after flash chromatography (Hex/AcOEt 7:3) a foam (101 mg, 
75%). 
[]D25 = +11,6 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) 7.35-6.97 (m, 9H), 6.95 (d, 1H, J 
= 6.0 Hz), 5.83 (d, 1H, J = 8.4 Hz), 5.07 (bs, 1H), 4.50 - 4.40 (m, 1H), 3.67 (s, 3H), 3.48 (dd, 
1H, J = 14.3, 8.7 Hz), 3.4 - 3.2 (m, 2H), 2.85 (dd, 1H, J = 13.4, 9.8 Hz), 2.78 - 2.68 (m, 2H) 
2.65 - 2.55 (m, 1H), 2.50 (dd, 1H, J = 13.6, 8.0 Hz), 2.44 (dd, 1H, J = 15.9 Hz, J = 5.1 Hz), 
2.31 (dd, 1H, J = 15.9, 6.4 Hz), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3)  172.8, 171.7, 
156.0, 138.9, 137.1, 129.3, 128.9, 128.6, 126.7, 126.6, 79.3, 51.8, 49.7, 46.9, 42.9, 39.7, 37.0, 
36.4, 28.4. HRMS (ESI) calcd. for [C26H34N2O5]+: 454.2468, found 455.2429. (MH+) 
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1H and 13C NMR of compound 34a 
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1H and 13C NMR of compound 34b 
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Synthesis of 35: 
 
 
 
(R)-methyl 2-benzyl-3-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanamido) 
propanoate (35a) 
Following the general procedure A for peptide coupling. Acid 11 (67 mg, 0.24 mmol), 
amine 27a (48 mg, 0.24 mmol), DIPEA (167 l, 0.96 mmol), HOBt (39 mg, 0.29 mmol), 
EDC (55 mg, 0.29 mmol) and CH2Cl2 (2 ml) afforded after flash chromatography 
(Hex/AcOEt 6:4) a white solid (49 mg, 45%).  
This compound appear as a mixture of conformers due to the Boc protecting group. 
Rf = 0.26 (Hex/AcOEt 6:4). [α]D25 = -21.3 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.36 
– 7.25 (m, 5H), 7.25 – 7.11 (m, 5H), 6.12 (bs, 1H), 6.01 (bs, 1H), 4.09 – 4.00 (m, 2H), 3.65 (s, 
3H), 3.64 – 3.47 (m, 3H), 3.35 (ddd, 1H, J = 13.5, 7.3, 6.1 Hz), 3.02 – 2.91 (m, 6H), 2.88 – 
2.71 (m, 4H), 2.46 (dd, 1H, J = 15.1, 4.9 Hz), 2.42 – 2.29 (m, 2H), 2.23 (dd, 1H, J = 15.1, 5.7 
Hz), 1.41 (s, 9H), 1.40 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 174.6, 171.1, 155.5, 138.2, 
138.0, 129.3 (3C), 128.9 (2C), 128.6 (2C), 128.5 (2C), 126.7, 126.6, 126.5, 79.4, 51.9, 49.6, 
46.8, 40.5, 40.2, 38.9, 36.1, 28.4. HRMS (ESI) calcd. for [C26H34N2O5]+: 454.2468, found 
455.2451. (MH+) 
 
(S)-methyl 2-benzyl-3-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanamido) 
propanoate (35b) 
Following the general procedure A for peptide coupling. Acid 11 (73 mg, 0.26 mmol), 
amine 27b (50 mg, 0.26 mmol), DIPEA (181 l, 1.04 mmol), HOBt (42 mg, 0.31 mmol), 
EDC (60 mg, 0.31 mmol) and CH2Cl2 (3 ml) afforded after flash chromatography 
(Hex/AcOEt 1:1) a white solid (72 mg, 61%).  
Rf = 0.25 (Hex/AcOEt 1:1). [α]D25 = -10.0 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.45 
– 7.10 (m, 10H), 5.95 (s, 1H), 4.19 – 3.94 (m, 1H), 3.67 (s, 3H), 3.60 – 3.49 (m, 1H), 3.46 – 
3.32 (m, 1H), 3.08 – 2.91 (m, 3H), 2.91 – 2.75 (m, 2H), 2.39 (dd, 1H, J = 15.0, 4.9 Hz), 2.27 
  
111 
(dd, 1H, J = 15.0, 5.7 Hz), 1.42 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 176.1, 172.5, 157.0, 
139.7, 139.6, 130.9 (2C), 130.4 (2C), 130.1 (2C), 130.0 (2C), 128.3, 128.0, 80.8, 53.4, 51.2, 
48.2, 41.9, 41.6, 40.7, 37.5, 29.9. HRMS (ESI) calcd. for [C26H34N2O5]+: 454.2468, found 
455.2497. 
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1H and 13C NMR of compound 35a 
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1H and 13C NMR of compound 35b 
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Synthesis of 36: 
 
 
 
(S)-methyl 3-((S)-3-(tert-butoxycarbonylamino)-4-phenylbutanamido)-4-phenyl 
butanoate (36) 
Following the general procedure A for peptide coupling. Acid 11 (66 mg, 0.25 mmol), 
amine 10 (48 mg, 0.25 mmol), DIPEA (174 l, 1.0 mmol), HOBt (41 mg, 0.30 mmol), EDC 
(57 mg, 0.30 mmol)and CH2Cl2 (3 ml) afforded after flash chromatography (Hex/AcOEt 
6:4) a white solid (65 mg, 59%).  
Rf = 0.27 (Hex/AcOEt 6:4). [α]D25 = -14.1 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.43 
– 7.04 (m, 10H), 6.13 (bs, 1H), 4.54 (bs, 1H), 4.04 (bs, 1H), 3.70 (s, 3H), 3.02 – 2.64 (m, 4H), 
2.63 – 2.44 (m, 2H), 2.43 – 2.29 (s, 1H), 2.29 – 2.16 (s, 1H), 1.41 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 172.0, 170.3, 155.4, 138.2, 137.4, 129.4 (2C), 129.2 (2C), 128.6 (2C), 128.5 
(2C), 126.8, 126.5, 79.3, 51.8, 49.7, 47.3, 40.3, 40.0, 39.2, 37.1, 28.4. HRMS (ESI) calcd. for 
[C26H34N2O5]+: 454.2468, found 455.2489. (MH+) 
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1H and 13C NMR of compound 36 
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Synthesis of 37: 
 
 
 
(S)-methyl 2-benzyl-3-((S)-2-benzyl-3-((tert-butoxycarbonyl)amino)propanamido) 
propanoate (37) 
Following the general procedure A for peptide coupling. Acid 26b (67 mg, 0.24 mmol), 
amine 27b (48 mg, 0.24 mmol), DIPEA (167 l, 0.96 mmol), HOBt (39 mg, 0.29 mmol), 
EDC (55 mg, 0.29 mmol) and CH2Cl2 (2 ml) afforded after flash chromatography 
(Hex/AcOEt 6:4) a white solid (55 mg, 51%).  
Rf = 0.33 (Hex/AcOEt 6:4). [α]D25 = +5.2 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.37 
– 7.02 (m, 10H), 5.65 (bs, 1H), 5.01 (bs, 1H), 3.57 (s, 3H), 3.51 – 3.30 (m, 2H), 3.31 – 3.11 
(m, 2H), 2.97 – 2.51 (m, 6H), 1.42 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 174.8, 171.1, 
155.6, 138.4, 138.2, 129.5, 129.0 (2C), 128.8 (2C), 128.7 (2C), 126.9, 126.7, 79.5, 52.1, 49.8, 
46.9, 40.5, 40.3, 39.3, 36.2, 28.5. HRMS (ESI) calcd. for [C26H34N2O5]+: 454.2468, found 
455.2455. (MH+) 
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1H and 13C NMR of compound 37 
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Synthesis of 46: 
 
 
 
(S)-methyl 2-(2-((S)-2-((R)-2-benzyl-3-((S)-2-(tert-butoxycarbonylamino)propanamido) 
propanoyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)acetamido) propanoate (47) 
Following the general procedure B for peptide coupling. Acid 46 (18 mg, 0.034 mmol), 
L-Alanine (5 mg, 0.034 mmol), TEA (16 l, 0.11 mmol), BOP-Cl (13 mg, 0.05 mmol) and  
CH2Cl2 (1 ml) afforded after flash chromatography (Hex/AcOEt 1:1) a foam (15 mg, 
74%). The following data has been collected on a complex conformer mixture. 
Rf = 0.36 (Hex/AcOEt 1:1). [α]D25 = +26.4 (c 1.0, CHCl3). 1H NMR (400 MHz, CD3CN) δ 
7.29 – 7.20 (2m, H), 7.20 – 7.04 (5m, H), 7.04 – 6.93 (2m, H), 6.85 (bs, 1H), 5.53 (bs, 1H), 
5.43 (bs, 1H), 5.10 (ddd, 1H, J = 9.1, 5.5, 2.5 Hz), 4.97 (d, 1H, J = 17.9 Hz), 4.67 (d, 1H, J = 
16.1 Hz), 4.45 – 4.37 (m, 1H), 4.10 (d, 1H, J = 17.9 Hz), 4.04 – 3.91 (m, 2H), 3.84 (t, 1H, J = 
7.1 Hz), 3.58 (s, 3H), 3.54 (s, 3H), 3.45 – 3.17 (m, 6H), 2.94 (dd, 1H, J = 15.8, 5.6 Hz), 2.81 
(m, 4H), 2.69 (dd, 1H, J = 16.0, 2.8 Hz), 2.47 – 2.33 (m, 2H), 2.30 – 2.14 (m, 2H), 2.04 (dd, 
1H, J = 16.2, 5.4 Hz), 2.00 – 1.94 (m, 1H), 1.39 (s, 9H), 1.36 (s, 9H), 1.23 (d, 3H, J = 7.1 Hz), 
1.06 (d, 3H, J = 7.1 Hz). 13C NMR (101 MHz, CD3CN) δ 174.0, 173.7, 172.0, 170.4, 159.2, 
140.5, 140.3, 134.0, 133.6, 133.4, 132.9, 130.1, 130.1, 129.9, 129.4, 129.4, 128.1, 127.6, 127.4, 
127.3, 127.0, 52.4, 52.2, 51.4, 51.2, 49.3, 46.4, 45.2, 44.2, 44.0, 42.2, 42.1, 42.1, 37.8, 37.7, 
37.2, 37.0, 33.6, 33.0, 28.6, 18.6 (2C). HRMS (ESI) calcd. for [C33H44N4O7]+: 608.3210, found 
609.3243. (MH+) 
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Synthesis of 43: 
 
 
 
tert-butyl ((S)-1-(((R)-2-benzyl-3-((S)-3-(2-(((S)-1-(methylamino)-1-oxopropan-2-
yl)amino)-2-oxoethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl)amino)-1-
oxopropan-2-yl)carbamate (43) 
Compound 47 (8 mg, 0.013 mmol) was dissolved at room temperature in a solution of 
methylamine in EtOH (1 ml, 7.5 M). The reaction mixture was stirred for 18 h and 
evaporated to give 43 (8 mg, 98%) as a white solid. The following data has been 
collected on a complex conformer mixture. 
Rf = 0.40 (AcOEt/MeOH 95:5). [α]D25 = +14.5 (c 0.7, CHCl3). 1H NMR (400 MHz, CD3CN) 
δ 7.40 (bs, 1H), 7.35 – 7.08 (m, 8H), 6.99 (d, 1H, J = 7.3 Hz), 6.91 (bs, 0.5H), 6.69 (bs, 0.5H), 
6.24 (bs, 0.5H), 5.70 (bs, 1H), 5.50 (bs, 0.5H), 5.16 (dd, 0.5H, J = 9.0, 2.6 Hz), 5.07 (d, 0.5H, 
J = 17.6 Hz), 4.72 (d, 0.5H, J = 16.1 Hz), 4.54 – 4.40 (m, 1H), 4.19 – 3.95 (m, 2.5H), 3.66 – 
3.46 (m, 1H), 3.41 – 3.19 (m, 1H), 2.82 (d, 1.5H, J = 6.7 Hz), 2.67 (d, 1.5H, J = 4.7 Hz), 2.61 
(d, 1.5H, J = 4.7 Hz), 2.57 – 2.00 (m, 5H), 1.92 – 1.78 (m, 0.5H), 1.42 (d, 12H, J = 8.2 Hz), 
1.29 (d, 3H, J = 7.0 Hz). 13C NMR (101 MHz, CD3CN) δ 174.7, 174.4, 172.3, 171.9, 156.9, 
140.9, 133.9, 133.8, 130.7, 130.6, 129.9, 129.6, 128.5, 128.0, 127.9, 127.7, 127.5, 80.4, 51.9, 
50.4, 47.3, 47.0, 45.8, 44.8, 44.3, 43.4, 42.5, 40.0, 39.3, 38.9, 37.8, 34.2, 33.5, 30.9, 29.1, 26.9, 
26.7, 19.5, 19.1. HRMS (ESI) calcd. for [C33H45N5O6]+: 607.3370, found 608.3357. (MH+) 
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1H and 13C NMR of compound 43 
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Compound 48a: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.36 (bs, 2H), 8.74 – 7.80 (m, 3H), 7.59 – 6.81 (m, 18H), 6.81 
– 6.55 (m, 8H), 5.37 – 5.13 (m, 1H), 5.05 (dd, 2H J = 25.0, 18.3 Hz), 4.77 – 4.61 (m, 1H), 
4.49 – 4.39 (m, 4H), 4.31 – 4.13 (m, 5H), 4.13 – 3.98 (m, 2H), 3.92 (dd, 2H, J = 25.1, 11.9 
Hz), 3.82 – 3.60 (m, 3H), 3.21 – 2.94 (m, 4H), 2.94 – 2.60 (m, 6H), 2.46 – 2.21 (m, 4H), 2.21 
– 2.01 (m, 3H), 2.01 – 1.59 (m, 4H), 1.40 – 1.15 (m, 3H). HRMS (ESI) calcd. for 
[C35H41N5O5]+: 611.3108, found 612.3102. (MH+) 
 
1H NMR of compound 48a 
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Compound 48b: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 8.30 – 8.20 (m, 1H), 8.14 – 7.95 (m, 3H), 7.95 – 7.77 (m, 1H), 
7.41 – 7.23 (m, 5H), 7.23 – 6.79 (m, 11H), 6.72 (dd, 2H, J = 14.1, 5.5 Hz), 5.39 – 5.03 (m, 
1H), 5.03 – 4.82 (m, 1H), 4.53 – 4.30 (m, 2H), 4.23 (dd, 2H, J = 14.0, 5.8 Hz), 4.04 (d, 2H, J = 
18.3 Hz), 3.40 – 2.95 (m, 9H), 2.95 – 2.57 (m, 7H), 2.20 – 2.05 (m, 4H), 1.89 (dd, 4H, J = 
18.5, 3.9 Hz), 1.83 – 1.62 (m, 4H), 1.59 (dd, 2H, J = 10.9, 6.1 Hz), 1.48 – 1.29 (m, 1H). 
HRMS (ESI) calcd. for [C35H41N5O5]+: 611.3108, found 612.3130. (MH+) 
 
1H NMR of compound 48b 
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Compound 49a: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.40 (s, 1H), 9.35 (s, 1H), 8.18 (bs, 1H), 8.00 (bs, 2H), 7.82 
(d, J = 7.8 Hz, 1H), 7.31 – 7.21 (m, 6H), 7.21 – 6.93 (m, 10H), 6.81 (m, 2H), 6.71 (d, 2H, J = 
8.4 Hz), 4.33 (dd, 1H, J = 8.0, 4.6 Hz), 4.24 – 4.18 (m, 2H), 3.90 – 3.60 (m, 3H), 3.35 – 3.10 
(m, 5H), 3.02 (dd, 2H, J = 14.3, 5.3 Hz), 2.94 – 2.69 (m, 5H), 2.69 – 2.56 (m, 2H), 2.34 (bs, 
1H), 2.20 – 2.04 (m, 3H), 2.03 – 1.86 (m, 2H), 1.85 – 1.73 (m, 2H), 1.71 - 1.66 (m, 1H), 1.64 
– 1.57 (m, 1H). HRMS (ESI) calcd. for [C34H41N5O5]+: 599.3108, found 600.3121. (MH+) 
 
1H NMR of compound 49a 
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Compound 49b: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 8.23 (bs, 1H), 8.14 – 7.82 (m, 2H), 7.74 (d, 1H, J = 8.4 Hz), 
7.56 – 6.93 (m, 12H), 6.93 – 6.81 (m, 4H), 6.72 (d, 4H, J = 8.5 Hz), 4.34 (dd, 1H, J = 8.1, 5.5 
Hz), 4.25 (m, 3H), 3.96 – 3.77 (bs, 1H), 3.72 – 3.58 (m, 3H), 3.33 - 3.23 (m, 3H), 3.22 – 3.00 
(m, 7H), 2.94 (dd, 1H, J = 13.4, 5.3 Hz), 2.89 – 2.76 (m, 2H), 2.76 – 2.56 (m, 7H), 2.28 – 1.99 
(m, 6H), 1.99 – 1.86 (m, 1H), 1.86 – 1.74 (m, 3H), 1.68 – 1.54 (m, 2H). HRMS (ESI) calcd. 
for [C34H41N5O5]+: 599.3108, found 600.3134. (MH+) 
 
1H NMR of compound 49b 
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Compound 50a: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.24 – 9.10 (m, 2H), 7.80 (dd, 1H, J = 15.5, 8.6 Hz), 7.60 (d, 
1H, J = 7.9 Hz), 7.48 – 7.34 (m, 2H), 7.30 – 6.95 (m, 16H), 6.90 (dd, 4H, J = 11.5, 8.5 Hz), 
6.71 – 6.59 (m, 4H), 4.81 (dd, 1H, J = 14.5, 5.5 Hz), 4.66 (d, 1H, J = 16.0 Hz), 4.55 – 4.41 (m, 
2H), 4.35 – 4.10 (m, 3H), 3.91 (t, 1H, J = 10.6 Hz), 3.62 – 3.54 (m, 4H,), 3.48 – 3.34 (m, 1H), 
3.27 – 2.97 (m, 5H), 2.97 – 2.71 (m, 5H), 2.71 – 2.58 (m, 4H), 2.48 – 2.06 (m, 5H), 1.96 – 
1.33 (m, 8H). HRMS (ESI) calcd. for [C35H41N5O5]+: 611.3108, found 612.3154. (MH+) 
 
1H NMR of compound 50a 
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Compound 50b: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.18 (bs, 2H), 7.80 (dd, 1H, J = 13.8, 8.4 Hz), 7.60 (dd, 1H, J 
= 13.2, 8.2 Hz), 7.52 – 7.34 (m, 2H), 7.31 – 6.97 (m, 16H), 6.97 – 6.80 (m, 4H), 6.73 – 6.59 
(m, 4H), 4.90 – 4.70 (m, 1H), 4.66 (d, 1H, J = 15.9 Hz), 4.57 – 4.33 (m, 3H), 4.33 – 4.09 (m, 
3H), 3.94 (t, 1H, J = 13.3 Hz), 3.67 – 3.49 (m, 3H), 3.49 – 3.28 (m, 2H), 3.28 – 2.97 (m, 4H), 
2.97 – 2.83 (m, 2H), 2.83 – 2.71 (m, 4H), 2.71 – 2.55 (m, 5H), 2.49 – 2.08 (m, 4H), 1.95 – 
1.67 (m, 2H), 1.67 – 1.28 (m, 7H). HRMS (ESI) calcd. for [C35H41N5O5]+: 611.3108, found 
612.3149. (MH+) 
 
1H NMR of compound 50b 
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Compound 51a: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.42 (bs, 1H), 9.33 (bs, 1H), 8.17 (bs, 1H), 8.00 (bs, 3H), 7.84 
(t, 2H, J = 5.7 Hz), 7.76 (dd, 1H, J = 11.2, 8.6 Hz), 7.35 – 7.06 (m, 22H), 6.93 (d, 1H, J = 8.4 
Hz), 6.79 (bs, 1H), 6.76 – 6.65 (m, 4H), 4.38 – 4.14 (m, 3H), 3.70 – 3.57 (m, 1H, J = 9.5 Hz), 
3.31 – 3.19 (m, 2H), 3.14 (t, 4H, J = 5.9 Hz), 3.02 (dd, 1H, J = 14.5, 5.4 Hz), 2.96 – 2.57 (m, 
9H), 2.43 – 2.21 (m, 2H), 2.16 (dd, 1H, J = 14.6, 6.6 Hz), 2.04 – 1.89 (m, 3H), 1.89 – 1.71 (m, 
3H), 1.71 – 1.59 (m, 3H), 1.53 (m, 2H), 1.48 – 1.35 (m, 2H). HRMS (ESI) calcd. for 
[C34H41N5O5]+: 599.3108, found 600.3128. (MH+) 
 
1H NMR of compound 51a 
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Compound 51b: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.28 – 9.05 (m, 2H), 8.06 – 7.76 (m, 3H), 7.55 (d, 1H, J = 8.4 
Hz), 7.38 (d, 1H, J = 8.5 Hz), 7.36 – 6.97 (m, 19H), 6.97 – 6.84 (m, 2H), 6.79 (bs, 2H), 6.64 
(t, 4H, J = 8.6 Hz), 4.40 – 4.10 (m, 2H), 4.10 – 3.89 (m, 1H), 3.67 – 3.46 (m, 1H), 3.46 – 3.36 
(m, 1H), 3.28 – 3.12 (m, 2H), 3.12 – 2.91 (m, 1H), 2.83 – 2.56 (m, 8H), 2.47 – 2.09 (m, 3H), 
2.09 – 1.85 (m, 3H), 1.85 – 1.68 (m, 2H), 1.68 – 1.40 (m, 7H), 1.00 – 0.76 (m, 4H). HRMS 
(ESI) calcd. for [C34H41N5O5]+: 599.3108, found 600.3163. (MH+) 
 
1H NMR of compound 51b 
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Compound 52: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.45 (bs, 1H), 9.34 (bs, 1H), 8.34 – 8.11 (m, 2H), 8.02 (bs, 
1H), 7.91 – 7.81 (m, 1H), 7.79 (d, 6H, J = 8.2 Hz), 7.37 (bs, 1H), 7.33 – 7.09 (m, 17H), 6.94 
(m, 4H), 6.76 – 6.67 (m, 4H), 5.15 (dd, 2H, J = 17.9, 5.4 Hz), 4.81 – 4.63 (m, 2H), 4.50 – 4.17 
(m, 4H), 4.04 (t, 2H, J = 17.1 Hz), 3.73 – 3.57 (m, 2H), 3.31 – 3.15 (m, 3H), 3.15 – 2.97 (m, 
3H), 2.97 – 2.77 (m, 7H), 2.77 – 2.55 (m, 6H), 2.37 (dd, 1H, J = 14.9, 8.5 Hz), 2.31 – 2.12 (m, 
2H), 2.12 – 2.03 (m, 1H), 2.03 – 1.54 (m, 8H), 1.46 – 1.34 (m, 1H). HRMS (ESI) calcd. for 
[C35H41N5O5]+: 611.3108, found 612.3121. (MH+) 
 
1H NMR of compound 52 
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Compound 53: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.43 (bs, 1H), 9.34 (bs, 1H), 8.19 (bs, 2H), 8.02 (bs, 2H), 7.92 
(d, 1H, J = 8.4 Hz), 7.79 (d, 1H, J = 8.4 Hz), 7.76 – 7.68 (m, 2H), 7.35 – 7.06 (m, 20H), 6.92 
(d, 2H, J = 8.5 Hz), 6.83 (bs, 2H), 6.74 – 6.63 (m, 4H), 4.36 – 4.19 (m, 3H), 4.19 – 4.09 (m, 
1H), 3.62 (dd, 1H, J = 11.7, 4.9 Hz), 3.59 – 3.52 (m, 1H), 3.31 – 3.18 (m, 3H), 3.03 (dd, 1H, J 
= 14.4, 5.4 Hz), 2.93 – 2.54 (m, 10H), 2.28 – 2.05 (m, 8H), 2.05 – 1.92 (m, 1H), 1.92 – 1.58 
(m, 4H), 1.58 – 1.53 (m, 2H), 1.39 (dd, 1H, J = 8.3, 6.9 Hz). HRMS (ESI) calcd. for 
[C34H41N5O5]+: 599.3108, found 600.3118. (MH+) 
 
1H NMR of compound 53 
  
 132 
Compound 54: 
 
The following data has been collected on a complex conformer mixture. 
1H NMR (400 MHz, DMSO) δ 9.43 (s, 1H), 9.35 (s, 1H), 7.98 – 7.92 (m, 2H), 7.91 – 7.78 
(m, 2H), 7.30 – 7.05 (m, 20H), 7.00 – 6.92 (m, 2H), 6.79 (d, 2H, J = 15.9 Hz), 6.70 (dd, 4H, J 
= 8.5, 2.0 Hz), 4.32 (dd, 1H, J = 8.2, 4.8 Hz), 4.21 (t, 1H, J = 5.9 Hz), 3.74 (t, 1H, J = 6.8 Hz), 
3.68 – 3.61 (m, 2H), 3.26 – 2.86 (m, 12H), 2.87 – 2.75 (m, 4H), 2.75 – 2.64 (m, 6H), 2.64 – 
2.52 (m, 3H), 2.12 – 1.97 (m, 1H), 1.95 – 1.72 (m, 4H), 1.65 – 1.56 (m, 1H). HRMS (ESI) 
calcd. for [C34H41N5O5]+: 599.3108, found 600.3160. (MH+) 
 
1H NMR of compound 54 
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3.1 -Carbolines 
 
Carbolines are benzofused tricyclic structures and they are a common motif in natural 
compounds. They consist of a pyridine ring fused to an indole skeleton. Their structure 
is similar to that of tryptamine, with a methylene connection on the indole position 2. 
 
 
Figure 35. -Carboline and tetrahydro--carboline. 
 
The β-carboline core is usually built from a suitable functionalized indole, such as a 
tryptamine derivative, onto which the fused pyridine ring is introduced. Indoles are 
activated substrates that efficiently undergo intramolecular Friedel–Crafts reactions 
such as the Pictet–Spengler (PS) and the Bischler–Napieralski (BN) reactions. Other 
methodologies based on organometallic catalyzed cyclizations or the synthesis of the 
pyrrole ring have also emerged in recent times. However, once the β-carboline system is 
on hand, many syntheses still need further transformations en route to natural products 
or synthetic drug candidates. In addition, transformation of the β-carboline system into 
other heterocycles or synthetically useful compounds (i.e., the use of the β-carboline as 
a synthetic intermediate) has been growing in importance in recent years. 
Carbolines can be easily transformed into fused tetracyclic derivatives like 
imidazolidin-2-ones (carbonyl bridge), imidazolidines (methylene bridge) and 
piperazin-2-ones.[91] The functionalization of the β-carboline system and its use as a 
synthetic intermediate for the synthesis of more complex heterocycles have reached a 
mature state with the use of various reactions such as carbon-carbon coupling, RCM, 
diverse cycloadditions and stereoselective organocatalytic functionalizations.[92] 
From a long time, the alkaloids containing the 1,2,3,4-tetrahydro--carboline (THBC) 
skeleton represent important lead structures in view of their wide range of biological 
activities.[93] Due to their unique rigid heterocyclic skeleton, such cyclic tryptophan 
analogues are known to bind with high affinity to various receptor sites, such as the 
                                               
[91] Pulka K., Feytens D., Misicka A., Tourw  D. “New tetracyclic tetrahydro-β-carbolines as tryptophan-derived 
peptidomimetics” Mol. Divers. 2010, 14, 97-108 
[92] Dominguez G., Perez-Castells J. “Chemistry of β-Carbolines as Synthetic Intermediates” Eur. J. Org. Chem. 2011, 
7243-7253 
[93] Cordell G.A. “The Alkaloids, Chemistry and Pharmacology” Academic Press: New York, 1993, Vol. 43 
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benzodiazepine (BzR),[94] serotonin,[95] and dopamine[96] ones and to inhibit monoamine 
oxidase A.[97] Moreover, in the recent years, some tetracyclic -carbolines have been 
described to act as selective inhibitors in the anticancer field,[98] or to be endowed with 
antimalarial properties.[99] 
  
                                               
[94] Oakley N.R., Jones B.J. “The proconvulsant and diazepam-reversing effects of ethyl-beta-carboline-3-
carboxylate” Eur. J. Pharmacol. 1980, 68, 381-382 
[95] (a) Khorana N., Smith C., Herrick-Davis K., Purohit A., Teitler M., Grella B., Dukat M., Glennon R.A. “Binding of 
tetrahydrocarboline derivatives at human 5-HT5A receptors” J. Med. Chem. 2003, 46, 3930-3937 (b) Audia J.E., 
Evrard D.A., Murdoch G.R., Droste J.J., Nissen J.S., Schenk K.W., Fludzinski P., Lucaites V.L., Nelson D.L., 
Cohen M.L. ”Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile 
receptor in the rat stomach fundus” J. Med. Chem. 1996, 39, 2773-2780 
[96] Abou-Gharbia M., Patel R.U., Webb M.B., Moyer J.A., Andree T.H., Muth T.A. “Antipsychotic activity of 
substituted gamma-carbolines” J. Med. Chem. 1987, 30, 1818-1823 
[97] (a) Callaway J.C., Gynther J., Poso A., Vepsäläinen J., Airksinen M.M. ” The Pictet-Spengler reaction and biogenic 
tryptamines: formation of tetrahydro-β-carbolines at physiological pH” J. Heterocyclic Chem. 1994, 31, 431-435 (b) 
Ho B.T. “Monoamine oxidase inhibitors” J. Pharm. Sci. 1972, 61, 821-837 
[98] (a) Jenkins P.R., Wilson J., Emmerson D., Garcia M.D., Smith M.R., Gray S.J., Britton R.G., Mahale S., Chaudhuri 
B. “Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based 
selective inhibitors of CDK4” Bioorg. Med. Chem. 2008, 16, 7728-7739 (b) Sunder-Plassmann N., Sarli V., Gartner 
M., Utz M., Seiler J., Huemmer S., Mayer T.U., Surrey T., Giannis A. “Synthesis and biological evaluation of new 
tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5” Bioorg. Med. Chem. 2005, 13, 6094-6111 
[99] Gupta L., Srivastava K., Singh S., Puri S.K., Chauhan P.M.S. “Synthesis of 2-[3-(7-Chloro-quinolin-4-ylamino)-
alkyl]-1-(substituted phenyl)-2,3,4,9-tetrahydro-1H-beta-carbolines as a new class of antimalarial agents” Bioorg. 
Med. Chem. Lett. 2008, 18, 3306-3309 
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3.2 Diketopiperazines 
 
2,5-Diketopiperazine (DKP)-based compounds are heterocyclic scaffolds structurally 
similar to peptides. They have attracted attention in recent years because of their broad 
biological activities[100] and therapeutic applications, ranging from antibiotics[101] to 
anticancer agents.[102] 
 
Figure 36. 2,5-Diketopiperazine ring. 
 
DKPs are a six member heterocycles possessing four points of functionalization. Two 
amidic positions and two stereocenters which belong to Amino acid constituting the 
DKP core. They are indeed the smallest cyclic peptide, commonly biosynthesized from 
amino acids by different organisms, including mammals, and are considered to be 
secondary functional metabolites or side products of terminal peptide cleavage. 
A 2,5-diketopiperazine has two s-cis secondary amide groups that can hydrogen bond 
horizontally within the ring plane. As a result of their rigid cyclic structures, bearing 
amide groups, DKPs are usually poorly soluble in organic solvents. In the solid state, 
the vast majority of N-unsubstituted DKPs adopt a linear tape orientation, whereas the 
presence of one N-substituent leads either to the formation of one-dimensional 
hydrogen-bonded tapes through the establishment of nonreciprocal hydrogen-bond 
networks, or to hydrogen-bonded dimers. 
                                               
[100] (a) Wang S., Golec J., Miller W., Milutinovic S., Folkes A., Williams S., Brooks T., Hardman K., Charlton P., 
Wren S., Spencer J. “Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from 
diketopiperazines” Bioorg. Med. Chem. Lett. 2002, 12, 2367–2370 (b) Houston D.R., Synstad B., Eijsink V.G., Stark 
M.J., Eggleston I.M., Van Aalten D.M. “Structure-based exploration of cyclic dipeptide chitinase inhibitors” J. 
Med. Chem. 2004, 47, 5713–5720 
[101] Fdhila F., Vazquez V., Sanchez J.L., Riguera R. “dd-diketopiperazines: antibiotics active against Vibrio 
anguillarum isolated from marine bacteria associated with cultures of Pecten maximus” J. Nat. Prod. 2003, 66, 
1299–1301 
[102] Nicholson B., Lloyd G.K., Miller B.R., Palladino M.A., Kiso Y., Hayashi Y., Neuteboom S.T. “NPI-2358 is a 
tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent” Anti-Cancer 
Drugs 2006, 17, 25–31 
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Some of the chemical properties of 2,5-diketopiperazines are very interesting for 
medicinal chemistry, such as resistance to proteolysis, mimicking of peptidic 
pharmacophoric groups, substituent group stereochemistry (deﬁned and controlled in 
up to four combinations), conformational rigidity, and donor and acceptor groups for 
hydrogen bonding (favouring interactions with biological targets). In addition, the 
compounds show a common scaffold, easily obtained by conventional procedures, that 
favours structural diversity as a function of substituent side chains particularly 
orientated. Favorable pharmacodynamic and pharmacokinetic characteristics are 
acquired by the compounds through these properties, leading to promising agents for 
the development of new drugs. Diketopiperazines are privileged structures for the 
discovery of new lead compounds by combinatorial chemistry and are considered ideal 
for the rational development of new therapeutic agents. 
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3.3 THBC-DKP Scaffold 
 
Structural unification of THBC and DKP pharmacophores has led to new classes of 
biologically active tetracyclic compounds, either occurring in nature and synthetically 
made.[103] Highly complex natural products displaying the fused, tetracyclic THBC-DKP 
ring system were recently isolated from the fermentation broth of the marine-derived 
fungus Aspergillus fumigatus, already known as a valuable source of bioactive secondary 
metabolites.[104] Some of these compounds exhibited significant cell growth-inhibitory 
activities against various cell lines.[105] Specifically designed THBC-DKP-based 
compounds have received considerable attention over the last years for their valuable 
biological activities, ranging from inhibition of the cyclic guanosine monophosphate 
type 5 specific phosphodiesterase (PDE 5) for treatment of erectile dysfunction 
(Tadalafil),[106] inhibition of plasmodial PDE activity for antimalarial drugs,[107] 
topoisomerase II inhibition,[108] to oral anti-thrombotic properties.[109] (Figure 37) 
                                               
[103] Chanda K., Chou C.-T., Lai J.J., Lin S.F., Yellol G.S., Sun C.M. “Traceless synthesis of diketopiperazine fused 
tetrahydro-β-carbolines on soluble polymer support” Mol Divers, 2011, 15, 569-581 
[104] Wang Y., Li Z.L., Bai J., Zhang L.M., Wu X., Zhang L., Pei Y.H., Jing Y.K., Hua H.M. “2,5-Diketopiperazines 
from the Marine-Derived Fungus Aspergillus fumigatus YK-7” Chem. & Biodiv. 2012, 9, 385-393 
[105] Deveau A.M., Costa N.E., Joshi E.M., Macdonald T.L. “Synthesis of diketopiperazine-based carboline 
homodimers and in vitro growth inhibition of human carcinomas” Bioorg. Med. Chem. Lett. 2008, 18, 3522-3525 
[106] Daugan A., Grondin P., Ruault C., Gouville A.C., Le M., Coste H., Linget J.M., Kirilovsky J., Hyafil F., 
Labaudiniere R. “The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-
hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues” J. Med. Chem. 2003, 46, 4533-4542 
[107] (a) Beghyn T.B., Charton J., Leroux F., Henninot A., Reboule I., Cos P., Maes L., Deprez B. “Drug-to-genome-to-
drug, step 2: reversing selectivity in a series of antiplasmodial compounds” J. Med. Chem. 2012, 55, 1274-1286 (b) 
Beghyn T.B., Charton J., Leroux F., Laconde G., Bourin A., Cos P., Maes L. Deprez B. “Drug to genome to drug: 
discovery of new antiplasmodial compounds” J. Med. Chem. 2011, 54, 3222-3240 
[108] Deveau A.M., Labroli M.A., Dieckhaus C.M., Barthen M.T., Smith K.S., Macdonald T.L. “The synthesis of 
amino-acid functionalized beta-carbolines as topoisomerase II inhibitors” Bioorg. Med. Chem. Lett. 2001, 11, 1251-
1255 
[109] Liu J., Wu G., Cui G., Wang W.X., Zhao M., Wang C., Zhang Z., Peng S. “A new class of anti-thrombosis 
hexahydropyrazino-[1',2':1,6]pyrido-[3,4-b]-indole-1,4-dions: design, synthesis, logK determination, and QSAR 
analysis” Bioorg. Med. Chem. 2007, 15, 5672–5693 
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Figure 37. THBC-DKP-based natural and synthetically made compounds. 
 
In our ongoing program of design of pharmacophore-based combinatorial libraries[110] 
and identification of new peptidomimetic scaffolds of potential interest in drug 
discovery,[111] we evaluated the THBC-DKP-based scaffold as a potential suitable motif 
for creation of unusual reverse turn nucleators.  
In addition to mostly occurring - and -turns, stabilized by ten- and seven-membered 
intramolecular H bonds respectively, reversal of the polypeptide chain direction in 
globular proteins can also occur thanks to less common substructures, for instance 
involving five amino acids residues, such as the case of the -turns. 
In many cases the -turn occurs at the ends of extended strands, and whenever it occurs 
at the loop regions connecting two extended strands, it brings about a hairpin bend. 
Even if a very large majority of -turns segments form part of regular -helices, isolated 
-turns have been reported,[112] which are stabilized by a 5→1 hydrogen bond between 
carbonyl oxygen at position i and amide at position i+4. The minor recurrence in 
proteins of this secondary structure is probably due to the necessity of particular 
combination of residues in the -turn as well as those immediately preceding and 
succeeding this turn, able to  hamper the propagation of the motif to -helices. 
However, quite recently the presence of α-turns in constrained peptides has been 
associated to some relevant biological activity. For instance, sugar amino acid based 
macrocyclic cationic peptides have been reported to show good bacteriolytic activity 
                                               
[110] Danieli B., Giovanelli P., Lesma G., Passarella D., Sacchetti A., Silvani A. “Combinatorial solid-phase synthesis 
of 6-hydroxy-1,2,3,4-tetrahydro-beta-carbolines from l-5-hydroxytryptophan” J. Comb. Chem. 2005, 7, 458-462 
[111] Lesma G., Landoni N., Sacchetti A., Silvani, A. “The spiropiperidine-3,3’-oxindole scaffold: a type II B-turn 
peptide isostere” Tetrahedron 2010, 66, 4474–4478 (b) Lesma G., Landoni N., Pilati T., Sacchetti A., Silvani A. 
“Tetrahydroisoquinoline-based spirocyclic lactam as a type II' beta-turn inducing peptide mimetic” J. Org. 
Chem. 2009, 74, 8098–8105 (c) Lesma, G.; Landoni, N.; Sacchetti, A.; Silvani A. “Pyrroloisoquinoline-based 
tetrapeptide analogues mimicking reverse-turn secondary structures” J. Org. Chem. 2007, 72, 9765–9768 
[112] Nataraj D.V., Srinivasan N., Sowdhamini R., Ramakrishnan C. “α-Turns in protein structures” Current Science 
1995, 69, 434-446 
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against the Gr+ve and Gr-ve bacteria while exhibiting low hemolytic activity.[113] In another 
work, a peptide was constrained in an α-helical conformation by means of cyclic α-turn 
mimetics, resulting in good activity in both a recombinant fusion assay and in a RSV 
antiviral assay.[114] Recently the antibody F425-B4e8, isolated from human (HIV-1) 
infected individuals, was showed to bind in complex with a V3 peptide through a five-
residue -turn, thus opening the way for HIV-neutralization.[115] Other examples of α-
turns are observed in synthetic peptidomimetics.[113,116]  
Despite the growing interest in this kind of reverse turn and the need for all kinds of 
conformationally constrained mimics as tools for medicinal chemistry, the development 
of constrained α-turn mimetics has received poor attention until now.  
So I planned the synthesis of the THBC-DKP-based peptidomimetic 1a (Figure 38) and 
performed the conformational evaluation for which molecular modeling let envisage a 
thirteen-membered hydrogen bond stabilized -turn conformation. 
 
 
Figure 38. THBC-DKP-based peptidomimetic 1a. 
 
  
                                               
[113] Chakraborty T.K., Koley D., Ravi R., Krishnakumari V., Nagaraj R., Kunwar A.C. “Synthesis, conformational 
analysis and biological studies of cyclic cationic antimicrobial peptides containing sugar amino acids” J. Org. 
Chem. 2008, 73, 8731–8744 
[114] Shepherd N.E., Hoang H.N., Desai V.S., Letouze E., Young P.R., Fairlie D.P. “Modular alpha-helical mimetics 
with antiviral activity against respiratory syncitial virus” J. Am. Chem. Soc. 2006, 128, 13284–13289 
[115]  Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., Wilson I.A. “Structure of 
antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization” J. Mol. 
Biol. 2008, 375, 969–978 
[116] (a) Hoang H.N., Driver R.W., Beyer R.L., Malde A.K., Le G.T., Abbenante G., Mark A.E., Fairlie D.P. “Protein α-
turns recreated in structurally stable small molecules” Angew. Chem. Int. Ed. 2011, 50, 11107–11111 (b) Kelso 
M.J., Beyer R.L., Hoang H.N., Lakdawala A.S., Snyder J.P., Oliver W.V., Robertson T.A., Appleton T.G., Fairlie 
D.P. “Alpha-turn mimetics: short peptide alpha-helices composed of cyclic metallopentapeptide modules” J. 
Am. Chem. Soc. 2004, 126, 4828-4842 
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3.4 Computational Design 
 
In order to investigate the presence of a preferred conformation able to mimic an 
ordered protein secondary structure, a computer aided conformational analysis was 
performed on 1a (6S, 12aS stereochemistry, IUPAC atom numbering as in Figure 37) 
and diastereoisomeric 1b (6R, 12aS). Compounds 1a and 1b were submitted to an 
unconstrained Monte Carlo (MC) conformational search combined with Molecular 
Mechanics (MM) minimization. For each compound 972 conformers were generated 
and after removal of duplicated minima, only conformations within 6 kcal/mol of the 
global minimum were considered. 35 and 33 conformers were kept for compound 1a 
and 1b, respectively. As a main indication of a stable secondary structure, the presence 
of intramolecular hydrogen bonds was first evaluated.  
Two H-bond have been identified, a 7-membered ring H-bond (H-bond A, Figure 39) 
between the N5H hydrogen and the C3 carbonyl and a 13 membered ring H-bond (H-
bond B) between the N5H hydrogen and the C1 carbonyl, here represented by the Cbz 
carbonyl. To assess the presence of turn conformations we also measured the 
interatomic distance dα between the terminal Cα5 atom and the benzyl oxygen of the 
Cbz (which emulates the Cα1 atom), assuming a value dα < 7Å as a probe of a generic 
reverse turn.  Results are reported as number of conformers which meet the geometrical 
features. 
 
Figure 39. Hydrogen bond pattern for scaffolds 1a and 1b. 
 
Table 6. MC/MM Conformational Analysis for peptidomimetics 1a and 1b.  
The + symbol indicates the presence in the global minimum. 
 
 Conf. within 6 kcal/mol H-bond A 
(7-membered) 
H-bond B 
(13-membered) 
dα < 7Å 
1a 35 17 4 + 4 + 
1b 33 22 + 1 1 
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The most frequently observed is the 5→3 H-bond (H-bond A) which is related to a 
classical γ-turn around these residues, and a 5→1 H-bond (H-bond B) which can be 
identified as an α-turn (this conformation is present in four conformers for compound 
1a). Inspection of the global minimum showed the α-turn conformation only for 
compound 1a. For this diastereoisomer, the first four low energy conformers all adopt 
the α-turn conformation (presence of the 5→1 H-bond and  average dα = 5.1 Å): 
according to a Boltzmann distribution analysis, these conformers take into account for 
the 94.5% of all the conformers obtained by the MC/MM analysis. On the other hand, 
for compound 1b, the lowest energy conformers all have the 5→3 H-bond (classical γ-
turn), with the only α-turn conformation lying 5.9 kcal/mol above the global minimum. 
Inspection of the virtual torsion angles of the amide backbone revealed the preference 
for an inverse  γ-turn of the low energy conformers of 1b (φ = -80.1°, ψ = 79.6° average 
based on the conformers accounting for the 93% of all the conformers from a Boltzmann 
distribution analysis). For compound 1a the averages of torsion angles value were φ 
(Cα2) = -81.5°, ψ (Cα2) = 64.5°, φ (Cα3) = 146.3°, ψ (Cα3) = 36.9°, φ (Cα4) = 120.5°, ψ (Cα4) = -
29.3°. According to the classification of α-turns in protein structures,[112] compound 1a is 
an α-turn mimetic with a B-αL-X designation. In Figure 40 the low energy conformers of 
1a and 1b are represented. These pictures well highlight the crucial role of the C6 
configuration in favoring either an α-turn conformation (1a) or a γ-turn conformation 
(1b). 
 
Figure 40. Perspective view of the low energy conformers of 1a and 1b.  
Hydrogen atoms are omitted for clarity. 
 
Finally, having ascertained by means of further calculations the irrelevance of the C3 
configuration on the expected secondary structure, we fixed it as 3S. Being interested in 
unusual reverse turns, we then pursued the synthesis of peptidomimetic 1a. 
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3.5 Synthesis 
 
Starting from L-tryptophan methyl ester and N-Cbz-aminoacetaldehyde dimethyl 
acetal, tetrahydro--carboline 2 was obtained in good yield and high 
diastereoselectivity (d.r. 6:1 from 1H NMR) by means of Pictet-Spengler reaction[117] and 
subsequent chromatographic separation. 
 
 
Scheme 14. Synthesis of 1a. 
 
The 6S, 12aS stereochemistry of the prevailing diastereoisomer was easily ascertained 
by application of the protocol of Ungemach et al.[118] on the 13C NMR spectrum of 
compound 2 and, conclusively, by the observation of an intense NOE contact between 
H-6 and H-12a in the 2D NOESY spectrum. Alkylation of L-alanine benzyl ester with 
ethyl bromoacetate afforded amine 3,[119] on which N-Fmoc protection and subsequent 
                                               
[117] Pulka K., Tymecka D., Frankiewicz L., Wilczek M., Kozminski W., Misicka A. “Diastereoselective Pictet–
Spengler condensation of tryptophan with α-amino aldehydes as chiral carbonyl components” Tetrahedron, 
2008, 64, 1506-1514 
[118] Ungemach F., Soerens D., Weber R., Di Pierro M., Campos O., Mokry P., Cook J.M., Silverton J.V. “General 
method for the assignment of stereochemistry of 1,3-disubstituted 1,2,3,4-tetrahydro-beta-carbolines by carbon-
13 spectroscopy” J. Am. Chem. Soc. 1980, 102, 6976-6984 
[119] Coppola G.M., Iwaki Y., Karki R.G., Kawanami T., Ksander G.M., Mogi M. PCT Int. 
Appl. (2010), WO 2010136493 A1 20101202 
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carefully conducted hydrogenolysis of the benzyl ester were performed,[120] to give acid 
4 in acceptable overall yield. 
Condensation of acid 4 with secondary amine 2 proved to be troublesome in a wide 
range of conditions, probably due to the severe steric hindrance of both the amine and 
acid coupling partners. At the end, acceptable yields could be obtained via formation of 
the chloride intermediate,[121] by reaction of acid 4 with thionyl chloride, and subsequent 
coupling with 2 in CH2Cl2 and 2,6-lutidine to give 5. The formation of the fused, 
tetracyclic THBC-DKP ring system was then easily achieved by removal of the N-Fmoc 
protecting group[122]and spontaneous lactamization to give the diketopiperazine ring of 
6. The obtained compound 6 represents a valuable peptidomimetic, whose potential is 
also related to the possibility of further derivatization with desired pharmacophoric 
groups, on both the terminal acid and amine functional groups, for the development of 
conformationally constrained tryptophan-containing peptide ligands. 
To investigate the actual secondary structure of the THBC-DKP scaffold also in 
solution, compound 6 was converted into the N-methyl carboxyamide derivative 1a, by 
a two step procedure (0.5 M LiOH, 0 °C, then MeNH2, TBTU, DIPEA), which was 
carefully conducted in order to avoid the easy epimerization of the C3 and C12a 
stereocenters. Direct transesterification performed with a methyl amine solution in 
ethanol showed such tendency to epimerize for the DKP constituting stereocenters. 
 The study of conformational behavior was conducted in CDCl3, to identify possible 
intramolecular hydrogen bonding. 
 
  
                                               
[120] Shoulders M.D., Kotch F.W., Choudhary A., Guzei I.A., Raines R.T. “The aberrance of the 4S diastereomer of 4-
hydroxyproline” J. Am. Chem. Soc. 2010, 132, 10857-10865 
[121] Tantry S.T., Venkataramanarao R., Chennakrishnareddy G., Sureshbabu V.V. “Total synthesis of cyclosporin O 
by convergent approach employing Fmoc-amino acid chlorides mediated by zinc dust” J. Org. Chem. 2007, 72, 
9360-9363 
[122] Wang H., Ganesan A. “Concise synthesis of the cell cycle inhibitor demethoxyfumitremorgin C” Tetrahedron 
Letters, 1997, 38, 4327-4328 
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3.6 Conformational Analysis 
 
The involvement of the NH amide protons in such bonding was first estimated from 
evaluation of their chemical shift value (δ) and of the temperature coefficients Δδ/ΔT 
(between 263 and 328 K). All data were measured at 2.0 mM concentration, that is in the 
absence of any noticeable intermolecular aggregation. While both NHMe and NHCbz 
chemical shift values are low (6.78 ppm for NHMe and 5.53 ppm for NHCbz), a 
significant difference could be appreciated between their temperature coefficients, 
ranging from  7.0 ppb K-1 (in absolute value) for the NHMe signal to 2.3 ppb K-1 (in 
absolute value) for the NHCbz signal. According to the literature,[123] these data could 
be attributed to a situation of equilibrium between hydrogen-bonded and non-
hydrogen-bonded states for the NHMe amide proton and a completely non-hydrogen-
bonded state for the NHCbz amide proton. In addition, a supplementary indication of 
the different hydrogen-bonding state for the two NH protons was obtained from DMSO 
titration studies in CDCl3,[124] indicating that the chemical shift of the NHMe has a minor 
variation (0.24 ppm) upon addition up to 30% of the competitive solvent DMSO, with 
respect to the chemical shift of NHCbz, varying of 0.82 ppm. 
 
Figure 41. VT-NMR for NH-Me and NH-Cbz (CDCl3, 2 mM, 1a). 
Taking into account the suggestions from the molecular modeling and these 
experimental results, for 1a we can presume the presence in solution of conformers 
bearing a thirteen-membered intramolecular hydrogen bond involving the NHMe 
proton and the Cbz carbonyl group, as visualized in the perspective view of the low 
energy conformer of 1a.  
                                               
[123] Belvisi L., Gennari C., Mielgo A., Potenza D., Scolastico C. “Conformational Preferences of Peptides Containing 
Reverse-Turn Mimetic Bicyclic Lactams: Inverse -Turns versus Type-II′ -Turns – Insights into -Hairpin 
Stability” Eur. J. Org. Chem. 1999, 389-400 
[124] For DMSO-d6/CDCl3 solutions, chemical shifts were standardized by reference to residual proton resonance for 
CHD2CD3SO (2.49 ppm). 
6,77 6,69 6,58 
5,49 5,55 5,58 
5,65 
y = -0,007x + 8,8934 
y = 0,0023x + 4,8754 
3
4
5
6
7
8
9
250 270 290 310 330

 p
p
m
 
T (K) 
  
147 
3.7 Conclusion 
 
We realized the synthesis of a new constrained THBC-DKP based scaffold able to mimic 
an α-turn. It was designed with the aid of computational tools, which highlight the 
relative cis arrangement of the substituents on the THBC piperidine ring as a crucial 
requirement in order to obtain the correct geometry for mimicry.  
Following these studies, the desired isomer 1a of the THBC-DKP based peptidomimetic 
was synthesized. 1H NMR conformational studies confirmed the presence of the 
intramolecular thirteen-membered hydrogen bond which characterizes the α-turn 
conformation, even if a situation of equilibrium between hydrogen-bonded and non-
hydrogen-bonded states can be observed. Nevertheless, this scaffold represents one of 
the rare examples of a designed constrained α-turn mimic.[125] 
 
  
                                               
[125] Airaghi F., Fiorati A., Lesma G., Musolino M., Sacchetti A., Silvani A. “The Diketopiperazine fused Tetrahydro-
-Carboline Scaffold as a Model Peptidomimetic with an Unusual -Turn Secondary Structure” submitted 
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3.8 Experimental Details 
 
Chemistry 
All solvents were distilled and properly dried, when necessary, prior to use. All 
chemicals were purchased from commercial sources and used directly, unless otherwise 
indicated. All reactions were run under nitrogen atmosphere, unless otherwise 
indicated. All reactions were monitored by thin layer chromatography (TLC) on 
precoated silica gel 60 F254; spots were visualized with UV light (254 nm) and by 
treatment with 1% aqueous KMnO4 solution, Ninhydrin solution in ethanol or Cerium-
ammonium-molybdate (CAM) reactive. Products were purified by flash 
chromatography on silica gel 60 (230‑400 mesh). 1H and 13C NMR spectra were recorded 
with 300 and 400 Mhz spectrometers using chloroform-d (CDCl3), dimethylsulfoxide-d6 
(DMSO-d6), acetonitrile-d3 (CD3CN) or methanol-d4 (CD3OD). Chemical shifts (δ) are 
expressed in ppm relative to TMS at δ = 0 ppm for 1H NMR and relative to CDCl3 at δ = 
77.16 ppm for 13C NMR. High‑resolution MS spectra were recorded with a FT‑ICR 
(Fourier Transform Ion Ciclotron Resonance) instrument, equipped with an ESI source, 
or a standard MS instrument, equipped with an EI source. Specific rotations were 
measured by a polarimeter “P-1030 Jasco” with 10 cm Optical path cells and 1 ml 
capacity. 
Computational details 
Conformational analysis was performed with the software Spartan ’08 using a MC/MM 
protocol. The obtained conformers were then optimized with the semiempirical method 
AM1. The structures were then analyzed and clustered according to their secondary 
structure motifs. 
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Synthesis of 1a: 
 
 
Benzyl (((3S,6S,12aS)-3-methyl-2-(2-(methylamino)-2-oxoethyl)-1,4-dioxo-
1,2,3,4,6,7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-6-
yl)methyl)carbamate (1a) 
Compound 6 (165 mg, 0.32 mmol, 518 g/mol) was dissolved in EtOH (3 ml). Aqueous 
LiOH (0.5 M, 2.54 mmol, 4.6 ml) was added and the reaction was stirred at 0 °C for 1 h. 
After then, the solution was acidified with HCl 1N (8 ml), extracted with AcOEt (3x20 
ml), dried, filtered and concentrated. The crude was suspended in DCM (10 ml) under 
N2, DIPEA (208 µl, 1.20 mmol) and TBTU (384 mg, 1.20 mmol) were added. After 
stirring for 30 minutes, MeNH2 (2.0 M THF solution, 1.20 mmol, 601 µl) was added. The 
reaction was stirred for 24 h under N2, then it was poured into water (20 ml) and 
extracted with AcOEt (3 x 20 ml), dried, filtered and concentrated. Purification by flash 
chromatography (AcOEt) afforded product 1a (110 mg, 68% overall yield) as an oil.  
The following data has been collected on a complex mixture of rotamers plus a 5% of 
1b.  
[α]D25 = -98.3 (c 0.75, MeOH). 1H NMR (500 MHz, CD3CN, major rotamer) δ 9.41 (bs, 1H) 
7.55 (d, 1H, J = 7.6 Hz) 7.38 (d, 1H, J = 7.8 Hz) 7.34-7.23 (m, 5H) 7.13 (ddd, 1H, J = 7.8, 7.6, 
0.9 Hz) 7.06 (dt, 1H, J = 7.6, 0.9 Hz), 6.95 (q, 1H, J = 4.7 Hz) 5.83 (q, 1H, J =  8.2, 5.1 Hz) 
5.43 (t, 1H, J = 3.4 Hz) 4.90 (d, 1H, J = 12.3 Hz) 4.87 (d, 1H, J = 12.3 Hz) 4.26 (d, 1H, J = 
17.0 Hz) 4.16 (q, 1H, J = 7.0 Hz) 4.14 (dd, 1H, J = 11.4, 5.5 Hz) 3.98 (ddd, 1H, J = 14.2, 8.2, 
3.8 Hz) 3.94 (d, 1H, J = 17.0 Hz) 3.43 (dd, 1H, J = 15.6, 5.5 Hz) 3.26 (ddd, 1H, J = 14.2, 5.1, 
3.2 Hz) 3.00 (dd, 1H, J = 15.6, 11.4 Hz) 2.69 (d, 3H, J = 4.7 Hz) 1.48 (d, 3H, J = 7.0 Hz). 13C 
NMR (125.8 MHz, CD3CN) δ 170.4, 170.0, 169.8, 157.8, 137.5, 135.2, 132.0, 129.0 (2C), 
128.5, 128.3 (2C), 126.9, 122.2, 119.8, 118.7, 112.0, 108.1, 66.7, 55.4, 55.3, 53.5, 46.7, 44.7, 
25.9, 22.7, 14.5. HRMS (EI) calcd. for [C27H29N5O5]+: 503.2169, found 503.2186. (M+) 
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1H and 13C NMR of compound 1a 
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Synthesis of 2: 
 
 
(1S,3S)-methyl 1-((benzyloxycarbonylamino)methyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (2) 
Under nitrogen atmosphere, L-tryptophan methyl ester (755 mg, 3.46 mmol, 1.0 eq) was 
dissolved in CH2Cl2 (30 ml, 0.12 M), then N-Cbz-aminoacetaldehyde dimethyl acetal 
(912 mg, 3.81 mmol, 1.1 eq) was added. The solution was cooled to -30 °C, then TFA 
was added (1.97 mg, 1.3 ml, 17.3 mmol, 5 eq). The mixture was kept for 2 hours at this 
temperature then reacted overnight at room temperature. The solution was diluted with 
AcOEt and washed three times with a saturated solution of NaHCO3 (3x15 ml), dried 
over Na2SO4, filtered and evaporated under reduced pressure. 
The crude mixture was purified by flash chromatography (Hex/AcOEt 6:4), 808 mg of 
(1S,3S)-2 and 143 mg of  the (1R,3S)-diastereoisomer were obtained (70% overall yield, 
6:1 d.r.) as colourless oil.  
[α]D25 = -44.4 (c 1.0, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 8.96 (bs, 1H) 7.55-7.10 (m, 9H) 
6.02 (dd, 1H) 5.03 (s, 2H) 4.40 (bs, 1H) 3.90-3.60 (m, 6H) 3.18 (dd, 1H, J = 15.0, 1.6 Hz) 
2.88 (dd, 1H, J = 15.0, 11.2 Hz) 2.77 (bs, 1H). 13C NMR (CDCl3, 101 MHz) δ 173.5, 157.3, 
136.5, 136.3, 132.3,128.5-127.8 (5C), 127.0, 122.0, 119.5, 118.0, 111.3, 109.2, 66.9, 56.3, 53.6, 
52.3, 44.3, 25.5. IR (cm-1) 3018, 1709, 1514, 1362, 1267, 1228. HRMS (EI) calcd. for 
[C22H23N3O4]+: 393.1689, found 393.1702. (M+) 
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1H and 13C NMR of compound 2 
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Synthesis of 3: 
 
 
(S)-benzyl 2-((2-ethoxy-2-oxoethyl)amino) propanoate (3) 
Under nitrogen atmosphere L-alanine-benzyl ester (500 mg, 2.79 mmol, 1 eq) was 
dissolved in CH3CN (6 ml, 0.47 M), then K2CO3 (3.85 g, 27.90 mmol, 10 eq) was added. 
Ethyl bromoacetate (466 mg, 2.79 mmol, 310 µl, 1 eq) was added to the suspension, then 
mixture was reacted overnight at room temperature. The solvent was evaporated under 
reduced pressure, then the crude was dissolved in AcOEt (20 ml). The solution was 
extracted with an aqueous solution of  H3PO4 5% (3x25 ml), the reunited aqueous layers 
were basified with Na2CO3 until pH 9 and extracted repeatedly with AcOEt. The 
reunited organic phases were dried with Na2SO4, filtered and evaporated under 
reduced pressure, to give compound 3 (503 mg, 67% yield), as a colourless oil.  
[α]D25 = -17.1 (c 1.0, CHCl3). 1H NMR (CDCl3, 300 MHz) δ 7.4-7.28 (m, 5H) 5.2-5.1 (m, 2H) 
4.15 (q, 2H, J = 8.6 Hz) 3.53 (q, 1H, J = 9.6 Hz) 3.49 (d, 1H, J = 17.3 Hz) 3.39 (d, 1H, J = 17.3 
Hz) 2.37 (bs, 1H) 1.38 (d, 3H, J = 9.6 Hz) 1.25 (t, 3H, J = 8.6 Hz). 13C NMR (CDCl3, 75.4 
MHz) δ 174.3, 171.4, 135.6, 128.6 (2C), 128.4, 128.2 (2C), 66.7, 61.0, 55.9, 48.7, 18.5, 14.2. 
HRMS (EI) calcd. for [C14H19NO4]+: 265.1314, found 265.1328. (M+) 
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1H and 13C NMR of compound 3 
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Synthesis of 4: 
 
 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(2-ethoxy-2-oxoethyl)amino)propanoic 
acid (4) 
Under nitrogen atmosphere, compound 3 (1.49 g, 5.62 mmol, 1 eq) and DIPEA (871 mg, 
6.74 mmol, 1.17 ml, 1.2 eq) were dissolved in CH2Cl2 (40 ml, 0.14 M), then Fmoc-Cl (1.48 
g, 5.73 mmol, 1.02 eq) was added. The mixture was stirred at room temperature 
overnight. Then CH2Cl2 (10 ml) was added, and the solution was washed with HCl 0.5 
M (3x30 ml), the organic layer was dried with Na2SO4, filtered and evaporated under 
reduced pressure. The crude was dissolved in MeOH (100 ml, 0.045 M), then under 
nitrogen atmosphere Pd/C 5 % w/w (150 mg) was added. The resulting suspension was 
stirred for 3 hours under hydrogen atmosphere at room temperature. Reaction was 
accurately monitored by TLC in order to prevent hydrogenolysis of the Fmoc group. 
The suspension was filtered on a layer of celite, the solution was evaporated under 
reduced pressure, the crude was dissolved in AcOEt and then was extract three times 
with a saturated solution of NaHCO3. The reunited aqueous phases were acidified with 
HCl 0.5 M and extracted with AcOEt (3x35 ml), dried with Na2SO4, filtered and 
evaporated under reduced pressure, to give pure 4 (1.76 g, 79% overall yield) as an oil.  
[α]D25 = -9.42 (c 1.0, MeOH). 1H NMR (DMSO at 95°C, 300 MHz) δ 7.88 (d, 2H, J = 7.5 Hz) 
7.64 (d, 2H, J = 7.4 Hz) 7.43 (t, 2H, J = 7.3 Hz) 7.34 (t, 2H, J = 7.3) 4.58 (q, 1H, J = 7.3 Hz) 
4.38 (d, 2H, J = 6.3 Hz) 4.26 (t, 1H, J = 6.3 Hz) 4.12 (q, 2H, J = 7.1 Hz) 3.98 (d, 2H, J = 18.0 
Hz) 1.37 (d, 3H, J = 7.3 Hz), 1.21 (t, 3H, J = 7.1 Hz). 13C NMR (CDCl3, 75.4 MHz, mixture 
of two rotamers) δ 175.4 and 174.5, 171.8 and 170.7, 155.7 and 155.6, 143.7, 143.6, 141.2 
(2C), 127.7 (2C), 127.1 (2C), 124.9 (2C), 120.0 (2C), 68.6 and 68.2, 62.2 and 61.8, 55.7 and 
55.5, 47.6 and 47.1, 47.0, 15.5 and 14.9, 14.1. IR (cm-1) 2954, 1750, 1709, 1467, 1451, 1325, 
1204. HRMS (EI) calcd. for [C22H23NO6]+: 397.1525, found 397.1541. (M+) 
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1H and 13C NMR of compound 4 
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Synthesis of 5: 
 
(1S,3S)-methyl 2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(2-ethoxy-2-
oxoethyl)amino)propanoyl)-1-((((benzyloxy)carbonyl)amino)methyl)-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (5) 
Under nitrogen atmosphere, compound 4 (302 mg, 0.76 mmol, 1 eq) was dissolved in 
CH2Cl2 (4 ml, 0.19 M), the solution was cooled at 0°C, then SOCl2 (904 mg, 7.60 mmol, 
550 µl, 10 eq) was added. The mixture was stirred at room temperature for 5 hours, then 
evaporated under reduced pressure. The obtained crude was dissolved in CH2Cl2 (3 ml) 
and slowly added to a solution of 2 (299 mg, 0.76 mmol, 1 eq) and 2,6 lutidine (110 mg, 
1.03 mmol, 120 μl, 1.35 eq) in CH2Cl2 (5 ml), cooled at 0° C under nitrogen atmosphere. 
The mixture was stirred at room temperature overnight, then CH2Cl2 (10 ml) was 
added, the organic layer was washed with HCl 0.5 M (5 ml), saturated aq. NaHCO3 (5 
ml) and brine (5 ml). The organic phase was dried with Na2SO4, filtered and evaporated 
under reduced pressure. The crude was purified by chromatographic column 
(Hex/AcOEt, 6:4), affording 5 (321 mg, 55% yield) as an oil.  
[α]D25 = +17.87 (c 1.0, CHCl3). 1H NMR (CDCl3, 300 MHz, major rotamer) δ 9.87 (bs, 1H) 
7.88-7.00 (m, 17H) 6.07 (bs, 1H) 5.45 (br, q, 1H) 5.32 (bs, 1H) 5.23 (bs, 2H) 4.71-4.32 (m, 
2H) 4.20-4.10 (m, 5H) 4.08-3.74 (m, 3H) 3.74-3.08 (m, 5H) 1.48 (d, 3H, J = 7.5 Hz) 1.25 (d, 
3H, J = 7.3 Hz). 13C NMR (CDCl3, 100 MHz, major rotamer) δ 171.1, 169.3, 169.1, 155.9, 
154.2, 143.9, 141.2, 136.4, 130.6, 128.5-111.5 (22C), 68.8, 67.1, 61.4, 56.3, 54.8, 52.1, 51.0, 
47.1, 47.0, 46.6, 24.4, 15.3, 14.2. HRMS (EI) calcd. for [C44H44N4O9]+: 772.3108, found 
772.3095. (M+) 
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1H and 13C NMR of compound 5 
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Synthesis of 6: 
 
Ethyl 2-((3S,6S,12aS)-6-((benzyloxycarbonylamino)methyl)-3-methyl-1,4-dioxo-
3,4,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-2(1H,6H,7H)-yl) acetate (6) 
Compound 5 (300 mg, 0.39 mmol) was dissolved in THF (13 ml, 0.03 M), then 
piperidine was added (2.6 ml). The solution was reacted overnight, then HCl 0.5 M was 
added and the mixture was extracted with AcOEt (3x30 ml). The reunited organic layers 
were dried with Na2SO4, filtered and evaporated under reduced pressure. The crude 
was purified by chromatographic column (Hex/AcOEt from 6:4 to 4:6), to give 6 (165 
mg, 81% yield) as an oil. 
[α]D25 = -59.5 (c 1.0, CHCl3). 1H NMR (CDCl3, 400 MHz, major rotamer) δ 9.27 (bs, 1H) 
7.55-7.10 (m, 9H) 5.91 (bs, 1H) 5.15-5.09 (m, 3H) 4.50 (d, 1H, J = 17.2 Hz) 4.26 (m, 4H) 
4.05 (m, 1H) 3.97 (d, 1H, J = 17.5 Hz) 3.68 (m, 1H) 3.57 (d, 1H, J  = 15.6 Hz) 3.07 (dd, 1H, J 
= 15.6, 11.8 Hz) 1.58 (d, 3H, J = 12.8 Hz) 1.31 (t, 3H, J = 7.2 Hz). 13C NMR (CDCl3, 75.4 
MHz) δ 168.9, 168.5, 167.3, 157.6, 136.5, 136.3, 130.7, 128.6, 128.2, 128.0, 126.2, 122.5, 
119.9, 119.8, 118.3, 111.7, 107.7, 67.1, 61.8, 57.6, 57.2, 56.3, 45.0, 44.7, 31.6, 25.2, 17.9, 14.2. 
IR (cm-1) 3016, 1742, 1667, 1506, 1455, 1326, 1222. HRMS (EI) calcd. for [C28H30N4O6]+: 
518.2165, found 518.2178. (M+) 
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1H and 13C NMR of compound 6 
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The research presented in the following chapter has been exclusively carried out at 
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4.1 Prolyl OligoPeptidase 
 
Prolyl Oligopeptidase family represents a relatively new class of serine peptidases. It 
was first described in 1991, based on the amino acid sequence homology of prolyl 
oligopeptidase, dipeptidyl peptidase IV and acyl-aminoacyl peptidase.[126] The fourth 
major member of the group was added when the amino acid sequence of 
oligopeptidase B was determined.[127] Several complementary DNAs (cDNAs) related to 
the proteins of the prolyl oligopeptidase family have also been cloned from various 
sources. Some of them lacking the catalytic serine residue were inactive. The prolyl 
Oligopeptidase group called family S9 has been grouped with other families into the SC 
clan of serine peptidases.[128] Based on the structural relationship between these 
enzymes and lipases, and on secondary structural studies,[129] these enzymes have been 
considered as members of the / hydrolase fold enzymes. The amino acid sequence 
homology of the four basic peptidases is rather low, but they apparently share a similar 
three-dimensional structure. They display distinct specificities and represent different 
types of peptidases. Thus, prolyl oligopeptidase and oligopeptidase B are 
endopeptidases and are found in the cytosol. Acyl-aminoacyl peptidase and dipeptidyl 
peptidase IV are exopeptidases, acyl-aminoacyl peptidase is a cytoplasmic omega 
peptidase, whereas dipeptidyl-peptidase IV is a membrane bound enzyme that cleaves 
a dipeptide from the amino terminus of oligopeptides. The catalytically competent 
residues, the so-called catalytic triad (Ser, Asp and His), are concentrated in the 
carboxyl terminal region within about 130 residues. 
The exopeptidases, can only cleave a few amino acids off the C-terminal or N-terminal 
ends of proteins, while others, the endopeptidases, can hydrolyze internal peptide 
bonds. Most proteases are highly specific and can only process a limited number of 
substrates with defined amino acid sequences. Similarly, some substrates are only 
processed by a very small number of proteases. 
                                               
[126] Rawlings N.D., Polgár L., Barrett A.J. “A new family of serine-type peptidases related to prolyl oligopeptidase” 
J. Biochem. 1991, 279, 907–908  
[127] Kanatani A., Masuda T., Shimoda T., Misoka F., Lin X.S., Yoshimoto T., Tsuru D. “Protease II from Escherichia 
coli: sequencing and expression of the enzyme gene and characterization of the expressed enzyme” J. Biochem. 
1991, 110, 315–320 
[128] Rawlings N.D., Barrett A.J. “Families of serine peptidases” Methods Enzymol. 1994, 244, 19–61 
[129] Goossens F., De Meester I., Vanhoof G., Hendricks D., Vriend G., Scharpé S. “The purification, characterization 
and analysis of primary and secondary-structure of prolyl oligopeptidase from human lymphocytes. Evidence 
that the enzyme belongs to the / hydrolase fold family” Eur. J. Biochem. 1995, 233, 432–441  
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Prolyl oligopeptidase was discovered in the human uterus as an oxytocin-degrading 
enzyme.[130] The peptidase was originally named post-proline cleaving enzyme since it 
preferentially hydrolyzed the peptide bond on the carboxyl side of proline residues. 
Several enzymes with similar specificity, like tyrotropin releasing hormone deaminase, 
endo-oligopeptidase B, brain kinase B and others were then described, which later 
proved to be identical with prolyl oligopeptidase. The selectivity of the enzyme for 
oligopeptides was discovered in the 1970s.[131] The name prolyl endopeptidases was first 
recommended by the Enzyme Nomenclature, but later it was changed to prolyl 
oligopeptidase, emphasizing the special characteristics of the enzyme. 
 
Figure 42. Crystal Structure of Prolyl OligoPeptidase. 
POP cleaves short peptides, up to 30 amino acids long, and specific assays have been 
developed to screen for its occurrence in complex samples. These include digestion 
assays of model substrates and/or sensitivity to Cbz-Pro-Prolinal or analogues. 
Accordingly, in most of the studies, the cleavage of these putative POP-specific 
substrates has previously been taken to indicate the presence of the enzyme. According 
to all genetic or structural information in higher eukaryotes, POP is considered to be a 
soluble cytoplasmic protein. 
                                               
[130] Koida M., Walter R. “Post-proline cleaving enzyme. Purification of this endopeptidase by affinity 
chromatography” J. Biol. Chem. 1976, 251, 7593–7599 
[131] Camargo A.C.M., Caldo H., Reis M.L. “Susceptibility of a peptide derived from bradykinin to hydrolysis by 
endooligopeptidases and pancreatic proteinases” J. Biol. Chem. 1979, 254, 5304–5307  
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The peptidase domain is formed by the N- and C-termini (residues 1–72 and 428–710) 
containing the catalytic triad (Ser554, Asp641 and His680), and is arranged in a classical 
/ hydrolase-fold. The seven-bladed -propeller domain (residues 73–427) is radially 
arranged around the central tunnel embedded within the cylinder, where the narrow 
active site is located. 
POP cleaves peptides at the carboxyl side of an internal proline (-Pro-Xaa-; where Xaa ≠ 
Pro), and it will not cleave an N-blocked peptide where Pro is the second amino acid 
(Figure 43).[132] The enzyme interacts maximally with six amino acid residues of the 
substrate peptide: those in positions P4, P3 and P2 from the N-side, and those in 
positions P10 and P20 from the C side of the proline which occupies the P1 position.[133] 
The highest reaction rates are obtained when P10 is a hydrophobic residue. 
 
Figure 43. Interaction sites of POP active site. 
It has been demonstrated that POP catalysis is controlled by a gating filter mechanism 
that only allows small peptides to gain access to the active site; in this way, larger 
structural peptides and proteins are protected from proteolysis.[134] The 3D structure of 
POP has helped to understand the mechanism for the specificity for small peptides and 
describe how the substrate-induced conformational change is the rate limiting step 
during catalysis.[135] 
The enzyme active site is located in a large cavity at the interface of the two domains,  
and it has been proposed that there is a narrow hole at the centre of the -propeller at 
the bottom of the enzyme, through which the substrate enters. This narrow entrance 
                                               
[132] Rosenblum J.S., Kozarich J.W. “Prolyl peptidases: a serine protease subfamily with high potential for drug 
discovery” Curr. Opin. Chem. Biol. 2003, 7, 496–504.  
[133] Fulop V., Szeltner Z., Renner V., Polgar L. “Structures of prolyl oligopeptidase substrate/inhibitor complexes. 
Use of inhibitor binding for titration of the catalytic histidine residue” J. Biol. Chem. 2001, 276, 1262–1266  
[134] Fulop V., Szeltner Z., Polgar L. “Catalysis of serine oligopeptidases is controlled by a gating filter mechanism” 
EMBO Rep. 1 2000, 277–281  
[135] Szeltner Z., Rea D., Juhasz T., Renner V., Fulop V., Polgar, L. “Concerted structural changes in the peptidase 
and the propeller domains of prolyl oligopeptidase are required for substrate binding” J. Mol. Biol. 2004, 340, 
627–637 
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could be widened by movements of residues with flexible bonds covering the central 
tunnel, thus this entrance would act as filter, permitting only small peptides to enter 
into the active site.[136] 
The catalytic mechanism of POP conforms to the general serine protease reaction 
mechanism via base assisted catalysis by histidine, which occurs through a tetrahedral 
intermediate, generating a covalent acyl enzyme complex that is subsequently 
hydrolyzed. The hydrolysis involves a second tetrahedral intermediate which breaks 
down via acid-assisted catalysis by histidine.[137] The cycle has been confirmed by 
elegant X-ray and NMR experiments.[138] 
Lithium is the standard treatment for bipolar depressions (manic depression/bipolar 
affective disorder) and is also effective in recurrent unipolar depression. It is used in 
conjunction with antidepressants or as a temporary mood stabilizer between 
treatments. The molecular basis of these disorders and their treatment by Li+ remains as 
yet unknown. A strongly supported theory is the inositol depletion theory (Figure 44). 
Li+ inhibits inositol monophosphatase and blocks the conversion of inositol 
monophosphate (IMP) to inositol. This causes a reduction of the free pool of inositol 
and ultimately lowers the cellular concentration of phosphatidyl(4,5)-biphosphate 
(PIP2). In addition, Li+ inhibits the enzyme inositol polyphosphatase which is required 
for the dephosphorylation of inositol(1,4)-biphosphate to IMP. In response to receptor 
stimulation, PIP2 is cleaved by phospholipase C to form the second messengers 
inositol(1,4,5)-triphosphate and diacylglycerol (DAG). These molecules cause the 
release of calcium from intracellular stores and activation of protein kinase C 
respectively. Li+ depletion of PIP2 therefore has the potential to cause a significant effect 
on signal transduction. The other primary target of Li+ in mammalian cells, next to the 
Inositol phosphate signaling is glycogen synthase kinase 3 (GSK-3), a multifunctional 
protein kinase.[139] 
Investigating processes that counteract the effect of Li+, demonstrated an inverse 
relationship between POP activity and IP3 (Inositol triphosphate) concentration. 
Mutants of the cellular slime mould Dictyostelium discoideum, which lack all POP 
                                               
[136] Fulop V., Bocskei Z., Polgar L. “Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis” 
Cell 1998, 94, 161– 170 
[137] Leung D., Abbenante G., Fairlie D.P. “Protease inhibitors: current status and future prospects” J. Med. Chem. 
2000, 43, 305–341 
[138] Kahyaoglu A., Haghjoo K., Guo F., Jordan F., Kettner C., Felfoldi F., Polgar L. “Low barrier hydrogen bond is 
absent in the catalytic triads in the ground state but is present in a transition-state complex in the prolyl 
oligopeptidase family of serine proteases” J. Biol. Chem. 1997, 272, 25547–25554 
[139] Williams R.S., Eames M,. Ryves W.J., Viggars J., Harwood A.J. “Loss of a prolyl oligopeptidase confers 
resistance to lithium by elevation of Inositol (1,4,5) trisphosphate” EMBO J 1999, 18, 2734–2745 
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activity, and wild-type cells treated with a selective POP inhibitor display an increase in 
basal concentrations of IP3. Other possible enzyme activities that generate or 
dephosphorylate IP3 were examined and found not to be present. The authors therefore 
concluded that loss of POP activity causes enhanced turnover of phosphoinositides 
which has the effect of increasing cellular concentration of IP3. Lithium had no direct 
effect on POP activity at up to 20 times the plasma concentrations used in therapeutic 
treatment of mood disorders, suggesting the enzyme may confer lithium resistance via 
an indirect mechanism. The authors state that if the pathway observed in Dictyostelium 
is conserved in the brain, it could explain the therapeutic effect of Li+. Depression could 
result from a reduction in POP activity that leads to an elevated IP3 concentration, 
which in turn is reversed by Li+ inhibition of inositol monophosphatase and inositol 
polyphosphatase. 
 
Figure 44. Mechanism of action for POP inhibition. 
Researchers have shown that POP participates in several aspects and functions of the 
central nervous system (CNS), including learning, memory, mood, hypertension, and 
eating, and in some neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
diseases. Subsequently, POP has been identified as a potential target in cognitive 
function, memory, and neurodegenerative disorders such as amnesia, Alzheimer’s 
disease, and depression. 
In the literature conflicting findings have been reported involving POP activity in brain 
tissue from control and AD cases.  The most contradictory finding is the over 
expression compared to a lower POP concentration in patients. There have been reports 
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that POP activity is enhanced in AD brain. Aoyagi and collaborators[140] reported a 
significant increase in intra-cerebral POP activity in AD patients (n=7) when compared 
with the control group (n=6). An age-related increase in POP activity/expression in the 
brain has also been reported.[141] Other groups state that POP activity is decreased in 
specific regions of the brain of AD patients compared to controls.[142] A reduction of the 
POP activity in cortical tissue from AD cases (n=5) to 65% of the control activity (n=5) 
was also found.[143] However in authors’ opinion the reduction in POP activity in AD 
tissue is not specific to this disorder, but a common factor in neurodegenerative 
disorders, since the activity was also reduced to 65–70% in comparison with control in 
tissue samples from Lewy body dementia (n=11), Parkinson's disease (n=13) and 
Huntington's disease (n=9). They suggested that loss of POP activity might be a marker 
of neuronal degeneration in the cerebral cortex in these disorders. 
Hagihara and Nagatsu[144] measured POP in human cerebrospinal fluid (CSF) and 
although the enzyme activity in the CSF was extremely low, the activity measured in 37 
control samples was significantly higher than in the CSF of 34 Parkinson patients. In 
contrast the enzyme activity in serum was not different between control patients (n=30) 
and Parkinson patients (n=13). 
 
  
                                               
[140] Aoyagi T., Wada T., Nagai M., Kojima F., Harada S., Takeuchi T., Takahashi H., Hirokawa K., Tsumita T. 
“Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease” 
Experientia 1990, 46, 94–97  
[141] Rossner S., Schulz I., Zeitschel U., Schliebs R., Bigl V., Demuth H.U. “Brain prolyl endopeptidase expression in 
aging, APP transgenic mice and Alzheimer's disease” Neurochem. Res. 2005, 30, 695–702 
[142] Laitinen K.S., van Groen T., Tanila H., Venäläinen J.I., Männistö P.T., Alafuzoff I. “Brain prolyl oligopeptidase 
activity is associated with neuronal damage rather than beta-amyloid accumulation” Neuroreport 2001, 12, 3309–
3312  
[143] Mantle D., Falkous G., Ishiura S., Blanchard P.J., Perry E.K. “Comparison of proline endopeptidase activity in 
brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease 
and Huntington's disease” Clin. Chim. Acta 1996, 249, 129-139  
[144] Hagihara M., Nagatsu T. “Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and 
parkinsonian patients” Biochem. Med. Metab. Biol. 1987, 38, 387–391 
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4.2 POP Inhibitors: State of the art 
 
Researchers have reported many synthetic POP inhibitors, of which most are substrate-
like short pseudopeptides that have little potential of crossing the BBB, a very 
unfavorable pharmacokinetics characteristic. The lead compound in development of 
POP inhibitors is Cbz-Pro-Prolinal (1) which is a covalent binder because of the highly 
reactive aldehydic moiety.[145] There are peptidic like inhibitors, analogues of 1, and non 
peptidic ligands which display complementary properties. For instance, S-17092 (3) 
reached the phase 1 clinical trial[146], and some of them were found to improve memory 
and learning in animal models of brain disorders (2).[147]  
 
 
Scheme 15. Selected active POP inhibitors. 
 
                                               
[145] Yoshimoto T., Kawahara K., Matsubara F., Kado K., Tsuru D. “Comparison of inhibitory effects of prolinal-
containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium” J. Biochem. 
1985, 98, 975–979 
[146] Morain P., Robin J.L., De Nanteuil G., Jochemsen R., Heidet V., Guez D. “Pharmacodynamic and 
pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy 
volunteers. A phase I study” Br. J. Clin. Pharmacol. 2000, 50, 350–359  
[147] Toide K., Shinoda M., Fujiwara T., Iwamoto Y. “Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on 
spatial memory and central cholinergic neurons in aged rats” Pharmacol., Biochem. Behav. 1997, 56, 427–434. 
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Compound 4 is an example of a very effective non peptidic POP inhibitor that abolished 
the formation of -amyloid protein.[148] Amyloid beta (Aβ or Abeta) is a peptide of 36–43 
amino acids that is processed from the Amyloid precursor protein. While best known as 
a component of amyloid plaques in association with Alzheimer's disease, evidence has 
been found that Aβ is a highly multifunctional peptide with significant non-
pathological activity. Aβ is the main component of deposits found in the brains of 
patients with Alzheimer's disease and it’s an indicator of generic proteases inhibition. 
However others demonstrated that POP inhibitors had no effect on β-amyloid levels in 
certain cell types, indicating that other proteases are involved or that the enzymes 
producing the β-amyloid peptides, as well as the β-amyloid precursor, were located in 
different cell compartments than the β-amyloid peptides.[149] 
ONO-1603 (5)[150] and KYP-2047 (6)[151] are probably the most studied and led to 
hundreds of natural or synthetic derivatives tested. Both effectively delay age-induced 
apoptosis of cerebral neurons. They display a neuroprotective action and, at the same 
time, a lower neurotoxicity compared to already known anti-dementia drugs like 
tetrahydroaminoacridine (THA), a benzofused -tetrahydroquinoline ring. 
A systematic analysis of POP inhibitors and different substitution is obtainable in a 
recent review here reported.[152] Summarizing, longer alkyl chains lead not only to poor 
solubility but also probably to steric clashes in the S3 pocket and large entropy penalties 
upon binding, resulting in less potent inhibitors.[153] Although most of the reported 
investigations on P3 inhibitor-enzyme interaction recommend flexible linkers to 
properly fill the S3 site of POP and to avoid any detrimental clashes with the protein, 
long and rigid moieties have also been successfully introduced. The carbonyl group 
between the two pyrrolidine rings of 1 has been shown to interact with the protein 
binding site (PDB code 1h2y). In fact, removal of this oxygen led to a complete loss of 
                                               
[148] Kato A., Fukunari A., Sakai Y., Nakajima T. “Prevention of amyloid-like deposition by a selective prolyl 
endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse” J. Pharmacol. Exp. Ther. 1997, 283, 328–335 
[149] Petit A., Barelli H., Morain P., Checler F. “Novel proline endopeptidase inhibitors do not modify Aβ40/42 
formation and degradation by human cells expressing wild-type and Swedish mutated β-amyloid precursor 
protein” Br. J. Pharmacol. 2000, 130, 1613–1617 
[150] Katsube N., Sunaga K., Aishita H., Chuang D.M., Ishitani R. “ONO-1603, a potential antidementia drug, delays 
ageinduced apoptosis and suppresses overexpression of glyceraldehyde-3-phosphate dehydrogenase in 
cultured central nervous system neurons” J. Pharmacol. Exp. Ther. 1999, 288, 6–13  
[151] Jalkanen A.J., Puttonen K.A., Venäläinen J.I., Sinervä V., Mannila A., Ruotsalainen S., Jarho E.M., Wallén E.A., 
Männistö P.T. "Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old 
scopolamine-treated rats" Basic Clin. Pharmacol. Toxicol. 2007, 100, 132–138 
[152] Lawandi J., Gerber-Lemaire S., Juillerat-Jeanneret L., Moitessier N. “Inhibitors of Prolyl Oligopeptidases for the 
Therapy of Human Diseases: Defining Diseases and Inhibitors” J. Med. Chem. 2010, 53, 3423–3438 
[153] Karoly K., Sandor E., Edit S., Miklos F., Judit S., Benjamin P., Andrea S., Istvan H. “Prolyl endopeptidase 
inhibitors: N-acyl derivatives of L-thioproline-pyrrolidine” Bioorg. Med. Chem. Lett. 1997, 7, 1701–1704 
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potency.[154] Once more, the structural modifications at P1 reported to date focused on 
proline mimics. However, as we can see from the structures of the substrates, POP is 
very selective for proline residues (alanine residues are tolerated but with a significant 
decrease in protease activity) and drastic changes at P1 are expected to correlate with a 
loss of inhibitory potency.[155] 
Key interactions between inhibitors and POP are summarized in Figure 45. A lipophilic 
interaction between Phe173 and an aromatic residue occurs in a pocket at a defined 
distance from the carbonyl group.  For this reason Cbz or longer side chain, terminating 
with an aromatic ring, have been exploited. Like 1, peptidic and non peptidic inhibitors 
posses two carbonyl groups able to accept hydrogen bonding from Trp595 and Arg643. 
While the most important interaction is located on the right side of the ligands. 
Covalent inhibitors are more potent than the noncovalent inhibitors developed thus far, 
although subnanomolar noncovalent inhibitors have been discovered.[156] The most 
exploited reactive group are aldehydes and nitriles which can interact with the 
nucleophilic Ser554. Still, correct stereochemistry of the reactive electrophilic specie is 
mandatory for high affinity, that is S configuration related to natural Pro properly 
functionalized at the carboxy group. 
 
Figure 45. Key interactions between inhibitors and POP. 
 
  
                                               
[154] Yoshimoto T., Tsuru D., Yamamoto N., Ikezawa R., Furukawa S. “Structure activity relationship of inhibitors 
specific for prolyl endopeptidase” Agric. Biol. Chem. 1991, 55, 37–43 
[155] Arai H., Nishioka H., Niwa S., Yamanaka T., Tanaka Y., Yoshinaga K., Kobayashi N., Miura N., Ikeda Y. 
“Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships: in vitro 
inhibition of prolyl endopeptidase from canine brain” Chem. Pharm. Bull. 1993, 41, 1583–1588  
[156] Kanai K., Aranyi P., Bocskei Z., Ferenczy G., Harmat V., Simon K., Batori S., Naray-Szabo G., Hermecz I. “Prolyl 
oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules” J. Med. Chem. 2008, 51, 7514–7522  
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4.3 Structural Study: Docking 
 
A structure of POP from porcine brain (PDB code: 2XDW) was downloaded from the 
Protein Data Bank and prepared as reported previously.[157] It was next prepared for 
docking using PROCESS, a module of the docking program FITTED.[158] The ligands 
were prepared using Maestro and SMART, a third module of FITTED. They were 
subsequently docked using the FITTED docking engine and defaults parameters. For 
the covalent docking to be used, the Ser554 has been selected as a reactive residue. To 
the best of our knowledge, MacDOCK[159] and FITTED are the only two programs 
considering covalent binding in a fully automated fashion.  
We have combined and applied X-ray crystallography data, docking predictions, higher 
level computations (e.g., density functional theory, DFT), and chemical tools, also 
evaluating the inhibition of enzymatic activity, to reveal insight into binding and 
inhibition modes that each of them alone cannot predict. Using this strategy, we have 
designed a series of pseudopeptidic and peptidomimetic inhibitors, built around 
bicyclic scaffolds. These scaffolds closely mimic the known prolyl oligopeptidase 
inhibitor Cbz-Pro-Prolinal (1, Scheme 15). 
Previous research was focused on the conformational restriction of lead compounds 1 
and 2. Recently, the research group were I spent part of the Ph.D. project, synthesized 
and tested different compounds library which are related to bicyclic scaffolds 7 and 8. 
Molecule 7, despite a low activity, showed a promising pharmacokinetic profile 
crossing the BBB and is characterized by a conformational restriction on the right side of 
the lead (green).[160] On the other hand, molecule 8 represents a candidate characterized 
by a cyclization on the left side of the lead compound (blue).[161] Both series, are 
composed by peptidic like Cbz-Pro-Prolinal analogues which display all the key 
interaction with the binding site. (Scheme 16) 
                                               
[157] Corbeil C.R., Englebienne P., Moitessier N. “Docking Ligands into Flexible and Solvated Macromolecules. 1. 
Development and Validation of FITTED 1.0” J. Chem. Inf. Model. 2007, 47, 435–449 
[158] Corbeil C.R., Englebienne P., Moitessier N., Therrien E. “FITTED Docking Program” www.fitted.ca 2009 
[159] Fradera X., Kaur J., Mestres J. “Unsupervised guided docking of covalently bound ligands” J. Comput.-Aided 
Mol. Des. 2004, 18, 635−650 
[160] Lawandi J., Toumieux S., Seyer V., Campbell P., Thielges S., Juillerat-Jeanneret L., Moitessier N. “Constrained 
Peptidomimetics Reveal Detailed Geometric Requirements of Covalent Prolyl Oligopeptidase Inhibitors” J. Med. 
Chem. 2009, 52, 6672–6684 
[161] De Cesco S., Deslandes S., Therrien E., Levan D., Cueto M., Schmidt R., Cantin L.D., Mittermaier A., Juillerat-
Jeanneret L., Moitessier N. “Virtual Screening and Computational Optimization for the Discovery of Covalent 
Prolyl Oligopeptidase Inhibitors with Activity in Human Cells” J. Med. Chem. 2012, 55, 6306–6315 
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Because of these interesting results, we developed a methodology for the synthesis of 
new conformationally constrained POP inhibitors, placing the bicyclic scaffold 
alternatively on the right (9) or the left side (10,11) of the lead compound. 
The difference between compounds 10 and 11 relies on the aromatic distance from the 
structure core 
 
Scheme 16. Cyclization Strategies. 
In Figure 46 is depicted the superimposition of Cbz-Pro-Prolinal (1) with compound 9 
in the POP binding site. Reference compound is not obtained by docking but it’s the 
crystallized structure bound to the enzyme. It is possible to recognize a good aromatic 
side chain positioning and a good overlap of the covalent binder moiety compared to 
reference. 
According to the docking and previous results, several key parameters have been 
drawn. These new bicyclic scaffolds should have the cyano-pyrrolidine ring with S 
configuration, as stated in previous works. Moreover, any substitution at position , 
relative to amide and nitrile, should be avoided because of clashing with POP binding 
site. The relative configuration of the junction ring stereocenters has to be anti favoring 
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the proper spatial orientation of the aromatic and the proline residue. Whereas the 
absolute configuration seems to poorly influence the correct ligand positioning. 
 
 
Figure 46. Binding mode towards the POP model of 1 (yellow) and 9 (green). 
Furthermore, docking was performed on derivatives 10 and 11 corresponding to Figure 
47 and 48 respectively. In this pictures is very clear the key factor related to - position 
which requires no steric hindrance. Moreover, the scaffolds seems to fit and overlap 
pretty well with reference 1. 
Compound 11 shows a one atom longer spacer which drives deeper in the hydrophobic 
cavity the aromatic residue. 
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Figure 47. Binding mode towards the POP model of 1 (yellow) and 10 (green). 
 
Figure 48. Binding mode towards the POP model of 1 (yellow) and 11 (green). 
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4.4 Synthesis 
Few years ago, the group where I recently worked with, reported preliminary results 
leading to a rigid Ala-Val dipeptide mimic.[162] As shown in Figure 49, conformational 
analysis revealed that the designed trans-cis-trans isomer adopts a conformation similar 
to the mimicked dipeptide. More specifically, the trans configuration of the methyl and 
amide groups resembles the staggered conformation of the Val side chain while a cis 
configuration would be closer to the eclipsed conformation. The successful preparation 
of these structures prompted us to look at other analogues and optimized synthesis. 
 
 
 
Figure 49. Ala-Val mimetics: chemical structures (top panel)  
and their corresponding 3D conformations optimized with ACE.[163] 
 
At the outset of this research program we set criteria including atom economy and 
expediency for the synthesis of bicyclic scaffolds that could be used in medicinal 
chemistry. In order to devise an expedient synthesis, we focused on telescoping the 
steps and relied on tandem or one-pot reactions. These reactions would build 
complexity using Diels Alder cycloadditions from very simple building blocks. 
 
                                               
[162] Huot M., Moitessier N. “Expedient synthesis of novel bicyclic peptidomimetic scaffolds” Tetrahedron Lett. 2010, 
51, 2820-2823 
[163] Weill N., Corbeil C.R., De Schutter J.W., Moitessier N. “Toward a computational tool predicting the 
stereochemical outcome of asymmetric reactions: Development of the molecular mechanics-based program 
ACE and application to asymmetric epoxidation reactions" J. Comp. Chem. 2011, 32, 2878-2889  
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Figure 50. Synthesis of Ala-Xaa mimetics. 
The following methodology has been extended to different unsaturated aldehyde which 
are then related to several amino acidic side chains. With the aim of preparing potential 
POP inhibitors, R = H became my point of investigation. 
With this designed strategy, three bonds and four stereogenic centers were formed in a 
single step. Reaching this high level of complexity within a few steps was in fact the 
major challenge. Through the key step, the major diastereomer formed was the Diels-
Alder exo adduct resembling the natural dipeptide conformation as discussed above. In 
order to reduce or eliminate the need for environmentally harmful reagents and 
protecting groups, we selected maleic anhydride. Due to the specific cyclic form of this 
chemical, the protecting group is the chemical itself. Through cleavage of the anhydride 
group and ring opening, the carboxylic acid is released. Thus, most of the low-toxicity 
chemicals used in the entire strategy would be incorporated into the final molecule. The 
only remaining issue is the stereocontrol of the reactions as exo and endo adducts are 
obtained. Furthermore, the modular nature of this synthesis should allow for the 
introduction of not only amino acid like structures but permit the incorporation of 
many functional groups to enable the synthesis of “drug-like” molecules that can 
interact with the hydrophobic and hydrophilic regions of enzymes and proteins. 
Based on our conformational analysis, the stereochemical outcome of the Diels-Alder 
(DA) reaction is critical as the trans configuration of the fused ring must be obtained. 
Considering this information, it was integral for us to find a set of conditions that 
would selectively lead to the trans fused ring. Cayzer et al. have previously reported a 
similar strategy using alcohols in place of hydrazide.[164] In particular a complete 
intramolecular Diels-Alder reaction (IMDA) preferentially affords exo adduct whereas 
an inter molecular reaction is more endo oriented.[165] A DFT computational study 
revealed a highly asynchronous transition state and indicated that the exo selectivity is 
most likely induced by the strain of the forming five-membered ring. 
                                               
[164] Cayzer T.N., Paddon-Row M.N., Moran D., Payne A.D., Sherburn M.S., Turner P. “Intramolecular Diels-Alder 
reactions of ester-linked 1,3,8-nonatrienes” J. Org. Chem. 2005, 70, 5561-5570 
[165] Cayzer T.N., Lilly M.J., Williamson R.M., Paddon-Row M.N., Sherburn M.S. “On the Diels–Alder reactions of 
pentadienyl maleates and citraconates” Org. Biomol. Chem. 2005, 3, 1302-1307 
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In order to achieve the desired bicyclic scaffolds I synthesized the required conjugated 
aldehyde 12 following a described procedure. This approach involves a malonic 
addition to acrolein followed by decarboxylation and a reductive-oxidative protocol to 
afford the volatile aldehyde.[166] Then I subjected 12 to reductive amination with Boc-
hydrazide. Subsequent DA reaction afforded with low diastereoselectivity the two exo 
and endo adduct as racemic mixture. An extensive study to improve diastereoselectivity 
have been performed on different scaffolds by varying environment lipophilicity. 
However, the diastereoselectivity and the difficult separation of the diastereomers 
remain a hurdle for the use of these scaffolds in medicinal chemistry. To tackle this 
problem, the use of various auxiliaries, Brønsted acids, reaction conditions were 
investigated but proved unsuccessful until we found that substituting the Boc group by 
a Cbz group and the use of dichloromethane for the tandem reaction led to selective 
precipitation of the major exo adduct. Not only does this optimized strategy provide a 
single isolated diastereomer but it also removed the need for chromatographic 
purification of the polar bicyclic scaffolds.[167] 
 
 
Scheme 17. IMDA reaction for bicyclic scaffolds. 
 
With this methodology available, I pursued the synthesis of rac-9 by coupling with a 
source of ammonia (NH4 HCO3) and then dehydration of the corresponding amide with 
TFAA.  
The synthesis of scaffolds 19 and 20 required the preparation of dienes 17 and 18 which 
was performed using standard reducing agent like NaBH4. The following DA reaction 
gave an unexpected result because if the diene 17 afforded a bicyclic compound in a 7:1 
                                               
[166] Mitton-Fry M.J., Cullen A.J., Sammakia T. “The Total Synthesis of the Oxopolyene Macrolide RK-397” Angew. 
Chem. Int. Ed. 2007, 46, 1066-1070 
[167] Airaghi F., De Cesco S., Huot M., Moitessier N. “Chiral Rigid Dipeptide Mimics – Design and Expedient 
Synthesis” submitted  
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exo/endo ratio, showing a clear intramolecular cyclization preceded by the coupling,[168]  
diene 18 afforded the bicyclic scaffold 20 in a 1:1 ratio, with no diastereoselectivity at all. 
Indeed, reaction took 72 hours to afford a reasonable yield. We think that such slow 
reactivity might promote first the DA reaction and then the coupling to form the five 
membered ring.  
 
 
Scheme 18. Synthesis of POP inhibitors. 
a) NaBH4, MeOH, 31% (17); DMAB, pTSA, MeOH, 28% (18); b) maleic anhydride, DCM, 
98% (19), 74% (20); c) PivCl, NH4 HCO3, Pyridine, CH3CN then TFAA, pyridine, THF, 
26% (9) (over two steps); d) Pyrrolidine, PivCl, TEA, DMF, 34% (21), 17% (22); e) S-
Cyanopyrrolidine, BOP, TEA, DMF, 31%, (10), 27% (11). 
Table 7. IMDA stereochemical outcome. 
 
R products yield (%) exo/endo 
Boc 15 65 1.5 
Cbz 16 66 1.5 
Bn 19 98 7 
Bn-O 20 74 1 
                                               
[168] Mellor J.M., Wagland A.M. “Synthesis of hydroisoindoles via intramolecular Diels–Alder reactions of 
functionalised amido trienes” J. Chem. Soc. Perkin Trans. 1, 1989, 997-1005 
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The racemic acid 16 has been coupled to a source of ammonia and then dehydrated 
with TFAA to afford the corresponding nitrile. The more obvious two steps conversion 
to methyl ester, followed by transesterification with an ammonia solution in methanol 
revealed to be unreactive, even under refluxing conditions. 
The two racemic acid 19 and 20 have been coupled with pyrrolidine and S-CN-Pro in 
order to give covalent and non covalent potential inhibitors. Coupling yields were low 
because of a lack of reactivity of the exocyclic carboxyl moiety to any coupling agent. 
We think that the shape of such small scaffold may exert a steric hindrance, shielding 
the activated acid from the nucleophile approach. Moreover, I observed an absence of 
reactivity for the endo DA adduct. For compound 19, the high IMDA selectivity has 
obviated any purification procedure, while derivative 20, in a 1:1 exo/endo ratio, led to a 
pure anti (exo) non covalent inhibitor 22 and a 5:1 anti:syn covalent inhibitor 11a/b. The 
steric hindrance occurring for the tight endo adduct together with a general lack of 
reactivity allowed us to obtain pure anti diastereomers derivatives, as racemates, 
explaining also the coupling yield below 50%. 
Once obtained the covalent and non-covalent ligands, they have been subjected to 
biological evaluation towards POP enzyme from cell extracts and living intact cells.[169] 
  
                                               
[169] In collaboration with Dr. Lucienne Juillerat-Jeanneret (University Institute of Pathology - CHUV-UNIL - 
Lausanne) 
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4.5 Biological Evaluation 
 
These various synthesized compounds were evaluated for their ability to inhibit POP. 
These assays were carried out on cell extracts and intact cells and on six different cell 
strains. All this data allowed us to measure the inhibitory potency and also to evaluate 
the selectivity for POP over DPP-IV, FAP--seprase, DPP8 and DPP9 as described in a 
previous report.[160] Preliminary results are presented in Table 8. 
Table 8. Inhibition of POP activity in cell extracts.a 
 
Compound 
human astrocyte 
derived cellsb 
human brain-derived 
endothelial cellsc 
 
+++ +++ 
1 (Cbz-Pro-Prolinal) +++ +++ 
6 (KYP-2047) +++ +++ 
7 +++ +++ 
8 +++ +++ 
rac-9 - - 
rac-21 +++ +++ 
10a/b +++ +++ 
rac-22 ++ ++ 
11a/b +++ +++ 
 
a -, No inhibition at 0.8 μM; +, 10-50% inhibition at 0.8 μM; ++, >50% inhibition at 0.8 μM; +++, >90% 
inhibition at 20 μM. b LN18, LN229, LNZ308: human glioblastoma cells. c HCEC, human brain-derived 
endothelial cells. 
According to preliminary data, compound 9 is not active at all, thus demonstrating not 
to be a valid surrogate of the lead compound 17, although the shape of the designed 
molecule was predicted to be optimal. On the other hand, the couples 21 and 10, 22 and 
11 are highly active with no distinction between covalent and non covalent binding in 
which the electrophilic nitrile can react with nucleophilic Ser554, key residue of the 
enzyme active site. The only exception is rac-22 which is less potent compared to 
analogues 11a/b. Apparently, the usage of this bicyclic scaffold for the rigidification on 
the right side of the lead compound 1 does not rise positive effects. Conformational 
restriction on the left side displayed a very good inhibition profile, in most cases above 
90% at low concentration. Non covalent ligands display almost the same activity, but 
covalent ones (10, 11) have higher potency.  
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4.6 Conclusions 
 
We performed the synthesis of a novel family of rigid Ala-Ala dipeptide mimics by 
mean of few synthetic steps with an high degree of complexity, forming simultaneously 
3 stereocenters. We were able to discriminate the two diastereomers through a selective 
precipitation for the IMDA derived hydrazide.  
I synthesized other bicyclic scaffolds varying the N- substitution in order to tune the 
aromatic ring distance from the core. This new compounds family has been subjected to 
coupling with pyrrolidine and S-CN-pyrrolidine for the synthesis of potentially POP 
inhibitors. 
They were designed with the aid of computational tools, which highlight the key 
requirements for valuable drug candidates: proper aromatic ring 3D positioning, no 
substitution on the bicyclic scaffold and the correct absolute and relative 
stereochemistry. 
Following these studies, compounds identified have been tested for their biological 
activity in cell extracts and intact living cells. According to preliminary results in our 
hand, we observed a very good POP inhibition profile for compounds 10, 11 and 21. 
We still observed inhibition for non covalent inhibitors (21, 22), however covalent 
binders display an higher potency. 
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4.7 Experimental Details 
 
Chemistry 
All solvents were distilled and properly dried, when necessary, prior to use. All 
chemicals were purchased from commercial sources and used directly, unless otherwise 
indicated. All reactions were run under argon atmosphere, unless otherwise indicated. 
All reactions were monitored by thin layer chromatography (TLC) on precoated silica 
gel 60 F254; spots were visualized with UV light (254 nm) and by treatment with 1% 
aqueous KMnO4 solution, Ninhydrin solution in ethanol or Cerium-ammonium-
molybdate (CAM) reactive. Products were purified by flash chromatography on silica 
gel 60 (230‑400 mesh). 1H and 13C NMR spectra were recorded with 300, 400 and 500 
Mhz spectrometers using chloroform-d (CDCl3), dimethylsulfoxide-d6 (DMSO-d6), 
acetonitrile-d3 (CD3CN) or methanol-d4 (CD3OD). Chemical shifts (δ) are expressed in 
ppm relative to TMS at δ = 0 ppm for 1H NMR and relative to CDCl3 at δ = 77.16 ppm 
for 13C NMR. High‑resolution MS spectra were recorded with a FT‑ICR (Fourier 
Transform Ion Ciclotron Resonance) instrument, equipped with an ESI source. 
Biology 
Inhibitory Potency. The human glioblastoma-derived cell lines LN18, LN229, and 
LNZ308 were a kind gift of A.C. Diserens, Neurosurgery Department, Lausanne, 
Switzerland, the immortalized human brain-derived HCEC cells were kindly provided 
by D. Stanimirovic, Ottawa, Canada. Cells were grown in DMEM culture medium 
containing 4.5 g/l glucose, 10% fetal calf serum (FCS) (HCEC cells), or 5% FCS (LN18, 
LN229, and LNZ308 cells), and antibiotics (all from Gibco, Basel, Switzerland). One to 
two days before evaluation, cells were seeded in 48-well plates (Costar, Corning, NY) in 
complete medium in order to reach confluence on the day of experiment. On the day of 
experiment, the culture medium was removed, and either 200 μl of phosphate-buffered 
saline (PBS, pH 7.2−7.4) were added in half of the wells or 200 μl of PBS containing 0.1% 
Triton X-100 (Fluka, Buchs, Switzerland) were added in the other half of the wells for 
the evaluation of the inhibition of enzyme activities in intact cells or cell extracts, 
respectively. Experiments were performed in duplicate wells. The synthetic molecules 
were dissolved at 10 mg/ml in methanol and then diluted 1:10 in H2O, and 1 or 5 μl of 
the water solution were added to duplicate PBS and PBS-Triton wells, followed after 
5−10 min at room temperature by either 1 μl of Gly-Pro-AMC (DPPIV activity) or Z-
Gly-Pro-AMC (POP activity) substrates (1 mg/ml DMSO, both from Bachem, 
Bubendorf, Switzerland), final concentration 10 μM. Increase in fluorescence at λex/λem 
= 360/460 nm was recorded for 30 min at 37 °C in a thermostatted multiwell 
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fluorescence reader (Cytofluor, PerSeptive BioSystems, Switzerland). For the 
determination of IC50, cells in PBS or in PBS-Triton X-100 were exposed to decreasing 
concentrations of the inhibitors, and then determination of residual activity was 
measured and plotted against inhibitor concentration. IC50 values were determined 
graphically. 
Recombinant human prolyl oligopeptidase/PREP (rhPOP/PREP, 0.5 mg/ml, catalogue 
no. 4308-SE) and fibroblast activation protein α (rhFAPα, 0.5 mg/mL, catalogue no. 
3715-SE) were obtained from R&D Systems (Abingdon, UK). The stock solutions were 
diluted in PBS containing 1 mg/ml bovine serum albumin (BSA, Sigma), a protein 
concentration comparable to the protein concentration of cell extracts. For comparison 
of inhibitory potencies, IC50 and KM in cell  extracts with rhPOP/PREP and rhFAPα, cells 
were grown in 6 cm Petri dishes (Falcon, BD, Erembodegem, Belgium) and extracted in 
3 ml of PBS-Triton (resulting in solutions of ∼0.5 mg protein/ml). For the evaluation of 
the inhibition of the recombinant human enzymes, the experimental design was similar 
to the experimental design of cell extracts. For KM determinations, increasing substrate 
concentrations were added to the cell extracts in PBS-Triton or to the recombinant 
enzymes in PBS-BSA, and the KM values were determined graphically using a double-
reciprocal Michaelis−Menten plot. 
Docking Simulations 
The protein structure (PDB code: 2XDW) was downloaded from the Protein Data Bank 
and prepared as reported previously. It was next prepared for docking using PROCESS, 
a module of our docking program FITTED. The ligands were prepared using Maestro 
and SMART, a third module of FITTED. They were subsequently docked using the 
FITTED docking engine and defaults parameters. For the covalent docking to be used, 
the Ser554 has been selected as a reactive residue. 
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Synthesis of rac-9: 
 
 
 
Benzyl ((3aR,7R,7aS)-7-cyano-1-oxo-3,3a,7,7a-tetrahydro-1H-isoindol-2(6H)-yl) 
carbamate (rac-9).  
The acid 16a (38 mg, 0.11 mmol) was dissolved, under argon atmosphere, in CH3CN (1 
ml), then PivCl (21 l, 0.17 mmol) was added. After 30 minutes NH4HCO3 (14 mg, 0.17 
mmol) was added followed by Pyridine (6 l, 0.08 mmol) and the mixture was reacted 
for 3 days. The reaction was quenched with water, then extracted 3 times with DCM. 
The organic phases were washed with saturated NaHCO3, HCl 1M, brine, dried over 
Na2SO4 and concentrated under reduced pressure. The crude was directly used in the 
next reaction step.  
To a cooled solution of the amide (16 mg, 0.05 mmol) in THF (1 ml) was added Pyridine 
(33 l, 0.41 mmol)  then TFAA (18 l, 0.13 mmol). After 4 hours the reaction was 
quenched with saturated NaHCO3 and extracted with AcOEt. The organic phases were 
washed with saturated NaHCO3, HCl 1M, brine, dried over Na2SO4 and concentrated 
under reduced pressure. The crude was purified by flash chromatography (Hex/AcOEt 
4:6) to afford nitrile 9 as a white solid (8 mg, 26% over two steps).  
Rf = 0.35 (1:1 Hex/AcOEt). IR (film) max: 3278, 2923, 2241, 1754, 1738, 1711. 1H NMR (300 
MHz, CDCl3) δ 7.45 – 7.29 (m, 5H), 6.94 (bs, 1H), 5.92 (d, 1H, J = 9.8 Hz), 5.74 – 5.65 (m, 
1H), 5.26 – 5.06 (m, 2H), 3.70 – 3.42 (m, 3H), 3.21 – 2.99 (m, 1H), 2.63 – 2.54 (m, 2H), 2.46 
(bd, J = 9.4 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 154.9, 135.3, 128.6 (2C), 128.5 (2C), 
128.2, 126.0, 125.6, 119.4, 68.0, 51.9, 44.7, 33.5, 29.8, 23.6. HRMS (ESI) calcd. for 
[C17H17N3O3]+: 311.1270, found 334.1160 (MNa+) 
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1H and 13C NMR of compound rac-9 
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Synthesis of 10a/b: 
 
 
(S)-1-((3aS,4R,7aR)-2-benzyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-
carbonyl)pyrrolidine-2-carbonitrile (10a/b).  
The acid rac-19 (23 mg, 0.08 mmol) was dissolved, under argon atmosphere, in DMF (1 
ml). The solution was cooled to 0° and BOP (58 mg, 0.11 mmol) was added, followed by 
S-CN-Proline•pTSA salt (34 mg, 0.13 mmol) and TEA (60 l, 0.34 mmol). The mixture 
was reacted for 18h at rt. The reaction was quenched with H2O, extracted with DCM 
and the organic phases washed with HCl 1M, saturated NaHCO3, brine, dried over 
Na2SO4 and concentrated under reduced pressure. The crude was purified by flash 
chromatography (gradient Hex/AcOEt from 3:7 to 1:9) to afford the product 10 as a 
white solid (26 mg, 31%). The following data has been collected on a 1:1 diastereomeric 
mixture. 
Rf = 0.32 (2:8 Hex/AcOEt). IR (film) max: 3476, 2968, 2043, 1689, 1632. 1H NMR (300 MHz, 
CDCl3) δ 7.38 – 7.27 (m, 6H), 7.21 – 7.13 (m, 4H), 5.89 – 5.80 (m, 2H), 5.76 – 5.62 (m, 2H), 
4.75 (dd, 2H, J = 6.3, 3.7 Hz), 4.58 (d, 2H, J = 14.8 Hz), 4.27 (d, 2H, J = 14.8 Hz), 3.74 – 3.56 
(m, 2H), 3.47 – 3.21 (m, 6H), 3.05 – 2.79 (m, 4H), 2.60 – 2.32 (m, 6H), 2.32 – 2.00 (m, 8H). 
13C NMR (75 MHz, CDCl3) δ 173.5, 173.0, 172.8, 172.7, 136.3, 136.2, 128.8, 128.8, 128.8, 
128.2, 127.9, 127.8, 127.8, 127.7, 127.5, 127.4, 126.9, 125.9, 125.3, 124.8, 119.5, 118.5, 49.7, 
49.3, 48.5, 48.4, 47.1, 47.0, 46.6, 46.5, 36.6, 34.9, 34.6, 34.3, 34.1, 34.0, 32.2, 30.1, 29.0, 28.8, 
25.4, 23.1. HRMS (ESI+) calcd. for [C21H23N3O2]+: 349.1790, found 372.1863. (MNa+) 
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1H and 13C NMR of compound 10a/b 
 
  
  
189 
Synthesis of 11a/b: 
 
 
 
(S)-1-((3aS,4R,7aR)-2-benzyloxy-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-
carbonyl)pyrrolidine-2-carbonitrile (11a/b). 
The acid rac-20 (45 mg, 0.16 mmol) was dissolved, under argon atmosphere, in DMF (1 
ml). The solution was cooled to 0°C and BOP (83 mg, 0.34 mmol) was added, followed 
by S-CN-Proline•pTSA salt (42 mg, 0.16 mmol) and TEA (48 l, 0.34 mmol). The 
mixture was reacted for 18h at RT. The reaction was quenched with H2O, extracted with 
DCM and the organic phases washed with HCl 1M, saturated NaHCO3, brine, dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by flash 
chromatography (gradient Hex/AcOEt from 2:8 to 1:9) to afford the product 11 as a 
white solid (16 mg, 27%). The following data has been collected on a 1:1 diastereomeric 
mixture.  
Rf = 0.35 (1:9 Hex/AcOEt). IR (film) max: 2926, 2880, 2238, 1708, 1648. 1H NMR (300 MHz, 
CDCl3) δ 7.48 – 7.30 (m, 5H), 5.92 – 5.84 (m, 0.5H), 5.77 – 5.63 (m, 1.5H), 5.03 – 4.82 (m, 
2H), 4.79 – 4.67 (m, 0.5H), 4.67 – 4.53 (m, 0.5H), 3.72 – 3.59 (m, 0.5H), 3.52 – 3.29 (m, 3H), 
3.18 – 3.13 (m, 0.5H), 3.05 – 2.95 (m, 2H), 2.53 – 1.97 (m, 7H). 13C NMR (75 MHz, CDCl3) 
δ 172.6, 172.3, 169.7, 169.6, 135.4, 135.1, 129.9 (2C), 129.7 (2C), 129.1, 129.0, 128.8 (2C), 
128.7 (2C), 128.0, 127.5, 125.4, 124.7, 119.6, 118.6, 77.9, 76.9, 51.4, 51.1, 47.7, 47.2, 46.7, 
46.5, 46.3, 46.2, 34.3, 34.1, 32.3, 31.8, 31.1, 30.2, 28.6 (2C), 25.6, 23.1. HRMS (ESI+) calcd. 
for [C21H23N3O3]+ 365.1739, found 366.1814. (MH+)  
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1H and 13C NMR of compound 11a/b 
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Synthesis of 13: 
 
 
 
tert-Butyl 2-((3E)-penta-2,4-dienyl)hydrazinecarboxylate (13).  
To a solution of dienal 12 (100 mg, 1.2 mmol) in DCM/MeOH (5 ml, 5:1) was added Boc-
hydrazide (158 mg, 1.2 mmol). The mixture was stirred for 30 minutes. The resulting 
solid was dissolved in MeOH (5 ml) and Me2NH·BH3 (110 mg, 1.9 mmol) was added 
slowly at 0°C followed by a solution of pTSA (1.37 g, 7.2 mmol) in MeOH (10 ml). After 
stirring for another 2h, a solution of Na2CO3 (aq) (20 ml, 10% w/v) was added and the 
mixture stirred for 2h then concentrated under reduced pressure, extracted with 
CH2Cl2, dried over Na2SO4 and concentrated under reduced pressure to afford the 
product as a yellow oil (159 mg, 67%).  
IR (film) max: 3308.95, 2977.22, 2931.35, 1706.19. 1H NMR (300 MHz, CDCl3)  6.52 - 6.03 
(m, 2H), 5.78 – 5.59 (m, 1H), 5.17 (d, 1H, J = 15.8 Hz), 5.06 (d, 1H, J = 9.0 Hz), 3.48 (d, 2H, 
J = 6.6 Hz), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3)  156.6, 136.4, 134.2, 129.6, 117.2, 
80.5, 53.6, 28.3. HRMS (ESI) calcd. for [C13H16N2O2]+: 198.13683, found 221.12605. (MNa+) 
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1H and 13C NMR of compound 13 
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Synthesis of 14: 
 
 
 
Benzyl 2-((2E)-penta-2,4-dienyl)hydrazinecarboxylate (14).  
To a solution of dienal 12 (121 mg, 1.5 mmol) in DCM/MeOH (5 ml, 5:1) was added 
Cbz-hydrazide (245 mg, 1.5 mmol). The mixture was stirred for 30 minutes. The 
resulting solid was dissolved in MeOH (5 ml) and Me2NH·BH3 (132 mg, 2.25 mmol) was 
added slowly at 0°C followed by a solution of pTSA (1.7 g, 9.0 mmol) in MeOH (10 ml). 
After stirring for another 2h, a solution of Na2CO3 (aq) (20 ml, 10% w/v) was added and 
the mixture stirred for 2h then concentrated under reduced pressure, extracted with 
CH2Cl2, dried over Na2SO4 and concentrated under reduced pressure to afford the 
product as a white solid (250 mg, 73%). 
IR (film) max: 3314.85, 2972.36, 2891.14, 1686.76. 1H NMR (300 MHz, CDCl3) 7.45-7.30 
(m, 5H), 6.32 (dt, 1H, J = 16.7, 10.2 Hz), 6.25 – 6.15 (m, 1H), 5.76 – 5.62 (m, 1H), 5.20 (d, 
1H, J = 16.5 Hz), 5.14 (s, 2H), 5.11 – 5.02 (m, 1H), 3.58 – 3.48 (m, 2H). 13C NMR (75 MHz, 
CDCl3)  157.2, 136.3, 136.0, 134.5, 129.2, 128.6 (2C), 128.3 (2C), 128.2, 117.5, 67.1, 53.5. 
HRMS (ESI) calcd. for [C13H16N2O2] +: 232.12118, found 233.12845. (MH+) 
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1H and 13C NMR of compound 14 
 
  
  
195 
Synthesis of 15: 
 
 
 
Rac-(3aS,4R,7aR)-2-(tert-butoxycarbonylamino)-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-
isoindole-4-carboxylic acid (15a) and Rac-(3aS,4R,7aS)-2-(tert-butoxycarbonylamino)-
3-oxo-2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-carboxylic acid (15b). 
To a solution of 13 (99 mg, 0.5 mmol) in CHCl3 (2 ml) was added maleic anhydride (49 
mg, 0.5 mmol) and stirred at rt for 18h. The solution was concentrated under reduced 
pressure and the residue purified by flash chromatography (Hex/AcOEt 3:1) to afford 
the product as a white solid (96 mg, 65%). The following data has been collected on a 
1.5:1 mixture.  
IR (film) max: 3275, 3063, 2924, 2886, 1659, 1651, 1645. 1H NMR (400 MHz, CDCl3)  6.60 
(s, 0.7H), 6.48 (s, 0.3H), 5.97-5.92 (s, 0.3H), 5.84 - 5.79 (m, 0.7H), 5.75 – 5.67 (m, 0.7H), 5.59 
(d, 0.3H, J = 10.0 Hz), 3.99 – 3.88 (m, 0.3H), 3.58 (t, 0.7H, J = 7.5 Hz), 3.48 – 3.40 (m, 0.7H), 
3.38 – 3.31 (m, 1H), 3.25 (d, 0.7H, J = 9.1 Hz), 3.07 – 3.01 (m, 0.3H), 3.01 - 2.9 (m, 0.3H), 
2.91 – 2.81 (m, 0.3H), 2.75 (d, 0.7H, J = 19.4 Hz), 2.5 - 2.4 (m, 1H), 2.40 – 2.27 (m, 1H), 1.46 
(s, 9H). 13C NMR (75 MHz, CDCl3)  175.8 , 174.0, 157.6, 154.5, 128.6, 127.8, 126.8, 125.2, 
82.4, 82.0, 54.0, 52.5, 45.2, 40.4, 39.1, 35.9, 32.6, 32.3, 29.7, 28.1 (2C), 23.6. HRMS (ESI) 
calcd. for [C14H20N2O5] +: 296.13722, found 295.12994. (M-) 
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1H and 13C NMR of compound 15 
 
 
  
  
197 
Synthesis of 16: 
 
 
 
Rac-(3aS,4R,7aR)-2-(benzyloxycarbonylamino)-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-
isoindole-4-carboxylic acid (16a). 
To a solution of 14 (116 mg, 0.5 mmol) in CHCl3 (2 ml) was added maleic anhydride (49 
mg, 0.5 mmol) and stirred at rt for 18h. The solution was concentrated under reduced 
pressure and the residue purified by flash chromatography (Hex/AcOEt 3:1) to afford 
the product  as a white solid (165 mg, 99%). The exo compound was selectively 
precipitated using CH2Cl2 and afforded the pure compound as a white solid (105 mg, 
66%).  
IR (film) max: 3030, 2941, 2922, 2853, 1739, 1720, 1709. 1H NMR (400 MHz, CDCl3) 7.4 – 
7.2 (m, 5H), 5.77 (bd, 1H, J = 10.0 Hz), 5.67 (bd, 1H, J = 6.9 Hz), 5.14 (s, 2H), 3.58 (dd, 1H, 
J = 7.5, 7.4 Hz), 3.5 - 3.41 (m, 1H), 3.4 - 3.31 (m, 1H), 3.1 - 3.0 (m, 1H), 2.68 (bd, 1H, J = 
20.0 Hz), 2.45 – 2.4 (m, 1H). 13C NMR (125 MHz, CDCl3)  175.4 (2C), 155.3, 135.5, 128.6 
(2C), 128.5, 128.5, 128.3, 128.3, 127.8, 125.1, 67.8, 45.1, 40.3, 35.8, 32.7, 28.1. HRMS (ESI) 
calcd. for [C17H18N2O5]+: 330.12157, found 329.11429. (M-) 
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1H and 13C NMR of compound rac-16 
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1H and 13C NMR of compound rac-16a 
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Synthesis of 18: 
 
 
 
(E)-O-benzyl-N-(penta-2,4-dien-1-yl)hydroxylamine (18). 
To a solution of O-benzylhydroxylamine (142 mg, 1.16 mmol) in MeOH (1 ml), was 
added a solution of dienal (95 mg, 1.16 mmol) in DCM dropwise. The mixture was 
stirred for 30 minutes at rt. The solution was cooled to 0°C and Me2NH·BH3 (109 mg 
1.86 mmol) was added slowly, followed by a solution of pTSA (1.3 g, 6.9 mmol) in 
MeOH (10 ml). After stirring for another 2 h, a solution of Na2CO3(aq) (20 ml, 10% w/v) 
was added and the mixture reacted for 2 h then concentrated under reduced pressure, 
extracted with CH2Cl2, washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. The crude was purified by flash chromatography (Hex/AcOEt 95:5) 
to afford the product as a colorless oil (61 mg, 28%).  
Rf = 0.36 (9:1 Hex/AcOEt). IR (film) υmax 3265, 3087, 1603 cm-1. 1H NMR (300 MHz, 
CDCl3) δ 7.42 – 7.27 (m, 5H), 6.43 – 6.14 (m, 2H), 5.77 (dt, 1H, J = 14.6, 6.7 Hz), 5.26 – 5.14 
(m, 1H), 5.14 – 5.03 (m, 1H), 4.76 (s, 2H), 3.66 – 3.55 (m, 2H). 13C NMR (75 MHz, CDCl3) 
δ 136.4, 134.5, 129.0, 128.5 (2C), 128.4 (2C), 128.3, 128.0, 117.4, 76.3, 53.7. HRMS (ESI) 
calcd. for [C12H15NO]+: 189.1154, found 190.1151. (MH+)  
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1H and 13C NMR of compound 18 
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Synthesis of 19: 
 
 
 
rac-(3aS,4R,7aR)-2-benzyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-carboxylic 
acid (rac-42).  
Diene 17 (41 mg, 0.23 mmol) was dissolved in CHCl3 (2 ml). To the solution was added 
maleic anhydride (23 mg, 0.23 mmol) After stirring for 18 h, the solution was 
concentrated under reduced pressure and the residue purified by flash chromatography 
(Hex/AcOEt 4:6) to afford the product as a white solid (55 mg, 98%). The following data 
has been collected on a 7:1 diastereomeric mixture.  
Rf = 0.29 (4:6 Hex/AcOEt). IR (film) max: 3028, 1722, 1697, 1650. 1H NMR (400 MHz, 
CDCl3) δ 7.44 – 7.06 (m, 5H), 5.96 – 5.89 (m, 0.2H), 5.76 (bd, 0.8H, J = 10.1 Hz), 5.73 – 5.58 
(m, 0.8H), 5.43 (d, 0.2H, J = 10.1 Hz), 4.49 (s, 2H), 3.53 (dd, 0.2H, J = 10.0, 6.4 Hz), 3.42 
(dd, 0.8H, J = 8.0, 3.9 Hz), 3.35 – 3.28 (m, 1H), 3.09 – 2.84 (m, 2.2H), 2.75 (bd, 0.8H, J = 
19.1 Hz), 2.56 – 2.34 (m, 2H).13C NMR (75 MHz, CDCl3) δ 175.7, 174.5, 136.2, 128.8 (2C), 
128.0 (3C), 127.7, 125.31, 49.4, 46.9, 46.8, 36.3, 34.4, 28.2. HRMS (ESI) calcd. for 
[C16H17NO3]+: 271.1208, found 294.1096. (MNa+) 
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1H and 13C NMR of compound rac-19 
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Synthesis of 20: 
 
 
 
rac-(3aS,4R,7aR)-2-benzyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-carboxylic 
acid (rac-20). 
Diene 18 (60 mg, 0.31 mmol) was dissolved in CHCl3 (2 ml). To the solution was added 
maleic anhydride (31 mg, 0.31 mmol) After stirring for 3 days, the solution was 
concentrated under reduced pressure and the residue purified by flash chromatography 
(Hex/AcOEt 4:6) to afford the product as a white solid (66 mg, 74%). The following data 
has been collected on a 1:1 diastereomeric mixture.  
Rf = 0.24 (7:3 Hex/AcOEt). IR (film) max: 3030, 1734, 1709. 1H NMR (300 MHz, CDCl3) δ 
7.47 – 7.30 (m, 5H), 5.92 – 5.81 (m, 0.5H), 5.73 – 5.60 (m, 1H), 5.37 (d, 0.5H, J = 10.2 Hz), 
5.05 – 4.94 (m, 2H), 3.55 (dd, 0.5H, J = 8.7, 6.7 Hz), 3.39 (dd, 0.5H, J = 8.0, 3.6 Hz), 3.30 – 
3.15 (m, 1H), 3.07 – 2.95 (m, 1H), 2.91 (bs, 0.5H), 2.86 – 2.66 (m, 1.5H), 2.52 – 2.38 (m, 
0.5H) 2.37 – 2.20 (m, 1.5H). 13C NMR (75 MHz, CDCl3) δ 174.9 (2C), 170.3 (2C), 135.0, 
134.3, 129.8, 129.8, 129.3, 129.1, 129.0, 128.6, 128.6, 127.8, 126.4, 124.8, 77.1 (2C), 52.7, 51.3, 
44.8, 41.0, 39.4, 35.8, 32.0, 31.8, 27.8, 24.3. HRMS (ESI) calcd. for [C16H17NO4]+: 287.1158, 
found 310.1049. (MNa+)  
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1H and 13C NMR of compound rac-20 
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Synthesis of 21: 
 
 
 
rac-(3aR,7R,7aS)-2-benzyl-7-(pyrrolidine-1-carbonyl)-2,3,3a,6,7,7a-hexahydro-1H-
isoindol-1-one (rac-21). 
The acid 19 (34 mg, 0.125 mmol) was dissolved, under argon atmosphere, in DMF (1.2 
ml). The solution was cooled to 0°C and TEA (87 l, 0.625 mmol) was added followed 
by PivCl (23 l, 0.18 mmol). After 1 h Pyrrolidine (52 l, 0.625 mmol) was added and the 
mixture was reacted for 18h. The reaction was quenched with H2O, extracted with 
AcOEt and the organic phases washed with HCl 1M, saturated NaHCO3, brine, dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by flash 
chromatography (Hex/AcOEt 2:8) to afford the product 21 as a white solid (14 mg, 34%). 
Rf = 0.36 (2:8 Hex/AcOEt). IR (film) max: 3480, 1689, 1638, 1623. 1H NMR (300 MHz, 
CDCl3) δ 7.38 – 7.09 (m, 5H), 5.83 (dd, 1H, J = 9.8, 1.9 Hz), 5.68 (dt, 1H, J = 9.8, 3.2 Hz), 
4.64 (d, 1H, J = 6.3 Hz), 4.6 – 4.54 (m, 1H) 4.33 – 4.11 (m, 2H), 3.70 – 3.38 (m, 5H), 3.30 
(dd, 1H, J = 8.6, 7.2 Hz), 2.90 (dd, 1H, J = 11.0, 8.7 Hz), 2.51 – 2.28 (m, 2H), 2.11 – 1.73 (m, 
4H). 13C NMR (75 MHz, CDCl3) δ 173.6, 172.4, 136.7, 128.7 (2C), 128.0 (2C), 127.4, 127.4, 
126.2, 49.6, 48.4, 46.9, 46.7, 45.8, 33.9, 33.6, 28.9, 26.2, 24.3. HRMS (ESI+) calcd. for 
[C20H24N2O2]+ 324.1838, found 347.1732. (MNa+)  
 
  
  
207 
1H and 13C NMR of compound rac-21 
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Synthesis of 22: 
 
 
 
rac-(3aR,7R,7aS)-2-benzyloxy-7-(pyrrolidine-1-carbonyl)-2,3,3a,6,7,7a-hexahydro-1H-
isoindol-1-one (rac-22).  
The acid 20 (34 mg, 0.12 mmol) was dissolved, under argon atmosphere, in DMF (1 ml). 
The solution was cooled to 0°C and TEA (50 l, 0.29 mmol) was added followed by 
PivCl (23 l, 0.18 mmol). After 1 h Pyrrolidine (25 l, 0.29 mmol) was added and the 
mixture was reacted for 18h. The reaction was quenched with H2O, extracted with 
AcOEt and the organic phases washed with HCl 1M, saturated NaHCO3, brine, dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by flash 
chromatography (Hex/AcOEt 2:8) to afford the product 22 as a white solid (7 mg, 17%). 
The following data has been collected on a 5:1 diastereomeric mixture.  
Rf = 0.27 (2:8 Hex/AcOEt). IR (film) max: 3480, 2951, 1705, 1634. 1H NMR (300 MHz, 
CDCl3) δ 7.49 – 7.39 (m, 2H), 7.39 – 7.29 (m, 3H), 5.82 – 5.69 (m, 1H), 5.62 (bd, 0.8H, J = 
10.2 Hz), 5.52 (bd, J = 10.2 Hz, 0.2H), 5.01 – 4.88 (m, 2H), 3.71 – 3.29 (m, 6H), 3.29 – 3.18 
(m, 0.8H), 3.18 – 3.06 (m, 0.2H), 3.01 – 2.74 (m, 2H), 2.46 – 2.13 (m, 2H), 2.13 – 1.63 (m, 
4H). 13C NMR (75 MHz, CDCl3) δ 171.4, 171.2, 135.6 (2C), 129.8, 129.7, 129.4 (2C), 128.6, 
128.5, 128.4 (2C), 127.1, 126.5, 125.8, 124.7, 76.8, 76.0, 52.0, 51.4, 46.7, 46.1, 45.9, 39.8, 38.6, 
37.2, 35.6, 29.7, 29.0, 28.64, 26.4, 26.2, 25.0, 24.2, 24.1, 24.0. HRMS (ESI+) calcd. for 
[C20H24N2O3]+: 340.1769, found 363.1686. (MNa+)  
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